Interim Financial Information

Rede D'Or São Luiz S.A.

September 30, 2024 with Independent Auditor's Review Report

Interim financial information

September 30, 2024

Contents

Independent auditor's review report on interim financial information	1
Interim financial information	
Statements of financial position	3
Statements of profit or loss	5
Statements of comprehensive income	
Statements of changes in equity	7
Statements of cash flows	
Statements of value added	9
Notes to interim financial information	



Centro Empresarial PB 370 Praia de Botafogo, 370 8° ao 10° andar - Botafogo 22250-040 - Rio de Janeiro - RJ - Brazil

Phone: +55 21 3263-7000

ey.com.br

A free translation from Portuguese into English of Independent Auditor's Review Report on interim financial information prepared in Brazilian currency in accordance with NBC TG 21 and IAS 34 - Interim Financial Reporting and the rules issued by the Brazilian Securities and Exchange Commission (CVM) applicable to the preparation of Quarterly Information (ITR)

Independent auditor's review report on interim financial information

To the Shareholders, Board of Directors and Officers of **Rede D'Or São Luiz S.A.**Rio de Janeiro - RJ, Brazil

Introduction

We have reviewed the accompanying individual and consolidated interim financial information, contained in the Quarterly Information Form (ITR) of Rede D'Or São Luiz (the "Company") for the quarter ended September 30, 2024, comprising the statement of financial position as of September 30, 2024 and the related statements of profit or loss, of comprehensive income for the three and ninemonth periods then ended, and of changes in equity and of cash flows for the nine -month period then ended, including explanatory information.

The executive board is responsible for the preparation of the individual and consolidated interim financial information in accordance with Accounting Pronouncement NBC TG 21 - Interim Financial Reporting, and IAS 34 - Interim Financial Reporting, issued by the International Accounting Standards Board (IASB), as well as for the fair presentation of this information in conformity with the rules issued by the Brazilian Securities and Exchange Commission (CVM) applicable to the preparation of the Quarterly Information Form (ITR). Our responsibility is to express a conclusion on this interim financial information based on our review.

Scope of review

We conducted our review in accordance with Brazilian and international standards on review engagements (NBC TR 2410 and ISRE 2410 - Review of Interim Financial Information Performed by the Independent Auditor of the Entity, respectively). A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with auditing standards and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.



Conclusion on the individual and consolidated interim financial information

Based on our review, nothing has come to our attention that causes us to believe that the accompanying individual and consolidated interim financial information included in the quarterly information referred to above is not prepared, in all material respects, in accordance with NBC TG 21 and IAS 34 applicable to the preparation of Quarterly Information Form (ITR), and presented consistently with the rules issued by the Brazilian Securities and Exchange Commission.

Other matters - Statements of value added

The abovementioned quarterly information includes the individual and consolidated statement of value added (SVA) for the nine-month period ended September 30, 2024, prepared under the Company executive board's responsibility and presented as supplementary information under IAS 34. These statements have been subject to review procedures performed together with the review of the quarterly information with the objective to conclude whether they are reconciled to the interim financial information and the accounting records, as applicable, and if their format and content are in accordance with the criteria set forth by NBC TG 09 – Statement of Value Added. Based on our review, nothing has come to our attention that causes us to believe that they were not prepared, in all material respects, in accordance with the criteria set forth by this Standard and consistently with the overall individual and consolidated interim financial information.

Rio de Janeiro, November 12, 2024.

ERNST & YOUNG Auditores Independentes S/S Ltda. CRC SP-015199/F

Diogo Afonso da Silva

Accountant CRC RJ-114783/O

A free translation from Portuguese into English of Interim Financial Information prepared in Brazilian currency in accordance with NBC TG 21 and IAS 34 - Interim Financial Reporting and the rules issued by the Brazilian Securities and Exchange Commission (CVM) applicable to the preparation of Quarterly Information (ITR)

Rede D'Or São Luiz S.A.

Statements of financial position September 30, 2024 and December 31, 2023 (In thousands of reais)

		Indiv	idual	Consolidated	
	Note	09/30/2024	12/31/2023	09/30/2024	12/31/2023
Assets					
Current assets					
Cash and cash equivalents	4	495,446	257,423	5,499,255	3,267,408
Marketable securities	4	7,839,684	9,239,876	29,679,716	28,463,882
Accounts receivable	5	5,227,784	4,840,796	9,874,005	8,939,144
Inventories	6	358,126	365,793	743,460	705,896
Taxes recoverable		705,344	545,021	1,227,224	1,002,564
Insurance contract assets	12	-	-	13,202	41,419
Reinsurance contract assets		-	-	51,893	64,934
Derivative financial instruments	24	72,434	49,550	72,434	49,550
Transactions with related parties	7	440,598	245,080	189,210	36,492
Dividends receivable		45,782	70,593	-	3,154
Other		416,913	230,183	772,236	549,038
Total current assets		15,602,111	15,844,315	48,122,635	43,123,481
Noncurrent assets					
Transactions with related parties	7	1,707,049	1,985,841	61,176	191,803
Marketable securities	4	-	=	1,786,179	1,702,460
Accounts receivable	5	-	-	1,768,603	1,674,369
Taxes recoverable		8,677	8,677	492,898	490,566
Insurance contract assets	12	-	-	27,406	40,595
Reinsurance contract assets		-	=	18,453	3,525
Judicial deposits	14	384,241	362,366	2,749,599	2,682,556
Deferred taxes	17	25,062	12,222	3,720,803	3,600,118
Derivative financial instruments	24	361,608	570,513	2,711,661	1,917,874
Investments in subsidiaries, associates and joint					
ventures	8	30,639,580	27,296,375	2,482,501	2,563,868
Property and equipment	9	5,548,894	5,294,123	14,422,351	12,909,403
Intangible assets	10	7,400,446	7,508,728	16,135,850	16,449,568
Right of use - leases	11	2,325,648	2,158,506	2,918,448	2,680,462
Other		209,444	94,612	442,253	311,708
Total noncurrent assets		48,610,649	45,291,963	49,738,181	47,218,875

Total assets **64,212,760** 61,136,278 **97,860,816** 90,342,356

Statements of financial position September 30, 2024 and December 31, 2023 (In thousands of reais)

		Individual		Conso	lidated	
	Note	09/30/2024	12/31/2023	09/30/2024	12/31/2023	
Liabilities and equity						
Current liabilities						
Trade accounts payable		635,946	636,124	1,469,934	1,355,666	
Derivative financial instruments	24	421,464	466,050	549,364	639,580	
Loans, financing and debentures	13	2,960,243	2,587,944	3,006,658	2,918,435	
Transactions with related parties	7	-	-	4,968	-	
Salaries, accruals and social charges		615,738	539,971	1,270,907	1,101,223	
Tax obligations		297,674	192,729	988,083	757,933	
Accounts payable for acquisitions		64,102	59,041	497,223	468,135	
Dividends and IOE payable	16	308,365	88,499	331,153	99,769	
Insurance contract liabilities	12		-	6,703,043	4,683,939	
Leases	15	621,323	534,822	777,973	872,949	
Other		65,229	49,550	1,031,457	1,339,918	
Total current liabilities		5,990,084	5,154,730	16,630,763	14,237,547	
Noncurrent liabilities	24	923,282	E74 242	000 000	E71 242	
Derivative financial instruments	24		571,342	923,283	571,342	
Loans, financing and debentures	13	28,814,224	29,062,394	32,700,517	31,667,514	
Transactions with related parties	7	-	-	4,312	5,179	
Tax obligations		34,928	35,826	190,325	200,119	
Accounts payable for acquisitions		776	200	289,168	354,662	
Insurance contract liabilities	12	-	-	13,091,430	12,458,584	
Deferred taxes	17	-	-	234,640	168,667	
Provision for contingencies	14	751,722	820,185	3,372,670	3,268,354	
Provision for losses on investments	8	707,533	613,560	-	-	
Leases	15	2,163,613	2,037,512	2,675,713	2,299,676	
Other		357,328	300,823	1,291,492	1,275,066	
Total noncurrent liabilities		33,753,406	33,441,842	54,773,550	52,269,163	
Equity	16					
Capital	10	15,711,360	15,711,360	15,711,360	15,711,360	
Share issue costs		(253,031)	(253,031)	(253,031)	(253,031)	
		• • •	, ,	• • •		
Capital reserves		4,959,024	4,914,555	4,959,024	4,914,555	
Treasury shares		(853,486)	(519,418)	(853,486)	(519,418)	
Income reserves		1,533,490	2,508,424	1,533,490	2,508,424	
Retained earnings		2,921,920	4 00 4	2,921,920	4 00 4	
Future capital contribution		4,224	4,224	4,224	4,224	
Other comprehensive income		445,769	173,592	445,769	173,592	
Total equity attributable to the Company's shareholders		24,469,270	22,539,706	24,469,270	22,539,706	
Noncontrolling interests		_	_	1,987,233	1,295,940	
Total equity		24,469,270	22,539,706	26,456,503	23,835,646	
-						
Total liabilities and equity		64,212,760	61,136,278	97,860,816	90,342,356	
· ·						

Statements of profit or loss Nine-month periods ended September 30, 2024 and 2023 (In thousands of reais, unless otherwise stated)

			Individual				Consolidated				
	Note	07/01/2024 to 09/30/2024	01/01/2024 to 09/30/2024	07/01/2023 to 09/30/2023	01/01/2023 to 09/30/2023	07/01/2024 to 09/30/2024	01/01/2024 to 09/30/2024	07/01/2023 to 09/30/2023	01/01/2023 to 09/30/2023		
Operating revenue, net	18	3,807,683	10,855,502	3,419,450	9,932,677	13,023,160	37,722,297	11,835,088	34,696,350		
Operating costs	19	(2,613,176)	(7,483,323)	(2,294,891)	(6,804,763)	(10,580,670)	(30,658,054)	(9,969,981)	(29,308,933)		
Gross profit		1,194,507	3,372,179	1,124,559	3,127,914	2,442,490	7,064,243	1,865,107	5,387,417		
General and administrative expenses Selling expenses Equity pickup Other operating income (expenses), net	20 8 21	(299,573) (4,191) 695,540 306,721	(838,198) (15,568) 2,056,792 219,813	59,744 (29,560) 337,470 (32,864)	(352,883) (37,776) 887,768 (101,431)	(512,617) (4,159) 19,976 241,562	(1,473,436) (29,879) 34,143 84,355	(116,450) (144,378) 8,851 (123,586)	(886,834) (171,051) (2,178) (319,947)		
Income before finance income (costs) and income and social contribution taxes		1,893,004	4,795,018	1,459,349	3,523,592	2,187,252	5,679,426	1,489,544	4,007,407		
Finance income Finance costs	22 22	689,096 (1,398,920)	1,804,135 (3,829,461)	563,807 (1,351,464)	2,749,055 (5,017,509)	2,065,367 (2,727,092)	5,537,007 (7,459,338)	1,956,995 (2,598,878)	6,828,022 (9,232,086)		
Income before income taxes		1,183,180	2,769,692	671,692	1,255,138	1,525,527	3,757,095	847,661	1,603,343		
Income taxes	17	(37,503)	152,228	10,798	17,428	(357,217)	(757,759)	(158,713)	(281,115)		
Net income for the period		1,145,677	2,921,920	682,490	1,272,566	1,168,310	2,999,336	688,948	1,322,228		
Income attributable to controlling interests Income attributable to noncontrolling interests		1,145,677 -	2,921,920 -	682,490 -	1,272,566 -	1,145,677 22,633	2,921,920 77,416	682,490 6,458	1,272,566 49,662		
Basic earnings per share (in reais) Diluted earnings per share (in reais)	23 23	0.5010 0.5010	1.3032 1.3032	0.3027 0.3027	0.5644 0.5644	0.5010 0.5010	1.3032 1.3032	0.3027 0.3027	0.5644 0.5644		

Statements of comprehensive income Nine-month periods ended September 30, 2024 and 2023 (In thousands of reais)

		Indiv	idual		Consolidated				
	07/01/2024 to 09/30/2024	01/01/2024 to 09/30/2024	07/01/2023 to 09/30/2023	01/01/2023 to 09/30/2023	07/01/2024 to 09/30/2024	01/01/2024 to 09/30/2024	07/01/2023 to 09/30/2023	01/01/2023 to 09/30/2023	
Net income for the period	1,145,677	2,921,920	682,490	1,272,566	1,168,310	2,999,336	688,948	1,322,228	
·	.,,	_,,	,	-,,	.,,	_,,		-,,	
Other comprehensive income									
Cash flow hedge	(17,875)	12,819	3,942	(142,761)	(21,716)	1,296	102	(154,283)	
Gain/loss on insurance and reinsurance liability	-	-	-	-	(90,765)	474,051	35,390	(164,083)	
Unrealized gains/(losses) on financial assets at fair value through OCI					16,854	(17,562)	1,588	36,557	
Tax effects	6,078	(4,358)	(1,340)	48,539	37,374	(182,498)	(14,377)	104,660	
Gains/(losses) on changes in equity interest	(7,165)	(8,950)	-	(5,244)	(8,950)	(8,950)	-	-	
Other comprehensive income of associates and subsidiaries, by equity pickup	(40,833)	272,666	15,218	(88,311)	7,408	5,840	(4,882)	(10,628)	
	(59,795)	272,177	17,820	(187,777)	(59,795)	272,177	17,821	(187,777)	
Total comprehensive income	1,085,882	3,194,097	700,310	1,084,789	1,108,515	3,271,513	706,769	1,134,451	
Attributable to: Controlling interests Noncontrolling interests	1,085,882	3,194,097 -	700,310 -	1,084,789 -	1,085,882 22,633	3,194,097 77,416	700,310 6,459	1,084,790 49,661	

Statements of changes in equity Nine-month periods ended September 30, 2024 and 2023 (In thousands of reais)

							Attr	ibutable to con	trolling interests					
	Ca	pital		Capital reserves	5		Income	e reserves	=					
Description	Capital	Share issue costs	Premium reserve (issue of shares)	Premium on capital transactions	Share-based payment reserve	Treasury shares	Legal reserve	Investment reserve	Future capital contribution	Retained earnings	Other comprehensive income	Total equity	Noncontrolling interests	Total
Balances at December 31, 2022	15,711,360	(253,031)	6,166,296	(1,251,796)	-	(544,610)	8,666	1,291,612	4,224	-	310,082	21,442,803	1,264,931	22,707,734
Acquisitions of subsidiaries (Note 3) Capital transactions in subsidiaries and acquisition of	-	-	-	-	-	-	-	-	-	-	-	-	(65)	(65)
noncontrolling interests Changes - RSU (Note 16)	-	-	(10,922)	235	(31,701)	25,193	-	-	-	-	-	235 (17,430)	21,526	21,761 (17,430)
Share-based payment (Note 16) Income for the period Dividends and interest on equity (Note 16)	-	-	-	-	31,701 -	-	-	- (416,288)	-	1,272,566	-	31,701 1,272,566 (416,288)	49,662 (52,963)	31,701 1,322,228 (469,251)
Cash flow hedge (Note 16) Net finance income (costs) from insurance and	-	-	-	-	-	-	-	(410,200)	-	-	(101,804)	(101,804)	(32,903)	(101,804)
reinsurance contracts Equity adjustments		-	-	-	-	-	-	-	-		(98,424) 12,451	(98,424) 12,451	-	(98,424) 12,451
Balances at September 30, 2023	15,711,360	(253,031)	6,155,374	(1,251,561)	-	(519,417)	8,666	875,324	4,224	1,272,566	122,305	22,125,810	1,283,091	23,408,901
Balances at December 31, 2023	15,711,360	(253,031)	6,166,442	(1,251,887)	-	(519,418)	8,666	2,499,758	4,224	-	173,592	22,539,706	1,295,940	23,835,646
Acquisitions of subsidiaries (Note 3) Capital transactions in subsidiaries and acquisition of	-	-	-	-	-	-	-	-	-	-	•	-	7,078	7,078
noncontrolling interests Changes - RSU (Note 16)	-	-	- 18,913	25,556	- (14,198)	- 7,671	-	-	-	-	-	25,556 12,386	672,062	697,618 12,386
Share-based payment (Note 16) Income for the period	-	-	-	-	14,198	-	-	-	-	- 2,921,920	-	14,198 2,921,920	- 77.416	14,198 2.999.336
Dividends and interest on equity (Note 16)	-	-	-	-	-	-	-	(1,000,000)	-	2,921,920	-	(1,000,000)	(65,263)	(1,065,263)
Reinvested dividends Share buyback	-	-	-	-	-	(341,739)	-	25,066	-	-	-	25,066 (341,739)	-	25,066 (341,739)
Cash flow hedge (Note 16) Equity adjustments	-	-	-	-	-	-	-	-	-	-	(12 222)	855 (13,200)	-	855 (13,200)
Net finance income (costs) from insurance and reinsurance contracts	-	-	-	-	-	-	-	-	-	-	284,522	284,522	-	284,522
Balances at September 30, 2024	15,711,360	(253,031)	6,185,355	(1,226,331)		(853,486)	8,666	1,524,824	4,224	2,921,920	445,769	24,469,270	1,987,233	26,456,503

Statements of cash flows Nine-month periods ended September 30, 2024 and 2023 (In thousands of reais)

Cash flows from operating activities 1,000		Indi	vidual	Cons	olidated
1,000,000 1,00		01/01/2024 to	01/01/2023 to	01/01/2024 to	01/01/2023 to
1,000,000 1,00	Cash flows from operating activities				
Depreciation and amontization	Income before income and social contribution taxes Adjustments to reconcile income before taxes to cash flows from operating	2,769,692	1,255,138	3,757,095	1,603,343
Gain on property sales (2,940) (2,940) (2,940) (2,940) (2,940) (2,940) (2,940) (2,940) (2,940) (2,940) (2,940) (2,940) (2,940) (2,940) (2,940) (354,103) - 19,87 - 19,8		605 3/18	664 927	1 108 830	1 22/1 373
Impairment					
Gain on divestiture (354,103) - (354,103) - Fair value of debt (993,529) 504,258 (674,119) 167,956 Interest, monetary variations and FX differences, net 3,208,449 1,506,639 1,221,859 610,736 Share-based payment 58,430 31,701 58,430 31,701 Provision for (reversal of) contingencies (64,869) (431,722) 264,786 (198,565) Equity pickup (205,6792) (887,768) 343,143 3,275,183 Increase) decrease in assets and increase (decrease) in liabilities 400,000 40,000 (2020,630) (2,159,768) Accounts receivable (75,660) (14,25,540) (2,020,630) (2,159,768) Increase) decrease in assets and increase (decrease) in liabilities 7,667 2,896 (30,089) (20,757) Increase) decrease in assets and increase (decrease) in liabilities 7,656 (18,254) (2,202,630) (2,157,680) Increase) decrease in assets and increase (decrease) in liabilities 7,656 (2,386) (30,089) (2,157,680) Increase) decrease in assets		(=,0.10)	-	(=,0.0)	
Interest, monetary variations and FX differences, net 3,208,449 1,506,639 1221,859 31,701 58,430 31,701 58,430 31,701 58,430 31,701 58,430 31,701 58,430 31,701 58,430 31,701 58,430 31,701 58,430 31,701 58,430 31,701 58,430 31,701 58,430 31,701 58,430 31,701 58,430 31,701 58,430 31,701 58,430 31,701 58,430 31,701 58,430 31,701 58,430 31,701 58,430 33,751,851 58,401 58,430 58,43		(354,103)	-	(354,103)	-
Share-based payment	Fair value of debt	(903,529)	504,258	(674,119)	167,996
Provision for (reversal of) contingencies	,		, ,		,
Equity pickup (2,056,792) (887,768) (34,143) 2,176 1,100 1,000					
Income from (loss on) insurance services 575,538 545,245 599,031 3,975,183 3,0					, , ,
Milowance for expected redit loss 575,538 545,245 999,031 1,070,890 Increase) decrease in assets and increase (decrease) in liabilities		(2,056,792)	(887,768)		
Contract		- E7E E20	- E4E 04E		
Accounts receivable 1962,528 (1,425,540) (2,020,630) (2,159,768) (1) (1,750) (1,75	Allowance for expected credit loss	5/5,536	545,245	999,031	1,070,890
Inventorios	(Increase) decrease in assets and increase (decrease) in liabilities				
Taxes recoverable					
Judicial deposits 121,875 (48,252 33,261 68,252 75,504					
Other assets 400,476 (43,142) 564,772 79,504 Trade accounts payable (178) 216,976 98,793 285,268 Salaines and social charges 50,482 164,227 144,373 300,835 Tax obligations 125,203 (40,453) 7,264 (23,306) Transactions with related parties 195,983 (555,365) (17,993) (92,540) Provision for contingencies (11,732) (1,273) (12,771) (23,9972) Other liabilities 3650,011 1,318,638 7,653,640 4,125,044 Payment of interest (2,374,535) (2,927,335) (2,367,077) (3,202,801) Payment of income and social contribution taxes 1,275,476 (1,608,697) 4,395,240 532,034 Cash flows from investing activities 1,275,476 (1,608,697) 4,395,240 532,034 Cash flows from investing activities 1,275,476 (1,608,697) 4,395,240 532,034 Cash flows from investing activities 1,275,476 (1,608,697) 4,395,240 532,034			, , ,		
Trade accounts payable 1178 216,976 98,793 285,268 281ains and social charges 50,482 164,227 114,373 30,935 72.00 30,805 72.00 30,8					
Salaries and social charges 50,482 (40,453) (7,284 (23,306)) 144,373 (23,306) 300,835 (23,306) 172,804 (23,306) 172,203 (40,453) (40,453) (23,506) 17,930 (32,540) (23,306) (11,793) (32,540) (11,793) (32,540) (23,506) (11,793) (32,540) (23,717) (239,372) (24,408,300) (24,12,782) (24,412,782) (24,412,782) (24,412,782) (24,127,824) (24,12					
Tax abiligations 125,203 (40,453) 7,284 (23,306) Transactions with related parties 195,983 (555,365) (17,93) (92,540) Provision for contingencies (11,732) (1,273) (312,717) (239,972) Insurance and reinsurance assets (liabilities) 97,257 (28,381) (228,728) (24,728) (24,728) (24,728) (24,728) (28,728) (28,728) (28,738) (28,728) (28,738) (
Transactions with related parties 195,983 (555,365) (17,993) (92,540) Provision for contingencies (11,732) (1,273) (1,273) (239,772) (239,77					
Provision for contingencies 11,732 (1,273) (312,717) (239,972) Insurance and reinsurance assets (liabilities) 97,257 (28,381) (2469,390) (2,412,782) Other liabilities 97,257 (28,381) (228,729) 56,720 3,650,011 1,318,638 7,653,640 4,125,044 Payment of interest (2,374,535) (2,927,335) (2,367,077) (3,202,801) Payment of income and social contribution taxes (2,374,535) (1,608,697) 4,395,240 532,034 Cash from (used in) operating activities 1,275,476 (1,608,697) 4,395,240 532,034 Cash flows from investing activities (2,7706)			· , ,		
Distribution Payment of interest Payment of income and social contribution taxes Payment of income and social contribution Payment of Income and Income and Payment of Income and Income and Payment of In					
Description Payment of interest Payment of income and social contribution taxes Payment of income and social contribution Payment in business acquisition, net of cash acquired Payment of interest		-	(. , = . 0 /		
Payment of interest (2,374,535) (2,927,335) (2,367,077) (3,202,801) Payment of income and social contribution taxes (2,374,535) (2,927,335) (2,367,077) (3,202,801) Payment of income and social contribution taxes (1,275,476 (1,608,697) 4,395,240 532,034 Payment in justinesting activities (1,608,697) 4,395,240 532,034 Cash flows from investing activities (1,608,697) 4,395,240 532,034 Payment in business acquisition, net of cash acquired (1,771) (27,706)		97.257	(28.381)		
Payment of income and social contribution taxes 1,275,476					
Payment of income and social contribution taxes 1,275,476	Dowmant of interest	(2 274 525)	(2.027.225)	(2.267.077)	(2 202 204)
Net cash from (used in) operating activities Cash flows from investing activities Payment in business acquisition, net of cash acquired Receipt upon disposal of equity interest, net of cash Acquisition of equity interest Acquisition of equity interest (1,811,240) (805,252) (805,252) (27,066) (27,066) Addition of property and equipment ((1,811,240) (805,252) (805,252) (27,066) Addition of property and equipment ((770,049) (817,609) (2,034,401) (1,868,874) Addition of intangible assets (31,031) (56,479) (101,621) (168,735) Acquisitions of marketable securities (16,521,659) (16,010,154) (46,931,946) (41,230,597) Redemption of marketable securities (163,261) (845,844) (84,746) (845,844) (845,844) (845,844) (845,844) (845,446) (845,844) (845,446) (845,844) (845,446) (845,843) (846,841,739)		(2,374,333)	(2,921,333)		
Cash flows from investing activities Payment in business acquisition, net of cash acquired Receipt upon disposal of equity interest, net of cash Acquisition of equity interest (27,706) Receipt upon disposal of equity interest, net of cash Acquisition of equity interest (5,000) Future capital contribution (1,811,240) (805,252) - (27,066) Addition of property and equipment (770,049) (817,609) (2,034,401) (1,868,874) Addition of intangible assets (31,031) (56,479) (101,621) (168,735) Acquisitions of marketable securities (16,521,659) (16,010,154) (46,931,946) (41,230,597) Dividends and interest on equity received (603,261) (645,844) (454,746) (454,746) (454,746) (46,931,946) (47,01,929) Dividends and interest on equity received (603,261) (645,844) (454,746) (454,746) (454,746) (454,746) (46,931,946) (47,01,929) (47,01,929) (47,01,541) (48,031,946) (48,041) (48,031,946) (48,041) (48,031,946) (48,041) (48,031,946) (48,041) (48,031,946) (48,041) (48,041) (48,041) (48,041) (48,041) (48,041) (48,041) (4	Taymon of moonie and oodie, continuation takes			(001,020)	(000,200)
Payment in business acquisition, net of cash acquired Receipt upon disposal of equity interest, net of cash 147,719 - 147,135 - (5,000) Future capital contribution Future capital contribution (1,811,240) (805,252) - (27,066) Addition of property and equipment (770,049) (817,609) (2,034,401) (1,868,874) Addition of intangible assets (31,031) (56,479) (101,621) (168,735) Acquisitions of marketable securities (16,521,659) (16,010,154) (46,931,946) (41,230,597) Redemption of marketable securities 18,569,145 18,317,863 48,478,827 45,001,929 Dividends and interest on equity received 603,261 645,844 14,966 6,465 Net cash flows used in investing activities Treasury shares Treasury shares Treasury shares Treasury shares (341,739) - (341,739) Fayment of dividends and interest on equity (641,063) (113,758) (712,412) (161,690) Loans, financing and debentures raised 2,000,000 3,914,594 2,518,901 4,528,333 Payment of loans, financing and debentures (Settlement) receipt of swap Accounts payable for acquisitions (Settlement) receipt of swap Accounts payable for acquisitions (1,863,819) (2,932,949) (2,570,631) (3,771,651) (Settlement) receipt of swap Accounts payable for acquisitions (1,223,599) 491,456 (1,708,647) 58,888	Net cash from (used in) operating activities	1,275,476	(1,608,697)	4,395,240	532,034
Payment in business acquisition, net of cash acquired Receipt upon disposal of equity interest, net of cash 147,719 - 147,135 - (5,000) Future capital contribution Future capital contribution (1,811,240) (805,252) - (27,066) Addition of property and equipment (770,049) (817,609) (2,034,401) (1,868,874) Addition of intangible assets (31,031) (56,479) (101,621) (168,735) Acquisitions of marketable securities (16,521,659) (16,010,154) (46,931,946) (41,230,597) Redemption of marketable securities 18,569,145 18,317,863 48,478,827 45,001,929 Dividends and interest on equity received 603,261 645,844 14,966 6,465 Net cash flows used in investing activities Treasury shares Treasury shares Treasury shares Treasury shares (341,739) - (341,739) Fayment of dividends and interest on equity (641,063) (113,758) (712,412) (161,690) Loans, financing and debentures raised 2,000,000 3,914,594 2,518,901 4,528,333 Payment of loans, financing and debentures (Settlement) receipt of swap Accounts payable for acquisitions (Settlement) receipt of swap Accounts payable for acquisitions (1,863,819) (2,932,949) (2,570,631) (3,771,651) (Settlement) receipt of swap Accounts payable for acquisitions (1,223,599) 491,456 (1,708,647) 58,888	Cash flows from investing activities				
Receipt upon disposal of equity interest, net of cash 147,719 - 147,135 -		-	-	(27.706)	-
Future capital contribution (1,811,240) (805,252) - (27,066) Addition of property and equipment (770,049) (817,609) (2,034,401) (1,868,874) Addition of intangible assets (31,031) (56,479) (101,621) (168,735) Acquisitions of marketable securities (16,521,659) (16,010,154) (46,931,946) (41,230,597) Redemption of marketable securities 18,569,145 18,317,863 48,478,827 45,001,929 Dividends and interest on equity received 603,261 645,844 14,966 6,465		147,719	-		-
Addition of property and equipment (770,049) (817,609) (2,034,401) (1,868,874) Addition of intangible assets (31,031) (56,479) (101,621) (168,735) Acquisitions of marketable securities (16,521,659) (16,010,154) (46,931,946) (41,230,597) Redemption of marketable securities Dividends and interest on equity received (603,261) (645,844) (44,946) (44,230,597) Redemption of marketable securities (603,261) (645,844) (44,946) (44,230,597) Redemption of marketable securities (603,261) (645,844) (454,746) (454,	Acquisition of equity interest	· -	-	· •	(5,000)
Addition of intangible assets	Future capital contribution	(1,811,240)	(805,252)	-	(27,066)
Acquisitions of marketable securities Redemption of feet, 45,45,444 Redemption of feet, 45,45,445 Rede					
Redemption of marketable securities 18,569,145 18,317,863 48,478,827 45,001,929 19,0			* ' '	• • •	
Dividends and interest on equity received 603,261 645,844 14,966 6,465 Net cash flows used in investing activities 186,146 1,274,213 (454,746) 1,708,122 Cash flows from financing activities Treasury shares (341,739) - (341,739) - (341,739) - (341,739) - (341,739) - (161,690) Loans, financing and debentures raised 2,000,000 3,914,594 2,518,901 4,528,333 Payment of loans, financing and debentures (1,863,819) (2,932,949) (2,570,631) (3,771,651) (Settlement) receipt of swap (376,978) (376,431) (541,311) (526,208) Accounts payable for acquisitions - - - (61,455) (9,896) Net cash from financing activities (1,223,599) 491,456 (1,708,647) 58,888 Increase in cash and cash equivalents 238,023 156,972 2,231,847 2,299,044 Cash and cash equivalents at beginning of period 257,423 96,360 3,267,408 1,109,796					
Net cash flows used in investing activities Treasury shares Payment of dividends and interest on equity Loans, financing and debentures raised Payment of loans, financing and debentures raised Payment of loans, financing and debentures (1,863,819) (2,932,949) (2,570,631) (3,771,651) (Settlement) receipt of swap Accounts payable for acquisitions (1,223,599) Accounts from financing activities (1,708,647)					
Cash flows from financing activities Treasury shares Payment of dividends and interest on equity Loans, financing and debentures raised Payment of loans, financing and debentures (1,863,819) (2,932,949) (2,570,631) (3,771,651) (Settlement) receipt of swap Accounts payable for acquisitions Net cash from financing activities (1,223,599) Accounts and cash equivalents (1,223,599) Accounts and a	· ·				
Treasury shares (341,739) - (341,739) - (161,690) Payment of dividends and interest on equity (641,063) (113,758) (712,412) (161,690) Loans, financing and debentures raised 2,000,000 3,914,594 2,518,901 4,528,333 Payment of loans, financing and debentures (1,863,819) (2,932,949) (2,570,631) (3,771,651) (Settlement) receipt of swap (376,978) (376,431) (541,311) (526,208) Accounts payable for acquisitions - - (61,455) (9,896) Net cash from financing activities (1,223,599) 491,456 (1,708,647) 58,888 Increase in cash and cash equivalents 238,023 156,972 2,231,847 2,299,044 Cash and cash equivalents at beginning of period 257,423 96,360 3,267,408 1,109,796	ver cash hows used in investing activities	100,140	1,414,413	(+3+,1+0)	1,100,122
Payment of dividends and interest on equity (641,063) (113,758) (712,412) (161,690) Loans, financing and debentures raised 2,000,000 3,914,594 2,518,901 4,528,333 Payment of loans, financing and debentures (1,863,819) (2,932,949) (2,570,631) (3,771,651) (Settlement) receipt of swap (376,978) (376,431) (541,311) (526,208) Accounts payable for acquisitions - - (61,455) (9,896) Net cash from financing activities (1,223,599) 491,456 (1,708,647) 58,888 Increase in cash and cash equivalents 238,023 156,972 2,231,847 2,299,044 Cash and cash equivalents at beginning of period 257,423 96,360 3,267,408 1,109,796	Cash flows from financing activities				
Loans, financing and debentures raised 2,000,000 3,914,594 2,518,901 4,528,333 Payment of loans, financing and debentures (1,863,819) (2,932,949) (2,570,631) (3,771,651) (Settlement) receipt of swap (376,978) (376,431) (541,311) (526,208) Accounts payable for acquisitions - - - (61,455) (9,896) Net cash from financing activities (1,223,599) 491,456 (1,708,647) 58,888 Increase in cash and cash equivalents 238,023 156,972 2,231,847 2,299,044 Cash and cash equivalents at beginning of period 257,423 96,360 3,267,408 1,109,796			-		-
Payment of loans, financing and debentures (1,863,819) (2,932,949) (2,570,631) (3,771,651) (Settlement) receipt of swap (376,978) (376,431) (541,311) (526,208) Accounts payable for acquisitions - - - (61,455) (9,896) Net cash from financing activities (1,223,599) 491,456 (1,708,647) 58,888 Increase in cash and cash equivalents 238,023 156,972 2,231,847 2,299,044 Cash and cash equivalents at beginning of period 257,423 96,360 3,267,408 1,109,796					
(Settlement) receipt of swap Accounts payable for acquisitions (376,978) (376,431) (541,311) (526,208) Net cash from financing activities - - - (61,455) (9,896) Increase in cash and cash equivalents 238,023 156,972 2,231,847 2,299,044 Cash and cash equivalents at beginning of period 257,423 96,360 3,267,408 1,109,796					
Accounts payable for acquisitions - (61,455) (9,896) Net cash from financing activities (1,223,599) 491,456 (1,708,647) 58,888 Increase in cash and cash equivalents 238,023 156,972 2,231,847 2,299,044 Cash and cash equivalents at beginning of period 257,423 96,360 3,267,408 1,109,796					
Net cash from financing activities (1,223,599) 491,456 (1,708,647) 58,888 Increase in cash and cash equivalents 238,023 156,972 2,231,847 2,299,044 Cash and cash equivalents at beginning of period 257,423 96,360 3,267,408 1,109,796		(3/6,9/6)	(3/0,431)		
Increase in cash and cash equivalents 238,023 156,972 2,231,847 2,299,044 Cash and cash equivalents at beginning of period 257,423 96,360 3,267,408 1,109,796	· ·	(1 223 599)	491 456		
Cash and cash equivalents at beginning of period 257,423 96,360 3,267,408 1,109,796	Tot odon non initiationing doublines	(1,220,000)	701,700	(1,700,047)	30,000
	Increase in cash and cash equivalents	238,023	156,972	2,231,847	2,299,044
Cash and cash equivalents at end of period 495,446 253,332 5,499,255 3,408,840	Cash and cash equivalents at beginning of period	257,423		3,267,408	1,109,796
	Cash and cash equivalents at end of period	495,446	253,332	5,499,255	3,408,840

Statements of value added Nine-month periods ended September 30, 2024 and 2023 (In thousands of reais, unless otherwise stated)

	Indi	vidual	Consolidated		
	09/30/2024	09/30/2023	09/30/2024	09/30/2023	
Revenue	11,537,169	10,526,238	39,298,521	36,023,202	
Sales of goods, products and services	12,109,767	11,068,543	18,482,512	17,166,858	
Revenues from insurance operations	-	=	21,738,411	19,804,284	
Allowance for expected credit loss	(575,538)	(545,245)	(999,031)	(1,070,890)	
Other revenues	2,940	2,940	76,629	122,950	
Benefits and claims	-	-	(14,738,678)	(14,516,046)	
Expenses with benefits and redemptions	-	=	(14,738,678)	(14,516,046)	
Inputs acquired from third parties	(3,819,283)	(3,454,078)	(9,038,062)	(8,415,121)	
Costs of sales	(3,961,173)	(3,664,057)	(8,598,268)	(7,940,271)	
Materials, power, third-party services and other expenses	77,021	(221,743)	(175,008)	(673,415)	
Loss on/recovery of assets	64,869	431,722	(264,786)	198,565	
Gross value added	7,717,886	7,072,160	15,521,781	13,092,035	
Depreciation and amortization	(695,348)	(664,927)	(1,198,839)	(1,224,373)	
Net value added	7,022,538	6,407,233	14,322,942	11,867,662	
Value added received in transfer	3,860,927	3,636,823	3,931,991	6,961,402	
Equity pickup	2,056,792	887,768	34,143	(2,178)	
Finance income	1,804,135	2,749,055	5,537,007	8,582,006	
Finance income (costs) from insurance contracts		-	(1,639,159)	(1,618,426)	
Total value added	10,883,465	10,044,056	18,254,933	18,829,064	
Value added distributed	(10,883,465)	(10,044,056)	(18,254,933)	(18,829,064)	
Personnel and charges	(3,404,109)	(2,977,247)	(6,661,954)	(6,101,363)	
Taxes, charges and contributions	(524,731)	(599,062)	(2,325,165)	(1,628,797)	
Interest, rents and other operating expenses	(4,032,705)	(5,195,182)	(6,268,478)	(9,776,677)	
Dividends and interest on equity	(1,000,000)	(416,288)	(1,065,263)	(469,251)	
Retained profits	(1,921,920)	(856,277)	(1,934,073)	(852,976)	

Notes to interim financial information September 30, 2024 (In thousands of reais, unless otherwise stated)

1. Operations

Rede D'Or São Luiz S.A. (the "Company" or "Parent Company" and jointly with its subsidiaries "Rede D'Or" or "Group"), headquartered at Rua Francisco Marengo, 1312, in the city and state of São Paulo, is engaged in the rendering of hospital services, offering assistance and hospitality concepts, creating medical and diagnostic excellence centers and generating medical knowledge and experience that ensure security to customers, either doctors, patients or healthcare plans. Through its subsidiaries and associates, the Company operates in the health (health and dental insurance, administrative services only (ASO) health and dental plans, and health and wellness solutions), life insurance, private pension, and asset management segments.

Rede D'Or operates in the states of Rio de Janeiro, São Paulo, Pernambuco, Maranhão, Bahia, Sergipe, Paraná, Ceará, Minas Gerais, Mato Grosso do Sul, Paraíba, Alagoas, Pará and the Federal District, with 71 own hospitals in operation and approximately 40 projects under development, in addition to oncology and radiotherapy clinics and laboratories. Currently, the Group has 9,830 hospital beds in total.

The first hospital unit, Hospital Barra D'Or, was opened in 1998, and Hospital Copa D'Or and Hospital Quinta D'Or were opened in 2000 and 2001, respectively. Since 2004, strategic partnerships have been made with other hospitals, thus increasing its range of expertise and reaching other areas in Rio de Janeiro. Also through partnerships and acquisitions, Rede D'Or started operations in the state of Pernambuco in 2007; in the states of Maranhão and Bahia in 2018; in the state of Sergipe in 2019; in the states of Paraná and Ceará in 2020; in the states of Minas Gerais, Mato Gross do Sul and Paraíba in 2021; and in the state of Alagoas in 2022.

In December 2022, the business combination between the Company and Sul América S.A. was completed through the merger of Sul América S.A. into Rede D'Or. As a result of the merger, Sul América S.A. was dissolved and succeeded by Rede D'Or as regards all its assets, rights and obligations, and Rede D'Or became the parent company of Sul América Group ("SASA" or "Sul América" - comprising the subsidiaries, associates and investment funds remaining from the merger of Sul América S.A.). Thus, since December 23, 2022, the shares of Sul América S.A. are no longer traded on B3 and the former shareholders of Sul América S.A. have become shareholders of the Company.

Seasonality

There are no significant seasonal effects on the Company's operations; however, a smaller volume of customers and, consequently, of claims in the insurance and health insurance businesses, is generally observed in December, January and February due to year-end celebrations and vacation period, and a larger volume of customers is observed in Winter.

Notes to interim financial information September 30, 2024 (In thousands of reais, unless otherwise stated)

1. Operations (Continued)

D'Or Consultoria Sale

On August 1, 2024, the Company concluded the sale of all of its stake held in the share capital of JTO Holding S.A., JTO Fundadores Participações LTDA and Rede D'Or São Luiz Soluções Corporativas em Saúde e Segurança do Trabalho Ltda. (such companies together, called "D'Or Consultoria") to MDS Corretora e Administradora de Seguros S.A. ("MDS"). The total enterprise value was R\$800,000, from which were deducted (i) the net debt; (ii) the acquisition of minority shareholders' interests; and (iii) related parties' transactions with the Company, totaling amount of the final sale R\$ 377,633, resulting in a gain of R\$ 354,103, recorded on Other operating income (expenses), net. The Company received, on the closing date, the amount of R\$ 223.495 related with related parties' transactions with the Company, the first installment of R\$147,719 and the remaining amount will be paid in three variable annual installments, restated by reference to the Extended Consumer Price Index (IPCA), pursuant to metrics established in the contract.

Notes to interim financial information (Continued) September 30, 2024 (In thousands of reais, unless otherwise stated)

2. Accounting policies

This individual and consolidated interim financial information was prepared in accordance with Accounting Pronouncement (CPC) 21 (R1) - Interim Financial Reporting, issued by the Brazilian Financial Accounting Standards Board - FASB ("CPC"), and in accordance with IAS 34 - Interim Financial Reporting, issued by the International Accounting Standards Board (IASB), and is presented in accordance with the rules issued by the Brazilian Securities and Exchange Commission ("CVM") applicable to the preparation of Quarterly Information (ITR). The statements of value added are presented as supplementary information for IFRS purposes.

The accounting policies as well as estimates and critical accounting judgments adopted by the Group in this interim financial information are consistent with those adopted in the financial statements for the year ended December 31, 2023, disclosed on March 26, 2024.

P&L for the nine-month period ended September 30, 2024 does not necessarily indicate the P&L expected for the entire year ending December 31, 2024. The interim financial information and related notes do not include all the information and disclosures required for the annual financial statements. As such, this interim financial information must be read together with the audited annual financial statements as of December 31, 2023.

Authorization to complete the preparation of this interim financial information was given by the Company management on November 12, 2024.

The individual and consolidated financial statements include the operations of the Company and of its subsidiaries, presented in Note 8. Additionally, on September 30, 2024, the Company has investments in funds of one that are fully consolidated.

Notes to interim financial information (Continued) September 30, 2024 (In thousands of reais, unless otherwise stated)

3. Business combination

On February 23, 2024, Rede D'Or, through its subsidiary GSH Corp Participações S.A., acquired 50.01% equity interest in R2 IBF Participações S/A, generating goodwill in the amount of R\$11,918. In 2023, the Company acquired 50.00% equity interest in YUCA Administração de bens Ltda., generating goodwill of R\$31,468. The outstanding payables are guarantees for certain liabilities assumed by the sellers (e.g. materialization of contingencies) and will be paid within six years on average after their execution dates, restated by reference to the Interbank Deposit Certificate (CDI), the Extended Consumer Price Index (IPCA) and the Central Bank benchmark rate (SELIC) included in the balance of "Accounts payable for acquisitions".

Notes to interim financial information (Continued) September 30, 2024 (In thousands of reais, unless otherwise stated)

4. Cash and cash equivalents and marketable securities

4.1. Cash and cash equivalents

	Indiv	ridual	Conso	lidated
	09/30/2024	12/31/2023	09/30/2024	12/31/2023
Cash and cash equivalents				
Cash and banks	34,581	34,391	155,383	190,162
Short-term investments	460,865	223,032	5,343,872	3,077,246
Cash and cash equivalents	495,446	257,423	5,499,255	3,267,408

Short-term investments classified as cash equivalents mature within three months from the investment date.

4.2. Marketable securities

Short-term investments are broken down in the table below, which shows their respective accounting classifications, curve value and market value, as well as the contractual average rates:

Description	Fair value through profit or loss Market value/ carrying amount	Average interest rate	Individual 09/30/2024 Total
Fixed income securities - corporate bonds Bank deposit certificates Floating rate CDI	7,839,618 7,813,160	- 103.05% CDI	7,839,618 7,813,160
Financial bills Floating rate CDI	20, 450		20, 450
ŭ	26,458	101.42% CDI	26,458
Investment fund shares	66	-	66
Investment fund shares – other than funds of one	66	- <u>-</u>	66
		_	7,839,684
		Current	7,839,684
		Noncurrent	-

Notes to interim financial information (Continued) September 30, 2024 (In thousands of reais, unless otherwise stated)

4. Cash and cash equivalents and marketable securities (Continued)

4.2. Marketable securities (Continued)

	Fair value through profit or loss	-	Individual 12/31/2023
Description	Market value/ carrying amount	Average interest rate	Total
Fixed income securities - corporate bonds Bank deposit certificates	9,239,574	-	9,239,574
Floating rate CDI	9,239,574	104.20% CDI	9,239,574
Investment fund shares	302	-	302
Investment fund shares - other than funds of one	302	-	302
		_	9,239,876
		Current	9,239,876
		Noncurrent	-

Notes to interim financial information (Continued) September 30, 2024 (In thousands of reais, unless otherwise stated)

4. Cash and cash equivalents and marketable securities (Continued)

4.2. Marketable securities (Continued)

	Fair value through	Falancelos (bassado a (b		A		_	Consolidated
-	profit or loss Market value/	Fair value through other	er comprehensive income Market value/	Amortized	cost	_ Average	09/30/2024
Description		0		Curve value/carrying	Manhatanha	•	T-1-1
Description	carrying amount	Curve value	carrying amount	amount	Market value	interest rate (a)	Total
Fixed income securities - corporate bonds Bank deposit certificates	14,191,789	1,545,160	1,567,815	-	-	-	15,759,604
Floating rate CDI % Debentures	10,483,095	101,729	101,729		-	102.98% CDI	10,584,824
Floating rate CDI +	1.583.270	318.197	326.847	-		CDI+1.84% p.a.	1,910,117
Floating rate CDI %	11,842	28,208	27,903	-		121.44% CDI	39,745
Floating rate IPCA	465	,	,		_	IPCA+7.66% p.a.	465
Floating rate IGP-M	-	103,790	100,027		_	IGPM+5.84% p.a.	100,027
Financial bills		100,770	100,027			101 111 0.0 170 p.a.	100,027
Floating rate CDI +	1,437,831	407,018	424,031	_		CDI+1.09% p.a.	1,861,862
Floating rate CDI %	613.043	555,871	556,398		_	112.47% CDI	1,169,441
Promissory notes	5.797	30,347	30,880			CDI+1.57% p.a.	36,677
Mortgage-backed Securities ("CRI")	3,403	30,347	30,000	_		15% p.a.	3,403
Time deposits with special guarantee (DPGE)	53,043					CDI+0.58% p.a.	53,043
Fixed income securities - government						0D110.3070 p.u.	
securities	6,931,974	1,451,399	1,379,050	1,813,695	1,786,806		10,124,719
Financial treasury bills	6,601,634	122,133	122,197	-	_	SELIC	6,723,831
National treasury bills	-,,	,	,				-,,
Fixed rate	204,826	-	-	-	-	12.44% p.a.	204,826
National treasury notes						•	
Series F- Fixed rate	614	33,127	31,441	-	-	8.87% p.a.	32,055
Series B – Floating rate IPCA	42,128	945,561	885,304	67,758	65,870	IPCA+4.65% p.a.	995,190
Series C – Floating rate IGP-M	82,772	350,578	340,108	1,745,937	1,720,936	IGPM+5.78% p.a.	2,168,817
Variable income securities	197,052	-	-	-	-	-	197,052
Shares	196,980	-	-	-	-	-	196,980
Impairment	72	-	-	-	-	-	72
Investment fund shares	5,380,399	-	-	-	-	-	5,380,399
Fixed income, equity and multi-market investment fund shares	5,351,815	-	-	-	-	-	5,351,815
Equity fund shares	28,584	-	-	-	-	-	28,584
Other investments	4,121	-	-	-	-	· <u>-</u>	4,121
						_	31,465,895
						Current	29,679,716
						Noncurrent	1,786,179

Notes to interim financial information (Continued) September 30, 2024 (In thousands of reais, unless otherwise stated)

4. Cash and cash equivalents and marketable securities (Continued)

4.2. Marketable securities (Continued)

	Fair value through					_	Consolidated
	profit or loss	Fair value through other	Fair value through other comprehensive income		cost		12/31/2023
	Market value/		Market value/	Curve value/carrying		Average	
Description	carrying amount	Curve value	carrying amount	amount	Market value	interest rate (a)	Total
Fixed income securities - corporate bonds	13,891,753	1,254,080	1,254,429	-	-		15,146,182
Bank deposit certificates							
Floating rate CDI %	11,412,274	<u>-</u>	-	-	-	104.16% CDI	11,412,274
Debentures							
Fixed rate	197	-	-	-	-	16.28% p.a.	197
Floating rate CDI +	1,081,082	160,148	161,153	-	-	CDI+1.65% p.a.	1,242,235
Floating rate CDI %	46,727	68,673	68,495	-	-	114.08% CDI	115,222
Floating rate IPCA	458	<u>-</u>	-	-	-	IPCA+6.9% a.a.	458
Financial bills							
Floating rate CDI +	816,238	383,582	387,178	-	-	CDI+1.7% p.a.	1,203,416
Floating rate CDI %	486.190	606.882	602,798	-	-	113.81% CDI	1,088,988
Promissory notes	107	34,795	34,805	-	-	CDI+1.66% p.a.	34,912
Time deposits with special guarantee (DPGE)	48,480	· -	· -	-	-	CDI+1.18% p.a.	48,480
Fixed income securities - government	•					•	,
securities	6.458.430	1,384,546	1,351,377	1,755,978	1,788,512	-	9,565,785
Financial treasury bills	6,125,439	113,055	113,072	-	-	SELIC	6,238,511
National treasury bills	-, -,	-,	-,-				-,,-
Fixed rate	199,940	2.174	2,168	-		9.72% p.a.	202,108
National treasury notes	,-	•	,				. ,
Series F- Fixed rate	654	34.128	33,450	-	-	8.85% p.a.	34,104
Series B - Floating rate IPCA	43,687	1,094,244	1,063,243	66,631	73,357	IPCA+4.47% p.a.	1,173,561
Series C - Floating rate IGP-M	88,710	140,945	139,444	1,689,347	1,715,155	IGPM+5.77% p.a.	1,917,501
Variable income securities	226,069		,	-	-	-	226,069
Shares	226,104	146	146	-		-	226,250
Impairment	(35)	(146)	(146)	-	_	-	(181)
Investment fund shares	5,216,366	(1.15)	-	-	-	-	5,216,366
Fixed income, equity and multi-market	-,,						-,,
investment fund shares	5,181,786	-	-	<u>-</u>	_	-	5,181,786
Equity fund shares	34,580	-	-	-	-	-	34,580
Other investments	11,940	-	-	<u>-</u>	_	-	11,940
	11,010					-	30,166,342
						Current	28,463,882
						Noncurrent	28,463,882 1 702 460

The amounts classified as marketable securities refer to securities maturing after three months, with substantially immediate liquidity.

Notes to interim financial information (Continued) September 30, 2024 (In thousands of reais, unless otherwise stated)

5. Accounts receivable

		Indiv	ridual 💮	Consolidated		
Description	Note	09/30/2024	12/31/2023	09/30/2024	12/31/2023	
Accounts receivable - hospital services	5,1	5,227,784	4,840,796	8,758,572	7,939,681	
Other accounts receivable	5,2	-	-	2,884,036	2,673,832	
		5,227,784	4,840,796	11,642,608	10,613,513	
Current		5,227,784	4,840,796	9,874,005	8,939,144	
Noncurrent		-	-	1,768,603	1,674,369	

5.1. Hospital services

Trade accounts receivable comprise receivables from healthcare companies and individuals, as follows:

	Indiv	idual	Consolidated		
	09/30/2024	12/31/2023	09/30/2024	12/31/2023	
Accounts receivable from health insurance and health plans	6,607,850	5,649,437	10,835,314	9,313,213	
Accounts receivable from individuals Allowance for expected credit losses and provision	141,697	137,584	281,653	274,185	
for disallowances	(1,521,763)	(946,225)	(2,358,395)	(1,647,717)	
	5,227,784	4,840,796	8,758,572	7,939,681	

Changes in provision for disallowances and allowance for expected credit losses

	Indiv	idual	Consolidated		
- -	09/30/2024	09/30/2023	09/30/2024	09/30/2023	
Balance at beginning of period	(946,225)	(843,770)	(1,647,717)	(1,477,168)	
Set up of provision for disallowances and allowance for expected credit losses	(575,538)	(545,245)	(989,262)	(1,053,660)	
Write-offs (a) Balance at end of period	- (1,521,763)	428,509 (960,506)	278,584 (2,358,395)	877,412 (1,653,416)	

⁽a) Write-offs include the derecognition of uncollectible amounts and elimination of the provision for disallowances of the Group companies.

Notes to interim financial information (Continued) September 30, 2024 (In thousands of reais, unless otherwise stated)

5. Accounts receivable

5.1. Hospital services (Continued)

<u>Changes in provision for disallowances and allowance for expected credit losses</u> (Continued)

At September 30, 2024 and December 31, 2023, the aging list of trade accounts receivable is as follows:

		Individual										
	Overdue											
	Total	Falling due	1 - 30 days	31 - 60 days	61 - 90 days	91 - 120 days	121 - 180 days	181 - 360 days	360 - 720 days			
09/30/2024 12/31/2023	6,749,547 5.787.021	3,907,311 3.872.484	163,490 124.381	239,179 149,745	196,138 157,292	216,195 69.848	477,378 256.869	692,667 505,329	857,189 651.073			

				U.	onsolidated				
		_				Overdue			
		_	1 -	31 -	61 -	91 -	121 -	181 -	360 -
	Total	Falling due	30 days	60 days	90 days	120 days	180 days	360 days	720 days
09/30/2024	11,116,967	5,811,204	445,147	401,453	430,559	317,965	746,031	1,246,151	1,718,457
12/31/2023	9,587,398	5,935,957	265,208	246,311	254,297	177,761	399,362	1,040,609	1,267,893

The Company's revenues arise from the provision of hospital services, including the use of medicines and hospital materials. Revenue is recognized to the extent that it is probable that the economic benefits will flow to the Company and the revenue can be reliably measured, i.e. upon rendering of medical services at an amount that reflects the consideration to which an entity expects to be entitled in exchange for providing services to a customer.

Changes in provision for disallowances and allowance for expected credit losses

The provision for disallowances and allowance for expected credit losses is presented reducing the balance of accounts receivable and recognized at an amount deemed sufficient by management to cover any expected losses on the realization of amounts billed.

The Company's criterion to recognize a provision for disallowances is to annually analyze the performance of notes overdue between 360 to 720 days, a period deemed sufficient for exhausting the collection process. The percentage reached is applied to the gross revenue recorded and recognized as a provision in current profit or loss, reflecting management's best expectation based on the analyzed history. The analysis is made individually by cash-generating unit, as well as the percentage recorded as a provision for disallowances in the year.

Notes to interim financial information (Continued) September 30, 2024 (In thousands of reais, unless otherwise stated)

5. Accounts receivable (Continued)

5.1. Hospital services (Continued)

<u>Changes in provision for disallowances and allowance for expected credit losses</u> (Continued)

As a criterion for the recognition of an allowance for expected credit losses, an individual analysis of receivables is performed to identify specific counterparty risks. If necessary, an allowance for expected credit losses is recorded for the partial or total balance of receivables outstanding of these customers.

5.2. Other accounts receivable

The receivables as at September 30, 2024 and December 31, 2023 presented in the consolidated financial statements are as follows:

		Consolidated			
Description	Note	09/30/2024	12/31/2023		
Other operating receivables Consideration receivable – pension plan	5.2.1	1,974,566	1,938,788		
administrator	5.2.2	791,244	601,109		
Other (a)		118,226	133,935		
		2,884,036	2,673,832		
Current		1,115,433	999,463		
Noncurrent		1,768,603	1,674,369		

⁽a) The "Other" balance is represented mainly by receivables related to real estate commitments and receivables not directly related to insurance operations, in subsidiaries that operate in this industry.

5.2.1. Other operating receivables

	Consolidated			
	09/30/2024	12/31/2023		
Receivables from FCVS - SFH				
Principal (Note 5.2.1.1)	2,046,802	1,963,933		
Impairment (Note 5.2.1.1)	(233,105)	(223,473)		
Frozen funds (a)	83,609	74,483		
Other (b)	77,260	123,845		
Total	1,974,566	1,938,788		
Current	211,005	270,146		
Noncurrent	1,763,561	1,668,642		

⁽a) These refer to funds frozen in bank accounts and investment funds due to lawsuits; and

⁽b) The balance of "Other" is mainly represented by advances to suppliers.

Notes to interim financial information (Continued) September 30, 2024 (In thousands of reais, unless otherwise stated)

5. Accounts receivable (Continued)

5.2. Other accounts receivable (Continued)

5.2.1. Other operating receivables (Continued)

5.2.1.1. Receivables from FCVS - SFH

	Consolidated
Description	09/30/2024
Balance of receivables FCVS-SFH at 12/31/2023	1,963,933
Additions	158,421
Write-offs	(75,552)
Balance of receivables FCVS-SFH at 09/30/2024	2,046,802
Balance of impairment at 09/30/2024	(233,105)
Closing balance net of impairment at 09/30/2024	1,813,697
	405.004
Current	125,231
Noncurrent	1,688,466
	Consolidated
Description	Consolidated 12/31/2023
<u> </u>	12/31/2023
Balance of receivables FCVS-SFH at 12/31/2022	12/31/2023 1,921,639
Balance of receivables FCVS-SFH at 12/31/2022 Additions	12/31/2023 1,921,639 266,755
Balance of receivables FCVS-SFH at 12/31/2022 Additions Write-offs	1,921,639 266,755 (224,461)
Balance of receivables FCVS-SFH at 12/31/2022 Additions	12/31/2023 1,921,639 266,755
Balance of receivables FCVS-SFH at 12/31/2022 Additions Write-offs	1,921,639 266,755 (224,461)
Balance of receivables FCVS-SFH at 12/31/2022 Additions Write-offs Balance of receivables FCVS-SFH at 12/31/2023	12/31/2023 1,921,639 266,755 (224,461) 1,963,933
Balance of receivables FCVS-SFH at 12/31/2022 Additions Write-offs Balance of receivables FCVS-SFH at 12/31/2023 Balance of impairment at 12/31/2023 Closing balance net of impairment at 12/31/2023	12/31/2023 1,921,639 266,755 (224,461) 1,963,933 (223,473) 1,740,460
Balance of receivables FCVS-SFH at 12/31/2022 Additions Write-offs Balance of receivables FCVS-SFH at 12/31/2023 Balance of impairment at 12/31/2023	12/31/2023 1,921,639 266,755 (224,461) 1,963,933 (223,473)

Notes to interim financial information (Continued) September 30, 2024 (In thousands of reais, unless otherwise stated)

5. Accounts receivable (Continued)

- **5.2.** Other accounts receivable (Continued)
 - 5.2.1. Other operating receivables (Continued)
 - 5.2.1.1. Receivables from FCVS SFH (Continued)

As at September 30, 2024, there are lawsuits related to the Housing Financial System (SH/SFH) in progress in which the Company has been summoned. Such lawsuits may give rise to future cash disbursement with the corresponding request for reimbursement to Caixa Econômica Federal (CAIXA), manager of the Wage Variation Compensation Fund (FCVS). In the cases in which the lawsuit is in the provisional enforcement phase to avoid early disbursement in cases whose decisions are not final and unappealable, the Company pledges in court surety bond policies. As at September 30, 2024, the total amount guaranteed through surety bond is R\$1,104,950 (R\$1,184,025 at December 31, 2023). The SH/SFH was created by article 14 of Law No. 4380/1964, and since 1967 has been guaranteed by the FCVS. Insurance companies have lawsuits filed against them because they are mischaracterized as representatives of the FCVS. which is the role of CAIXA, the manager of that Fund. In view of this role of FCVS representative in lawsuits, the insurance companies, which are the illegitimate parties, are entitled to receive reimbursements for all incurred expenditures. Law No. 12409/2011, amended by Law No. 13000/2014, as well as the CCFCVS Resolution No. 364 of March 28, 2014, expressly establish the responsibility of FCVS, through its manager CAIXA, for all lawsuits relating to the SH/SFH's public policy. In September 2018, the Federal Supreme Court (STF) recognized the general repercussion of the appeal to the Supreme Court filed by the Company to analyze the jurisdiction of the Federal Court in lawsuits of this nature. In June 2020, the merits of that appeal were judged and accepted to consolidate the interest of CAIXA, the FCVS administrator, in the SH/SFH-related lawsuits, and, consequently, establish the Federal Court's jurisdiction for processing and judging lawsuits of this nature. That appeal became final and unappealable on June 17, 2023. Currently, insurance companies are reimbursed by the FCVS for payments made in connection with SH/SFH-related lawsuits. based on the criteria established by Resolution CCFCVCS No. 448/2019 and restated by reference to the variation of the Referential Rate ("TR") between the date of payment of each expense and the date of effective reimbursement.

Notes to interim financial information (Continued) September 30, 2024 (In thousands of reais, unless otherwise stated)

5. Accounts receivable (Continued)

5.2. Other accounts receivable (Continued)

5.2.2. Consideration receivable - ASO health plans

Administrative service only (ASO) health plans are plans in which the Company administers medical and hospital expenses on behalf of its customers, and is fully reimbursed by the customers, recording only its administration fee as revenue. The amounts related to consideration receivable by maturity are as follows:

	Conso	Consolidated			
	09/30/2024	12/31/2023			
Falling due					
Falling due from 1 to 30 days	684,550	529,669			
Falling due from 31 to 60 days	35,275	33,325			
Falling due from 61 to 180 days	9,196	7,672			
Falling due from 181 to 365 days	-	2,985			
Total falling due	729,021	573,651			
Past due					
Overdue from 1 to 30 days	61,772	26,518			
Overdue from 31 to 60 days	254	128			
Overdue from 61 to 180 days	270	334			
Overdue from 181 to 365 days	34	21			
Overdue for more than 365 days	2,969	3,463			
Total	65,299	30,464			
Provision for impairment	(3,076)	(3,006)			
Total overdue	62,223	27,458			
Total unearned premiums	794,320	604,115			
Total provision for impairment	(3,076)	(3,006)			
Total	791,244	601,109			

6. Inventories

	Indiv	ridual	Consolidated		
	09/30/2024	12/31/2023	09/30/2024	12/31/2023	
Medicines	111,893	129,465	259,836	264,475	
Special materials	95,382	84,610	152,833	136,935	
Disposable materials	87,907	91,573	151,063	152,594	
Consumables	17,463	13,739	59,856	40,942	
Laboratory materials	7,824	5,071	24,886	18,127	
Surgical sutures	6,236	6,514	11,613	11,047	
Dressing room materials	2,783	2,936	10,292	10,165	
Food stuff	4,221	3,519	10,045	8,784	
Other	24,417	28,366	63,036	62,827	
	358,126	365,793	743,460	705,896	
	=======================================				

Notes to interim financial information (Continued) September 30, 2024 (In thousands of reais, unless otherwise stated)

7. Transactions with related parties

Significant related-party transactions

The nature of significant related-party transactions is summarized below:

- (i) Leases the Company leases properties owned by the controlling shareholders, namely: properties of the hospitals Copa D'Or and Quinta D'Or, and the property of the administrative unit. Leases are at market value and generated an expense in profit or loss for the period ended September 30, 2024 of R\$23,141 (R\$24,059 at September 30, 2023) referring to interest and amortization of the right of use. Leases are annually restated by reference to the Extended Consumer Price Index (IPCA).
- (ii) Transfers of funds between companies to enhance the operations of certain investees and provide funds for expansion and/or acquisitions, management transfers funds between Group companies, current account remittance agreements signed between the parties. These balances are substantially eliminated in the consolidated financial statements.
- (iii) Shared services these are centralized services rendered by the parent company, Rede D'Or, such as legal assistance, marketing, accounting, treasury, accounts payable and accounts receivable, which are shared among the other entities of the Group based on apportionment criteria that take into consideration the contribution of each entity to the consolidated gross revenue.
- (iv) Debentures certain subsidiaries issued nonconvertible debentures, which were acquired by the parent company. These debentures are intended to provide funds to the investees for investment in operations and expansion.
- (v) Revenues and accounts receivable partially arise from commercial transactions conducted in the ordinary course of business relating to medical care provided to members of Sul América plans. These transactions have reference tables by type of service provided by the Company with Sul América and the maturities of these services are stipulated in a contract entered into between the parties.

In addition to the balances presented in the tables below, the Parent Company and subsidiary Rede D'Or Finance carried out two transactions, a debenture issue and purchase transaction: i) on January 17, 2018, subsidiary Rede D'Or Finance issued senior notes totaling US\$500,000 thousand, and at the same time, the Parent Company issued debentures (10th issue), which were acquired by subsidiary Rede D'Or Finance (Note 13); and ii) on January 22, 2020, subsidiary Rede D'Or Finance carried out the second issue of senior notes, in the total amount of US\$850,000 thousand. On February 13, 2020, Rede D'Or Finance reopened the second issue of senior notes and issued an additional US\$350 thousand in notes with the same characteristics as the initial issue. In addition, on April 17, 2020, the Parent Company issued debentures (17th issue - 1st series), which were acquired by subsidiary Rede D'Or Finance.

Notes to interim financial information (Continued) September 30, 2024 (In thousands of reais, unless otherwise stated)

7. Transactions with related parties (Continued)

Balances with related parties

				Individual				
		09/30/2024			12/31/2023		09/30/2023	
	Current	Noncurrent		Current	Noncurrent			
Company	assets	assets	P&L	assets	assets	P&L	P&L	
Debentures Norte D'Or (e)	43,332	_	6,315	1,058	30.000	5.794	4.717	
Debentures São Lucas	43,332		2,217	41,411	30,000	6,308	4,922	
Debentures Hospital Nossa Senhora das Neves (d)	349,365	-	37,504	168,775	131,757	30,560	20,924	
Debentures Biocor (g)	42,802		3,865	33,836	131,737	145	20,324	
Book-entry trade notes Onco Star SP (h)	42,002	1,171,203	88,659	33,030	983,889	143		
Book-entry trade notes Mediax (i)	5,099	1,171,203	444	_	303,003			
Shared services	3,033	_	444	_	=	=	-	
Medise Medicina Diagnóstico e Serviços Ltda.	_	4,044	8,266		_	10,568	9,747	
Hospital Esperança S.A.	-	4,044	27,500	-	-	38,095	30,567	
Hospital São Marcos S.A.	-	-	4,614	-	-	5,542	5,031	
Hospital Norte D'Or de Cascadura S.A.	-	1,050	4,614 8,404		10,772	10,605	8,830	
	-			-	,			
J. Badim S.A.	-	22,218	3,575	-	18,643	4,034	2,683	
Oncologia D'Or S.A.	-	6,827	58,053	-	-	70,365	53,876	
Hospital Fluminense S.A.	-	-	12,980	-	-	16,494	13,950	
Clínica São Vicente	-	-	11,367	-	-	11,218	8,909	
Hospital Alpha-Med LTDA.	-		2,821	-	-	3,474	2,713	
URC	-	2,806		-	2,806	780		
Hospital UDI	-		11,540	-	-	15,036	14,150	
Onco Star SP	-	2,790	13,515	-	=	15,901	13,739	
DF Star	-	-	13,922	-	-	18,540	15,958	
Samer	-	-	5,068	-	-	6,029	4,950	
São Lucas	-	2,445	10,594	-	61,427	13,884	11,606	
São Rafael	-	3,281	29,635	-	-	38,424	35,528	
Casa de Saúde Laranjeiras	-	-	-	-	-	10,487	9,510	
Hospital Santa Cruz	-	-	9,591	-	-	11,027	8,341	
Hospital Aliança	-	-	16,876	-	-	20,806	17,206	
São Carlos	-	761	6,255	-	17,700	6,320	5,712	
Glória D'Or	-	-	8,559	-	-	10,206	6,938	
Cárdio Pulmonar	-	-	13,035	-	-	16,028	11,964	
Hospital Brasil Mauá (formerly Hospital América)	-	-	9,408	-	-	11,779	9,005	
Hospital Balbino	-	-	2,081	-	-	3,016	2,876	
Biocor Hospital de Doenças Cardiovasculares	-	_	7,512	-	-	4.841	8,179	
Proncor Unidade Intensiva Cardiorespiratória	-	669	2,797	-	6,549	3,356	2,528	
Hospital Nossa Senhora das Neves	_	908	8,784	_	934	9,509	7,730	
Hospital Novo Atibaia	_	-	8,971	_	-	10,089	8,447	
Hospital Memorial Arthur Ramos	_	_	8,242	_	_	10,655	7,512	
Other	_	569	36,292	_	2.333	50.197	38,388	
Hospital Norte D'Or de Cascadura S.A. (a)	_	1,737	-	_	3,570	-	-	
Unidade de Radiologia Clínica Ltda. (a)	_	14,672	_	_	14,393	_	_	
Jenner S.A. (a)	_	2,000	_		2,000		_	
JMJB Diagnósticos e Serviços Hospitalares S.A. (a)		12.021			12.021			
J. Badim S.A. (a)	-	7,154	-	-	8,975	-	-	
Instituto D'Or de Pesquisa e Ensino (a)	_	9,176	_	_	9,025	=	-	
JM&AM Empreendimentos Imobiliários S.A. (b)	-	370	22 072	-	9,025 370	31,686	23,987	
Onco Star SP (c)	-		23,073	-	3/0	31,000	23,901	
	-	12,254	-	-	210.262	-	-	
JTO Holding S.A. (a)	-	262.004	-	-	210,262	-	-	
Rede D'Or Finance	-	263,891	-	-	263,891	-	-	
Other	140 500	164,203	-	- 045.000	194,524	-	-	
	440,598	1,707,049	522,334	245,080	1,985,841	531,798	431,123	

Notes to interim financial information (Continued) September 30, 2024 (In thousands of reais, unless otherwise stated)

7. Transactions with related parties (Continued)

Balances with related parties (Continued)

Consolidated									
	09/30/2024					12/31/2023			
Current	Noncurrent	Current	Noncurrent	DOL	Current	ncurrent	Noncurrent	DOL	- Pol
	assets	liabilities	liabilities				liabilities		P&L
187,042	-	-	-	19,104	36,492	131,757	-	12,381	7,091
-	-	4,968	-	68	-	-	-	-	-
2,168	-	-	-	138	-	-	-	-	-
-	22,218	-	-	3,575	-	18,643	-	4,034	2,683
-	12,021	-	-	-					
					-	12,021	-	-	-
-	7,442	-	-	-	-	10,354	-	-	-
-	7,782	-	-	-	-	9,529	-	-	-
-	370	-	-	23,141					
					-	370	-	31,782	24,059
-	11,343	-	4,312	-	-	9,129	5,179	-	-
189,210	61,176	4,968	4,312	46,026	36,492	191,803	5,179	48,197	33,833
	assets 187,042 - 2,168	Current assets 187,042 - 2,168 - 22,218 - 12,021 - 7,442 - 7,782 - 370 - 11,343	Current assets Noncurrent assets Current liabilities 187,042 - - 2,168 - - 4,968 - 22,218 - - - 12,021 - - - 7,442 - - - 7,782 - - - 370 - - - 11,343 - -	Current assets Noncurrent assets Current liabilities Noncurrent liabilities 187,042 - - - 2,168 - - - - 22,218 - - - 12,021 - - - 7,442 - - - 7,782 - - - 370 - - - 11,343 - 4,312	Current assets Noncurrent assets Noncurrent assets Noncurrent assets P&L	Current assets	Current assets	Current assets	Current assets

- (a) Transfers of funds for acquisition of companies, properties, expansion of operations, among others. These balances are substantially eliminated in the consolidated financial statements.
- (b) Lease of properties owned by the controlling shareholders of Rede D'Or.
- (c) Onco Star SP was created in 2017 and, throughout the subsequent years, Rede D'Or provided funds for the acquisition of machinery and equipment, as part of the Company's operational routine.
- (d) On December 17, 2021, Hospital Nossa Senhora das Neves conducted a private issue of nonconvertible, single-series, registered debentures amounting to R\$185,000, initially maturing on December 18, 2023, however this term was extended to December 18, 2024. The debentures may be fully or partially subscribed until the maturity date by Rede D'Or São Luiz. Debentures not subscribed after this period will be automatically canceled. The debentures earn interest on a pro rata basis equivalent to 100% of the positive percentage variation of the CDI (Interbank Deposit Certificate) plus 2.9% p.a. Interest is paid semiannually, and the nominal value will be paid in full on the maturity date, plus yield. There are no guarantees for the debentures.

On March 15, 2023, Hospital Nossa Senhora das Neves conducted the 2nd private issue of nonconvertible, single-series, registered debentures amounting to R\$158,200, maturing on March 15, 2025. The debentures may be fully or partially subscribed until the maturity date by Rede D'Or São Luiz. Debentures not subscribed after this period will be automatically canceled. The debentures earn interest on a pro rata basis equivalent to 100% of the positive percentage variation of the CDI (Interbank Deposit Certificate) plus 2.9% p.a. Interest and the nominal value will be paid in full on the maturity date, plus yield. There are no guarantees for the debentures.

On December 18, 2023, Hospital Nossa Senhora das Neves conducted the third private issue of nonconvertible, single-series, registered debentures amounting to R\$16,900, maturing on December 18, 2024. The debentures may be fully or partially subscribed until the maturity date by Rede D'Or São Luiz S.A. Debentures not subscribed after this period will be automatically canceled. The debentures earn interest on a pro rata basis equivalent to 100% of the positive percentage variation of the CDI (Interbank Deposit Certificate) plus 4.00% p.a. Interest and the nominal value will be paid in full on the maturity date, plus yield. There are no guarantees for the debentures.

On January 02, 2024, Hospital Nossa Senhora das Neves conducted the fourth private issue of nonconvertible, single-series, registered debentures amounting to R\$16,800, maturing on January 02, 2025. The debentures may be fully or partially subscribed until the maturity date by Rede D'Or São Luiz S.A. Debentures not subscribed after this period will be automatically canceled. The debentures earn interest on a pro rata basis equivalent to 100% of the positive percentage variation of the CDI (Interbank Deposit Certificate) plus 4.00% p.a. Interest and the nominal value will be paid in full on the maturity date, plus yield. There are no guarantees for the debentures.

On February 06, 2024, Hospital Nossa Senhora das Neves conducted the fifth private issue of nonconvertible, single-series, registered debentures amounting to R\$41,504, maturing on February 06, 2025. The debentures may be fully or partially subscribed until the maturity date by Rede D'Or São Luiz S.A. Debentures not subscribed after this period will be automatically canceled. The debentures earn interest on a pro rata basis equivalent to 100% of the positive percentage variation of the CDI (Interbank Deposit Certificate) plus 4.00% p.a. Interest and the nominal value will be paid in full on the maturity date, plus yield. There are no guarantees for the debentures.

(e) On April 1, 2022, Norte D'Or conducted the fifth private issue of nonconvertible, single-series, registered debentures amounting to R\$30,000, maturing on April 1, 2025, which were fully acquired by parent Rede D'Or. The debentures earn interest on a pro rata basis equivalent to 100% of the DI (Interbank Deposits) plus 3.00% p.a. Interest is paid semiannually, and the nominal value will be paid in full on the maturity date. There are no guarantees for the debentures.

On February 06, 2024, Hospital Norte D'Or conducted the sixth private issue of nonconvertible, single-series, registered debentures amounting to R\$34,686, maturing on February 06, 2025. The debentures may be fully or partially subscribed until the maturity date by Rede D'Or São Luiz S.A. Debentures not subscribed after this period will be automatically canceled. The debentures earn interest on a pro rata basis equivalent to 100% of the positive percentage variation of the CDI (Interbank Deposit Certificate) plus 4.00% p.a. Interest and the nominal value will be paid in full on the maturity date, plus yield. There are no guarantees for the debentures.

Notes to interim financial information (Continued) September 30, 2024 (In thousands of reais, unless otherwise stated)

7. Transactions with related parties (Continued)

Balances with related parties (Continued)

(f) On November 30, 2022, Mederi Distribuição e Importação de Produtos para Saúde S.A. conducted the 2nd private issue of nonconvertible, single-series, registered debentures amounting to R\$13,135, maturing on December 2, 2024. The debentures may be fully or partially subscribed until the maturity date by Hospital Nossa Senhora das Neves. Debentures not subscribed after this period will be automatically canceled. The debentures earn interest on a pro rata basis equivalent to 100% of the positive percentage variation of the CDI (Interbank Deposit Certificate) plus 2.90% p.a. Interest and the nominal value will be paid in full on the maturity date, plus yield. There are no guarantees for the debentures.

On March 15, 2023, Mederi Distribuição e Importação de Produtos para a Saúde S.A. conducted the 3rd private issue of nonconvertible, single-series, registered debentures amounting to R\$158,200, maturing on March 15, 2025. The debentures may be fully or partially subscribed until the maturity date by Hospital Nossa Senhora das Neves. Debentures not subscribed after this period will be automatically canceled. The debentures earn interest on a pro rata basis equivalent to 100% of the positive percentage variation of the CDI (Interbank Deposit Certificate) plus 2.9% p.a. Interest and the nominal value will be paid in full on the maturity date, plus yield. There are no guarantees for the debentures.

On December 18, 2023, Mederi Distribuição e Importação de Produtos para Saúde S.A. conducted the 4th private issue of nonconvertible, single-series, registered debentures amounting to R\$16,900, maturing on December 18, 2024. The debentures may be fully or partially subscribed until the maturity date by Hospital Nossa Senhora das Neves. Debentures not subscribed after this period will be automatically canceled. The debentures earn interest on a pro rata basis equivalent to 100% of the positive percentage variation of the CDI (Interbank Deposit Certificate) plus 4.00% p.a. Interest and the nominal value will be paid in full on the maturity date, plus yield. There are no guarantees for the debentures.

On January 02, 2024, Mederi Distribuição e Importação de Produtos para Saúde S.A. conducted the 5th private issue of nonconvertible, single-series, registered debentures amounting to R\$16,500, maturing on January 02, 2025. The debentures may be fully or partially subscribed until the maturity date by Hospital Nossa Senhora das Neves S.A. Debentures not subscribed after this period will be automatically canceled. The debentures earn interest on a pro rata basis equivalent to 100% of the positive percentage variation of the CDI (Interbank Deposit Certificate) plus 4.00% p.a. Interest and the nominal value will be paid in full on the maturity date, plus yield. There are no guarantees for the debentures.

- (g) On December 19, 2023, Biocor Hospital de Doenças Cardiovasculares S.A. conducted the 1st private issue of nonconvertible, single-series, registered debentures amounting to R\$33,691, maturing on December 19, 2024. The debentures may be fully or partially subscribed until the maturity date by Rede D'Or S\u00e3o Luiz S.A. Debentures not subscribed after this period will be automatically canceled. The debentures earn interest on a pro rata basis equivalent to 100% of the positive percentage variation of the CDI (Interbank Deposit Certificate) plus 4.0% p.a. Interest and the nominal value will be paid in full on the maturity date, plus yield. There are no guarantees for the debentures.
 - On August 26, 2024, Biocor Hospital de Doenças Cardiovasculares S.A. conducted the 2nd private issue of nonconvertible, single-series, registered debentures amounting to R\$10,000, maturing on August 30, 2025. The debentures may be fully or partially subscribed until the maturity date by Rede D'Or São Luiz S.A. and R\$4,900 by Biocor Indústria e pesquisa LTDA. Debentures not subscribed after this period will be automatically canceled. The debentures earn interest on a pro rata basis equivalent to 100% of the positive percentage variation of the CDI (Interbank Deposit Certificate) plus 4.0% p.a. Interest and the nominal value will be paid in full on the maturity date, plus yield. There are no guarantees for the debentures.
- (h) On December 29, 2023, Onco Star SP Oncologia Ltda. carried out a private placement of single-series book-entry trade notes, convertible into shares, without security interest or collateral security system, of first issue, in the amount of R\$R\$1,082,544, maturing on December 29, 2030. The trade notes may be fully or partially subscribed until the maturity date by Rede D'Or São Luiz. Trade notes not subscribed after this period will be automatically canceled. The trade notes earn interest on a pro rata basis equivalent to 100% of the positive percentage variation of the CDI (Interbank Deposit Certificate) plus 1.0% p.a. Interest and the nominal value will be paid in full on the maturity date, plus yield. There are no guarantees.
- (i) On February 06, 2024, Memorial Imagem e Diagnóstico Ltda. (Mediax) carried out a private placement of book-entry trade notes, convertible into shares, without security interest or collateral security system, in a single series, of the first issue, in the amount of R\$4,655, maturing on February 06, 2025. The trade notes may be fully or partially subscribed until the maturity date by Rede D'Or São Luiz. Trade notes not subscribed after this period will be automatically canceled. The trade notes earn interest on a pro rata basis equivalent to 100% of the positive percentage variation of the CDI (Interbank Deposit Certificate) plus 4.0% p.a. Interest and the nominal value will be paid in full on the maturity date, plus yield. There are no guarantees.
- (j) On May 22, 2024, Instituto de Radioterapia do Vale do Paraíba Ltda. (CENON) carried out a private placement of book-entry nonconvertible trade notes, without security interest or collateral security system, in a single series, of the first issue, in the amount of R\$2,525, maturing on May 22, 2025. The trade notes may be fully or partially subscribed until the maturity date by Centro Oncológico Do Vale Ltda. (IOV). Trade notes not subscribed after this period will be automatically canceled. The trade notes earn interest on a pro rata basis equivalent to 100% of the positive percentage variation of the CDI (Interbank Deposit Certificate) plus 4.0% p.a. Interest and the nominal value will be paid in full on the maturity date, plus yield. There are no guarantees.

Key management personnel compensation

The Company considers "Key management personnel" only the members of its Statutory Board and Board of Directors. At September 30, 2024 and 2023, key management personnel compensation is summarized as follows:

	09/30/2024	09/30/2023
Salaries and bonuses Benefits	106,933 135	92,423 147
Share-based payment	29,289	32,253
	136,357	124,823

Notes to interim financial information (Continued) September 30, 2024 (In thousands of reais, unless otherwise stated)

8. Investments

Breakdown and changes in investments - Individual

Company	12/31/2023	Equity pickup	Dividends	Capital increase/ Future capital contribution	Capital reduction	Transfer	Other	09/30/2024
Сопрапу	12/31/2023	Equity pickup	Dividends	CONTINUE	reduction	Hallstei	Other	09/30/2024
Medise Medicina Diagnóstico e Serviços S.A.	247,261	26,097	(29,967)	_	-	-	_	243,391
Hospital Esperança S.A.	4,350,628	343,725	(69,196)	474,769	-	-	(7,605)	5,092,321
PMJ Empreendimentos Imobiliários S.A.	902,254	11,616	(33,662)	3,477	-	_	-	883,685
Norte D'Or Participações S.A. (including goodwill)	126,956	8,775	-	20	-	-	-	135,751
Onco D'Or Oncologia S.A.	892,114	153,590	-	-	-	-	-	1,045,704
Jenner S.A. (including goodwill)	290,265	59,891	-	-	-	-	-	350,156
JMJB Diagnósticos e Serviços Hospitalares	45,287	439	-	-	-	-	-	45,726
Rodin Empreendimentos e Participações S.A.	283,335	(4,969)	-	139,700	-	-	-	418,066
Quinta Empreendimentos Imobiliários Ltda.	93,925	14,304	(28,059)	•	-	-	-	80,170
Hospital Fluminense S.A. (including goodwill)	294,761	20,110	(35,021)	20,472	-	-	-	300,322
Cardial Serviços Médicos (including goodwill)	117,990	26,839	(16,800)		-	_	-	128,029
TJK Empreendimentos Hospitalares	17,478	1,452	(1,915)	-	-	-	-	17,015
Villa Lobos Empreendimentos Imobiliários Ltda.	221,265	18,755	(46,342)	-	-	_	-	193,678
Santa Luzia II Empreendimentos Imobiliários Ltda.	63,408	(1,310)	-	-	-	-	-	62,098
Campinas Empreendimentos Imobiliários Ltda.	369,075	13,587	-	2,589	(25,069)	-	-	360,182
Sator Empreendimentos e Participações Ltda	3,540,316	185,454	-	243,285	-	-	-	3,969,055
Rede D'or São Luiz Serviços Médicos S.A.	316,878	75,265	-	3,000	-	-	-	395,143
Olimpia Projeto Rua do Rocio 86 SPE S.A.	617,864	26,269	(31,673)	1,238	-	_	-	613,698
Proncordis Pronto Atendimento Cardiológico Ltda.	451	(3)	-	-	-	_	-	448
Laboratórios Richet	328,103	(11,394)	-	52,221	-	-	-	368,930
Santa Luzia III	308,411	15,116	(22,067)	234	-	_	-	301,694
Qualicorp Consultoria e Corretora de Seguros S.A.	485,204	(1,710)	-	_	-	-	473	483,967
Clínica Médica São Remo	50,285	(7,362)	-	13,368	-	_	-	56,291
Hospital Santa Cruz	429,179	24,486	(53,503)	10,509	-	-	-	410,671
Advance Plano de Saúde S.A.	35,201	5,701	-	-	-	_	-	40,902
Prisma Capital	1,608,020	(5,399)	-	30	-	-	-	1,602,651
RDSLGF Greenfields Ltda. (a)	-	252	-	490,855	(414,906)	439,597	-	515,798
RDSL OH Operações Hospitalares Ltda. (a)	-	651	-	82,538	•	6,083	-	89,272
Traditio Companhia de Seguros	4,276,157	410,518	(99,034)	-	-	-	132,365	4,720,006
Cia Saúde – SulAmérica	3,351,225	506,015	(148,638)	13,658	-	_	153,154	3,875,414
SAEPAR Serviços e participações	1,630,657	163,120	(357)	267,247	-	-	54,391	2,115,058
Other	2,002,422	37,188	(19,941)	153,397	<u>-</u>	(445,680)	(3,098)	1,724,288
	27,296,375	2,117,068	(636,175)	1,972,607	(439,975)	-	329,680	30,639,580

⁽a) On August 16, 2024, the Company proceeded with consummation of closing of the Partnership with Atlântica Hospitais e Participações, S.A. ("Atlântica Hospitais") - a company focused on investing in hospitals, indirect controlled by Bradseg Participações S.A., which in its turn is the controlling shareholder of Grupo Bradesco Seguros -, for the creation of the new network of hospitals "Atlântica D'Or". The Partnership is established so that the Companhy, which will be the hospital operator, will have 50,01% and Atlântica Hospitais will have 49,99%. The Company received from Bradesco Seguros the amount of R\$690,004, of which R\$603,768 was reimbursed and supplemented to the works budget and R\$86,236 was monetary correction. On November 12, 2024, considering inauguration events subsequent to the third quarter, the partnership covered three hospital assets in operation (São Luiz Guarulhos, São Luiz Alphaville and Macaé D'Or) and two other projects under development (located in Taubaté and Ribeirão Preto).

Notes to interim financial information (Continued) September 30, 2024 (In thousands of reais, unless otherwise stated)

8. Investments (Continued)

Breakdown of and changes in investments - Individual (Continued)

Company	12/31/2023	Equity pickup	Dividends	Capital increase/ Future capital contribution	Capital reduction	Transfer	Other	09/30/2024
Onco Star	(322,217)	(61,585)	-	1	-	-	(38,312)	(422,113)
Centro Hospitalar São Marcos S.A.	(8,581)	(329)	-	-	-	-	•	(8,910)
Hospital São Marcos (including goodwill)	(107,717)	(2,779)	-	4,614	-	-	-	(105,882)
Rede D'or Finance	(175,045)	4,417	-	-	-	-	-	(170,628)
	(613,560)	(60,276)	-	4,615	-	-	(38,312)	(707,533)
Equity pickup	_	2,056,792	•					_

Notes to interim financial information (Continued) September 30, 2024 (In thousands of reais, unless otherwise stated)

8. Investments (Continued)

Breakdown of and changes in investments - Individual (Continued)

	10/01/0000		5	Capital increase/ Future capital	Capital		•	00/00/000
Company	12/31/2022	Equity pickup	Dividends	contribution	reduction	Transfer	Other	09/30/2023
Medise Medicina Diagnóstico e Serviços S.A.	244,620	22,082	(24,112)	-	-	-	(101)	242,489
Hospital Esperança S.A.	4,271,885	198,115	(699,834)	255,230	-	-	(7,605)	4,017,791
PMJ Empreendimentos Imobiliários S.A.	842,601	18,551	-	51,364	-	-	-	912,516
Norte D'Or Participações S.A. (including goodwill)	137,298	10,555	(9,585)	-	-	-	-	138,268
Onco D'Or Oncologia S.A.	726,351	130,648	-	-	-	-	-	856,999
Jenner S.A. (including goodwill)	217,067	52,997	-	-	-	-	-	270,064
JMJB Diagnósticos e Serviços Hospitalares	40,861	2,326	-	-	-	-	-	43,187
Rodin Empreendimentos e Participações S.A.	123,313	(1,523)	-	111,444	-	-	-	233,234
Quinta Empreendimentos Imobiliários Ltda.	71,617	10,612	(11,014)	1	-	-	-	71,216
Hospital Fluminense S.A. (including goodwill)	295,032	25,087	(26,495)	24,412	-	-	-	318,036
Cardial Serviços Médicos (including goodwill)	101,247	23,192	(16,099)	-	-	-	-	108,340
TJK Empreendimentos Hospitalares	18,323	1,499	-	-	-	-	-	19,822
Villa Lobos Empreendimentos Imobiliários Ltda.	187,920	12,962	(12,398)	-	-	-	-	188,484
Santa Luzia II Empreendimentos Imobiliários Ltda.	59,785	(370)	-	3,179	-	-	-	62,594
Campinas Empreendimentos Imobiliários Ltda.	311,087	(6,066)	-	62,086	-	-	-	367,107
Sator Empreendimentos e Participações Ltda	3,135,185	30,891	-	270,707	-	-	-	3,436,783
Rede D'or São Luiz Serviços Médicos S.A.	300,885	70,184	-	7,842	-	-	-	378,911
Olimpia Projeto Rua do Rocio 86 SPE S.A.	599,424	14,824	-	3,463	-	-	-	617,711
Proncordis Pronto Atendimento Cardiológico Ltda.	464	(11)	-	-	-	-	-	453
Laboratórios Richet	305,929	(11,816)	-	26,813	-	-	-	320,926
California Investimentos Imobiliários Ltda.	59,940	-	-	-	-	-	-	59,940
Hospital Aviccena S.A.	142,389	7,863	-	16,356	-	-	-	166,608
Santa Luzia III	310,107	13,807	-	93	(5,149)	-	-	318,858
Qualicorp Consultoria e Corretora de Seguros S.A. (a)	2,125,919	(4,116)	(1,323)	-	-	(1,632,305)	229	488,404
Clínica Médica São Remo	43,504	(6,570)	-	10,874	-	-	-	47,808
Casa de Saúde Laranjeiras S.A (Perinatal) (including goodwill)	926,298	34,716	-	15,134	-	-	-	976,148
Hospital Santa Cruz	400,555	18,293	(22,048)	18,928	-	-	-	415,728
Advance Plano de Saúde S.A.	42,397	2,467	(7,205)	-	-	-	-	37,659
Prisma Capital (a)	2	(13,657)	-	42	-	1,632,305	-	1,618,692
Traditio Companhia de Seguros	4,006,589	131,168	-	-	-	-	(1,081)	4,136,676
Cia Saúde SulAmérica	3,020,712	95,887	(9,024)	280	-	-	101	3,107,956
SAEPAR Serv. E Partic	1,546,682	44,974		.	-	-	1,090	1,592,746
Other	1,655,999	25,841	(1,185)	140,649	-	•	(11,921)	1,809,383
	26,271,987	955,412	(840,322)	1,018,897	(5,149)	-	(19,288)	27,381,537

⁽a) On January 2, 2023, Rede D'Or entered into an agreement under which it transferred the management of shares representing 19.85% of the voting and total capital of Qualicorp Consultoria e Corretora de Seguros S.A. ("Qualicorp") that it held to Prisma Capital ("Prisma"). Rede D'Or transferred the shares representing 19.85% interest in Qualicorp to a new company 100% owned by Rede D'Or called "PrismaQuali Gestão Ativa de Participações S.A." ("PrismaQuali Gestão Ativa").

Notes to interim financial information (Continued) September 30, 2024 (In thousands of reais, unless otherwise stated)

8. Investments (Continued)

Breakdown of and changes in investments - Individual (Continued)

Company	12/31/2022	Equity pickup	Dividends	Capital increase/ Future capital contribution	Capital reduction	Transfer	Other	09/30/2023
Onco Star	(259,546)	(40,294)	-	-	-	-	(4,480)	(304,320)
Centro Hospitalar São Marcos S.A.	(13,662)	(28)	-	-	-	-	1,507	(12,183)
Hospital São Marcos (including goodwill)	(83,865)	(9,721)	-	5,176	-	-	-	(88,410)
Rede D'Or Finance	(151,106)	(17,601)	-	-	-	-	-	(168,707)
Other	(865)	-	-	-	-	-	865	-
	(509,044)	(67,644)	-	5,176	-	=	(2,108)	(573,620)
Equity pickup		887,768	_					

Notes to interim financial information (Continued) September 30, 2024 (In thousands of reais, unless otherwise stated)

8. Investments (Continued)

Breakdown of and changes in investments - Consolidated

Company	12/31/2023	Equity pickup	Dividends	Capital increase/ Future capital contribution	Other	09/30/2024
JMJB Diagnósticos e Servicos Hospitalares S.A.	45,287	439	_	_	_	45,726
Instituto de Radioterapia do Vale do Paraíba Ltda.	15.874	714	-	_	(111)	16,477
Qualicorp Consultoria e Corretora de Seguros S.A. (a)	2,089,698	(7,366)	_	-	2,039	2,084,371
Eldorado do Sul Participações Ltda.	29,205	4,990	_	-	· -	34,195
Sharecare Brasil Serviços de Consult. Ltda.	(218)	· -	_	-	218	· -
Sul América Investimentos Distribuidora de Títulos e Valores	(-/					
Mobiliários S.A. (SAMI) (b)	88,108	21,398	-	-	(109,506)	-
Other	295,914	13,968	(14,966)	10,650	(3,834)	301,732
	2,563,868	34,143	(14,966)	10,650	(111,194)	2,482,501

Company	12/31/2022	Equity pickup	Acquisition of control	Dividends	Capital increase/ Future capital contribution	Other	09/30/2023
JMJB Diagnósticos e Serviços Hospitalares S.A.	40,861	2,326	_	-	_	-	43,187
Instituto de Radioterapia do Vale do Paraíba Ltda.	43,689	4,637	-	(500)	-	(976)	46,850
Qualicorp Consultoria e Corretora de Seguros S.A.	2,125,919	(17,728)	-	(5,699)	-	989	2,103,481
Eldorado do Sul Participações Ltda.	22,616	4,416	-	-	-	490	27,522
Sharecare Brasil Serviços de Consult.Ltda. Sul América Investimentos Distribuidora de Títulos e	9,662	(10,146)	-	-	-	-	(484)
Valores Mobiliários S.A. (SAMI)	78,242	7,677	-	-	-	-	85,919
Other	232,412	6,640	39,543	(6,465)	27,066	(3,979)	295,217
	2,553,401	(2,178)	39,543	(12,664)	27,066	(3,476)	2,601,692

⁽a) Based on the shareholders' agreement entered into in November 2019, considering the nominations to the Executive Board and Board of Directors that the Company is entitled to, it was concluded that Rede D'Or has significant influence over Qualicorp; therefore, it records the investment using the equity method. The Company recognized the equity pickup until June 30, 2024.

⁽b) On April 30, 2024, the Central Bank of Brazil - BCB approved the transfer of corporate control over Sul América Investimentos DTVM S.A. (SAMI), in the context of the merger of Sul América S.A. ("SASA") into Rede D'Or ("Company").

Notes to interim financial information (Continued) September 30, 2024 (In thousands of reais, unless otherwise stated)

8. Investments (Continued)

Summary of information on main subsidiaries

				09/30/2024				09/30/2023
	% Total	% Voting capital	Assets	Liabilities	Equity	Operating income (expenses)	P&L for the period	P&L for the period
Direct and indirect subsidiaries Medise Medicina Diagnóstico e Serviços S.A. ("Medise")	98.00	98.00	405,667	139,550	266,117	43,403	29,122	24,479
Hospital Esperança S.A. ("Esperança")	100.00	100.00	7,509,906	2,494,123	5,015,783	375,593	191,497	112,520
PMJ Empreendimentos Imobiliários S.A.	100.00	100.00	1,106,860	2,494,123	885,089	15,661	11,627	18,570
Norte D'Or Participações S.A.	100.00	100.00	107,590	190	107,400	8,774	8,784	10,566
Onco D'Or Oncologia S.A.	98.87	98.87	917,586	225,647	691,939	183,106	129,831	114,886
Jenner S.A.	91.24	91.24	614,227	2,002	612,225	119,781	104,809	92,745
Rodin Empreendimentos e Participações S.A.	100.00	100.00	432,028	13,989	418,039	(4,521)	(4,969)	(1,525)
Quinta Empreendimentos Imobiliários Ltda.	100.00	100.00	81,442	1,157	80,285	11,572	14,306	10,623
Hospital Fluminense S.A.	100.00	100.00	429,104	142,055	287,049	25,951	20,130	25,112
Cardial Serviços Médicos Ltda.	89.44	89.44	143,801	47,835	95,966	44,570	26,839	23,192
TJK Empreendimentos Imobiliários Ltda.	100.00	100.00	18,090	1,066	17,024	1,448	1,452	1,501
Villa Lobos Empreendimentos Imobiliários S.A.	100.00	100.00	194,514	573	193,941	14,252	18,757	12,975
Santa Luzia II Emp. Imobiliários Ltda.	100.00	100.00	66,015	3,867	62,148	(1,310)	(1,310)	(370)
Campinas Empreendimentos Imob.	100.00	100.00	375,489	14,690	360,799	11,924	13,589	(6,072)
Sator Empreendimentos e Participações Ltda.	100.00	100.00	3,721,497	19,358	3,702,139	185,472	185,472	30,922
Rede D'Or Finance	100.00	100.00	7,236,950	7,407,577	(170,627)	27	4,417	(17,601)
Rede D'Or São Luiz Serviços Médicos S.A.	100.00	100.00	562,515	167,085	395,430	108,742	75,273	70,255
Olimpia Projeto Rua do Rocio 86 SPE S.A.	100.00	100.00	617,463	3,100	614,363	19,727	26,296	14,839
Proncordis Pronto Atendimento Cardiológico Ltda.	100.00	100.00	7,050	611	6,439	(593)	(251)	(618)
Laboratórios Richet	100.00	100.00	252,284	102,009	150,275	(18,017)	(12,945)	(16,623)
Onco Star SP Oncologia Ltda.	84.00	84.00	1,206,755	1,717,097	(510,342)	(13,288)	(61,585)	(40,293)
Centro Hospitalar São Marcos S.A.	100.00	100.00	22	3,659	(3,637)	(329)	(329)	(28)
Santa Luzia IIII Empreendimentos Imobiliários Ltda.	100.00	100.00	305,111	3,112	301,999	15,203	15,117	13,821
Café Verde	100.00	100.00	10,569	8,525	2,044	682	(755)	(1,004)
Hospital São Marcos	100.00	100.00	238,178	355,143	(116,965)	(376)	(2,779)	(9,721)
Clínica Médica São Remo	100.00	100.00	75,332	21,524	53,808	(6,295)	(7,363)	(6,577)
California Investimentos Imobiliários Ltda.	100.00	100.00	365,831	8,490	357,341	(0,233)	(1,505)	(0,577)
Hospital Santa Cruz	100.00	100.00	395,956	232,891	163,065	46,114	24,347	20,700
Advance Plano de Saúde S.A.	100.00	100.00	54,003	12,994	41,009	5,360	5,701	2,469
RDSLGF Greenfields Ltda.	100.00	100.00	515,808	-	515,808	382	382	2,100
RDSL OH Operações Hospitalares Ltda.	100.00	100.00	89,282	10	89,272	661	661	_
GSH Corp Participações S.A.	50.00	50.00	1,179,528	969,632	209,896	98,059	4,273	6,845
Traditio Companhia de Seguros	100.00	100.00	6,947,004	487,465	6,459,539	528,134	561,812	179,853
Cia Saúde - SulAmérica	100.00	100.00	21,492,603	13,340,795	8,151,808	1,319,418	1,064,398	204,365
SAEPAR Serv. E Partic	100.00	100.00	2,126,961	11,902	2,115,059	153,805	163,120	44,974

Notes to interim financial information (Continued) September 30, 2024 (In thousands of reais, unless otherwise stated)

8. Investments (Continued)

Summary of the associates' and joint ventures' information

	09/30/2024							09/30/2023
	% Total	% Voting capital	Assets	Liabilities	Equity	Operating income (expenses)	P&L for the period	P&L for the period
Companies recognized by the equity method in the consolidated								
financial statements								
JMJB Diagnósticos e Serviços Hospitalares S.A.	50.00	50.00	101,850	9,781	92,069	877	439	2,326
Instituto de Radioterapia do Vale do Paraíba Ltda.	50.00	50.00	31,086	9,441	21,645	11,204	9,155	4,637
Eldorado do Sul Participações Ltda.	33.33	33.33	76,529		76,529	14,973	4,990	4,416
Qualicorp Consultoria e Corretora de Seguros S.A. (a)/(b)	25.85	25.85	4,330,566	3,007,148	1,323,418	(a)	(a)	(b)

⁽a) The Company recognized equity pickup until June 30, 2024.

<u>Impairment</u>

The recoverable amount of a CGU is determined based on the calculation of value in use. Value in use calculations use cash flow projections based on financial budgets approved by management covering a five-year period. Assumptions are described in Note 10.

There is no indication of impairment of investments to date.

⁽b) The Company recognized equity pickup until June 30, 2023.

Notes to interim financial information (Continued) September 30, 2024 (In thousands of reais, unless otherwise stated)

9. Property and equipment

Balance breakdown

	_			Indiv	dual		
	•		09/30/2024				
	Depreciation		Accumulated	Net		Accumulated	Net
Description	rate	Cost	depreciation	amount	Cost	depreciation	amount
Hospital machinery and equipment	12% to 20%	1,798,215	(1,435,735)	362,480	1,678,455	(1,321,300)	357,155
Surgical instruments	20%	141,739	(82,402)	59,337	136,301	(69,778)	66,523
Machinery and equipment	7% to 10%	1,000,601	(623,989)	376,612	875,363	(552,059)	323,304
Buildings	2.5% to 4%	892,653	(299,212)	593,441	887,453	(271,507)	615,946
Improvements in own buildings	4%	477,122	(186,155)	290,967	445,826	(172,642)	273,184
Leasehold improvements	3% to 4%	3,366,034	(735,729)	2,630,305	2,857,531	(642,186)	2,215,345
Furniture and fixtures	10%	270,897	(212,216)	58,681	256,789	(193,709)	63,080
Vehicles	20%	5,907	(4,761)	1,146	5,907	(4,606)	1,301
Facilities	10%	158,524	(100,257)	58,267	151,249	(90,749)	60,500
Land	-	147,698	-	147,698	169,698	· -	169,698
Construction in progress	-	962,410	-	962,410	1,140,363	-	1,140,363
Other	5% to 10%	14,778	(7,228)	7,550	14,605	(6,881)	7,724
	-	9,236,578	(3,687,684)	5,548,894	8,619,540	(3,325,417)	5,294,123

	Consolidated							
			09/30/2024	09/30/2024				
Description	Depreciation rate	Cost	Accumulated depreciation	Net amount	Cost	Accumulated depreciation	Net amount	
Hospital machinery and equipment	12% to 20%	3,459,976	(2,385,011)	1,074,965	3,133,364	(2,146,769)	986,595	
Surgical instruments	20%	324,957	(179,920)	145,037	305,903	(155,494)	150,409	
Machinery and equipment	7% to 10%	1,543,600	(973,970)	569,630	1,363,779	(854,475)	509,304	
Buildings	2.5% to 4%	3,859,116	(815,291)	3,043,825	3,839,290	(695,809)	3,143,481	
Improvements in own buildings	4%	783,890	(256,998)	526,892	679,784	(232,594)	447,190	
Leasehold improvements	3% to 4%	5,181,405	(1,075,327)	4,106,078	4,415,681	(930,721)	3,484,960	
Furniture and fixtures	10%	525,861	(355,482)	170,379	490,374	(324,193)	166,181	
Vehicles	20%	30,666	(26,593)	4,073	29,373	(26,295)	3,078	
Facilities	10%	419,650	(196,199)	223,451	326,015	(165,516)	160,499	
Land	-	1,271,859	-	1,271,859	1,181,599	-	1,181,599	
Construction in progress	-	3,234,354	-	3,234,354	2,625,219	-	2,625,219	
Other	5% to 10%	61,491	(9,683)	51,808	60,099	(9,211)	50,888	
	<u> </u>	20,696,825	(6,274,474)	14,422,351	18,450,480	(5,541,077)	12,909,403	

Notes to interim financial information (Continued) September 30, 2024 (In thousands of reais, unless otherwise stated)

9. Property and equipment (Continued)

Changes - Individual

	12/31/2023	Additions	Transfers (a)	09/30/2024
Cost				
Hospital machinery and equipment	1,678,455	124,781	(5,021)	1,798,215
Surgical instruments	136,301	5,438	-	141,739
Machinery and equipment	875,363	126,840	(1,602)	1,000,601
Buildings	887,453	5,202	(2)	892,653
Improvements in own buildings	445,826	748	30,548	477,122
Leasehold improvements	2,857,531	148,543	359,960	3,366,034
Furniture and fixtures	256,789	14,108	-	270,897
Vehicles	5,907	-	-	5,907
Facilities	151,249	7,872	(597)	158,524
Land	169,698	-	(22,000)	147,698
Construction in progress	1,140,363	462,024	(639,977)	962,410
Other	14,605	173	-	14,778
	8,619,540	895,729	(278,691)	9,236,578
Depreciation				
Hospital machinery and equipment	(1,321,300)	(114,435)	-	(1,435,735)
Surgical instruments	(69,778)	(12,624)	-	(82,402)
Machinery and equipment	(552,059)	(71,930)	-	(623,989)
Buildings	(271,507)	(27,705)	-	(299,212)
Improvements in own buildings	(172,642)	(13,513)	-	(186,155)
Leasehold improvements	(642,186)	(93,543)	-	(735,729)
Furniture and fixtures	(193,709)	(18,507)	-	(212,216)
Vehicles	(4,606)	(155)	-	(4,761)
Facilities	(90,749)	(9,508)	-	(100,257)
Other	(6,881)	(347)	-	(7,228)
	(3,325,417)	(362,267)	-	(3,687,684)
Property and equipment, net	5,294,123	533,462	(278,691)	5,548,894

⁽a) The amount of R\$278,691 refers to property and equipment items that were transferred to subsidiaries through future capital contributions.

Notes to interim financial information (Continued) September 30, 2024 (In thousands of reais, unless otherwise stated)

9. Property and equipment (Continued)

<u>Changes - individual</u> (Continued)

	12/31/2022	Additions	Transfers	09/30/2023
Cost				
Hospital machinery and equipment	1,485,605	113,021	-	1,598,626
Surgical instruments	122,273	12,768	-	135,041
Machinery and equipment	564,773	75,663	86,210	726,646
Buildings	827,109	9,027	15,296	851,432
Improvements in own buildings	328,716	446	11,254	340,416
Leasehold improvements	2,071,940	181,051	127,493	2,380,484
Furniture and fixtures	227,323	11,024	-	238,347
Vehicles	5,162	-	-	5,162
Facilities	138,789	7,334	-	146,123
Land	150,699	-	-	150,699
Construction in progress	1,091,391	562,537	(240,253)	1,413,675
Other	14,228	215	· · · · · · · · · · ·	14,443
	7,028,008	973,086	-	8,001,094
Depreciation				
Hospital machinery and equipment	(1,152,009)	(132,632)	-	(1,284,641)
Surgical instruments	(53,419)	(13,830)	-	(67,249)
Machinery and equipment	(453,248)	(56,299)	-	(509,547)
Buildings	(215,725)	(26,061)	-	(241,786)
Improvements in own buildings	(145,846)	(9,929)	-	(155,775)
Leasehold improvements	(550,296)	(65,723)	-	(616,019)
Furniture and fixtures	(156,051)	(17,376)	-	(173,427)
Vehicles	(4,200)	(116)	-	(4,316)
Facilities	(78,009)	(8,654)	-	(86,663)
Other	(6,398)	(341)	-	(6,739)
	(2,815,201)	(330,961)	-	(3,146,162)
Property and equipment, net	4,212,807	642,125	-	4,854,932

Notes to interim financial information (Continued) September 30, 2024 (In thousands of reais, unless otherwise stated)

9. Property and equipment (Continued)

Changes - Consolidated

			Sales/disposals		Business	
	12/31/2023	Additions	(a)	Transfers	combination	09/30/2024
Cost						
Hospital machinery and						
equipment	3,133,364	331,465	(25)	(5,041)	213	3,459,976
Surgical instruments	305,903	19,054	-	-	-	324,957
Machinery and equipment	1,363,779	146,583	(12,956)	(1,667)	47,861	1,543,600
Buildings	3,839,290	47,510	(485)	(27,199)	-	3,859,116
Improvements in own buildings	679,784	3,155	(371)	101,322	-	783,890
Leasehold improvements	4,415,681	382,609	(3,856)	385,212	1,759	5,181,405
Furniture and fixtures	490,374	34,157	(1,956)	(36)	3,322	525,861
Vehicles	29,373	-	(3)	` <u>-</u>	1,296	30,666
Facilities	326,015	61,169	(137)	(11,943)	44,546	419,650
Land	1,181,599	59,790	-	27,197	3,273	1,271,859
Construction in progress	2,625,219	1,077,518	(2,665)	(467,845)	2,127	3,234,354
Other	60,099	216	(24)	-	1,200	61,491
	18,450,480	2,163,226	(22,478)	-	105,597	20,696,825
Depreciation						
Hospital machinery and						
equipment	(2,146,769)	(238,054)	25	-	(213)	(2,385,011)
Surgical instruments	(155,494)	(24,426)	-	-	-	(179,920)
Machinery and equipment	(854,475)	(100,245)	7,081	-	(26,331)	(973,970)
Buildings	(695,809)	(119,482)		-	•	(815,291)
Improvements in own buildings	(232,594)	(24,432)	28	-	-	(256,998)
Leasehold improvements	(930,721)	(144,611)	18	-	(13)	(1,075,327)
Furniture and fixtures	(324,193)	(31,496)	1,043	-	(836)	(355,482)
Vehicles	(26,295)	(269)	3	-	`(32)	(26,593)
Facilities	(165,516)	(22,476)	34	-	(8,241)	(196,199)
Other	<u>(9,211)</u>	` (473)	1	-	• •	` (9,683 <u>)</u>
	(5,541,077)	(705,964)	8,233	-	(35,666)	(6,274,474)
Property and equipment, net	12,909,403	1,457,262	(14,245)	-	69,931	14,422,351

⁽a) Sales/disposals refer to the fixed assets of D'Or Consultoria. For more details, see note 1.

Notes to interim financial information (Continued) September 30, 2024 (In thousands of reais, unless otherwise stated)

9. Property and equipment (Continued)

Changes - Consolidated (Continued)

	12/31/2022	Additions	Transfers	Business combination	09/30/2023
Cost					
Hospital machinery and equipment	2,793,325	272,848	-	2,083	3,068,256
Surgical instruments	286,300	18,145	-	, <u>-</u>	304,445
Machinery and equipment	1,047,737	96,263	88,781	3	1,232,784
Buildings	3,184,273	27,596	617,881	-	3,829,750
Improvements in own buildings	577,485	1,307	15,540	-	594,332
Leasehold improvements	3,145,996	424,119	207,339	-	3,777,454
Furniture and fixtures	463,911	18,088	· -	12	482,011
Vehicles	28,512	247	-	-	28,759
Facilities	273,788	39,272	-	13	313,073
Land	1,168,390	13,200	-	10	1,181,600
Construction in progress	2,742,104	1,112,559	(929,541)	-	2,925,122
Other	59,627	374	-	-	60,001
	15,771,448	2,024,018	-	2,121	17,797,587
Depreciation					
Hospital machinery and equipment	(1,796,052)	(304,750)	-	(1,030)	(2,101,832)
Surgical instruments	(124,560)	(27,696)	-	-	(152,256)
Machinery and equipment	(737,044)	(102,283)	-	-	(839,327)
Buildings	(547,761)	(108,263)	-	-	(656,024)
Improvements in own buildings	(204,682)	(20,774)	-	-	(225,456)
Leasehold improvements	(803,341)	(89,631)	-	-	(892,972)
Furniture and fixtures	(279,331)	(33,672)	-	(8)	(313,011)
Vehicles	(24,350)	(1,692)	-	-	(26,042)
Facilities	(139,451)	(19,372)	-	(4)	(158,827)
Other	(8,590)	(466)	=	=	(9,056)
	(4,665,162)	(708,599)	-	(1,042)	(5,374,803)
Property and equipment, net	11,106,286	1,315,419	-	1,079	12,422,784

Notes to interim financial information (Continued) September 30, 2024 (In thousands of reais, unless otherwise stated)

9. Property and equipment (Continued)

Significant changes for the periods ended September 30, 2024 and 2023 were as follows:

2024

- (i) Investments in the construction of the new hospitals, São Luiz Alphaville and Guarulhos in São Paulo, the new Hospital Macaé, and the new tower of Hospital Barra D'Or II, in Rio de Janeiro;
- (ii) Expansion works of Hospital Vila Nova Star, in the city of São Paulo, the new building of Hospital Aliança in Salvador, Hospital Assunção, and Hospital Barra D'Or II.
- (iii) Purchases of hospital machinery and equipment for the ventures of new Hospitals São Luiz Alphaville, Guarulhos and Barra D'Or II. Also, investments for the new tower of Vila Nova Star, Aliança, and the update of imaging equipment at Copa D'Or and Copa Star hospitals.

2023

- (i) Purchases of hospital machinery and equipment for the beginning of operation of Hospital São Luiz Campinas and reformulation and remodeling of Clínica São Vicente and Hospital Aliança.
- (ii) Expenses with improvements in the real properties of Hospital e Maternidade São Luiz Itaim and Hospital e Maternidade São Luiz Anália Franco.
- (iii) Construction costs of hospitals São Luiz Campinas, Novo Barra and Memorial Star, and expansion and renovation works of Hospital São Luiz Itaim, Clínica São Vicente and Hospital Aliança.

Capitalized borrowing costs

The Company capitalizes borrowing costs attributable to qualifying assets. In2024, R\$128,827 (R\$156,223 in 2023) in interest on loans and financing were capitalized in Property and equipment.

Impairment testing of property and equipment

Management has assessed the existence of events or changes in economic, operational or technological circumstances and has not identified any evidence that could indicate deterioration or impairment of property and equipment.

Notes to interim financial information (Continued) September 30, 2024 (In thousands of reais, unless otherwise stated)

10. Intangible assets

	Annual	Individual		Consolidated	
	amortization rate	09/30/2024	12/31/2023	09/30/2024	12/31/2023
Finite useful life					
Software	20%	110,748	186,196	595,809	732,171
Customer portfolio - SASA	11% to 20%	144,892	171,782	144,892	171,782
Exclusive agreements	20%	20,889	26,833	253,139	281,762
Other		-	-	59,199	61,825
Indefinite useful life					
Goodwill					
Acquisition of Copa D'Or		80,058	80,058	80,058	80,058
Acquisition of HMSL		668,339	668,339	668,339	668,339
Acquisition of Hospital Brasil		121,398	121,398	121,398	121,398
Acquisition of Hospital Prontolinda		30,595	30,595	30,595	30,595
Acquisition of Vivalle		38,692	38,692	38,692	38,692
Acquisition of São Marcos		-	-	10,807	10,807
Acquisition of Santa Luzia		199,333	199,333	199,333	199,333
Acquisition of Sinisgalli		156,646	156,646	156,646	156,646
Acquisition of Hospital Esperança		-	-	108,408	108,408
Acquisition of Norte D'Or		_	_	28,450	28,450
Acquisition of IFOR		85,724	85,724	85,724	85,724
Acquisition of Sino Brasileiro		241,947	241,947	241,947	241,947
Acquisition of Villa-Lobos		136,074	136,074	136,074	136,074
Acquisition of Bartira		105,584	105,584	105,584	105,584
Acquisition of Onco ABC/Cardeal/JLD		100,004	100,00-	55,414	55,414
Acquisition of Oncoholding		_	_	159,445	159,445
Acquisition of Hospital Fluminense		_	_	10,658	10,658
Acquisition of Hospital Santa Helena		125,802	125,802	125,802	125,802
Acquisition of Acreditar		.20,002	-	155,720	155,720
Acquisition of Memorial São Jose		112,528	112,528	112,528	112,528
Acquisition of Alpha-Med		-		43,815	43,815
Acquisition of CEHON		-	-	68,757	68,757
Acquisition of Maximagem		46742	46,742	46,742	46,742
Acquisition of Ribeirão Pires		129,739	129,739	129,739	129,739
Acquisition of NEOH		, <u>-</u>	· -	33,422	33,422
Acquisition of JTO (b)		-	-	-	12,567
Acquisition of Salus		-	-	8,956	8,956
Acquisition of Prontimagem		-	-	6,220	6,220
Acquisition of Sator		-	-	163,089	163,089
Acquisition of Hospital São Rafael		-	-	509,363	509,363
Acquisition of Laboratório Richet		-	-	184,232	184,232
Acquisition of UDI		-	-	335,883	335,883
Acquisition of Samer		-	-	70,939	70,939
Acquisition of Hospital Rio Mar		-	-	94,833	94,833
Acquisition of Hospital São Lucas		-	-	223,079	223,079
Acquisition of Hospital Aviccena		60,476	60,476	60,476	60,476
Acquisition of Perinatal		655,580	655,580	655,580	655,580
Acquisition of Reseda (b)		-	-	-	54,198
Acquisition of Hospital Santa Cruz		-	-	299,583	299,583
Acquisition of Aliança		-	-	925,555	925,555
Acquisition of Salute		-	-	15,475	15,475
Acquisition of São Carlos		-	-	160,139	160,139
Acquisition of Clínica São Lucas		-	-	45,673	45,673
Acquisition of Clivalle		-	-	40,786	40,786
Acquisition of HCP/Cárdio Pulmonar		-	-	146,894	146,894
Acquisition of Saúde Corp (b)		-	-	-	11,555
Acquisition of Guaianases		-	-	115,751	115,751
Acquisition of Antônio Afonso		-	-	16,782	16,782

Notes to interim financial information (Continued) September 30, 2024 (In thousands of reais, unless otherwise stated)

10. Intangible assets (Continued)

	Annual Indiv		idual	Conso	lidated	
	amortization rate	09/30/2024	12/31/2023	09/30/2024	12/31/2023	
Indefinite useful life					<u> </u>	
Acquisition of Balbino		-	-	77,500	77,500	
Acquisition of América		-	-	456,511	456,511	
Acquisition of Serra Mayor		-	-	68,981	68,981	
Acquisition of Biocor		-	-	620,347	620,347	
Acquisition of Proncor		-	-	202,929	202,929	
Acquisition of Santa Emilia		-	-	121,991	121,991	
Acquisition of Hospital Nossa Senhora das Neves		-	-	326,634	326,634	
Acquisition of HNSN Empreendimentos		-	-	34,790	34,790	
Acquisition of Orthoservice		-	-	33,705	33,705	
Acquisition of HNA Emp. E Participações		-	-	12,401	12,401	
Acquisition of Hospital Novo Atibaia		-	-	173,020	173,020	
Acquisition of Hospital Arthur Ramos		-	-	272,686	272,686	
Acquisition of Hospital Santa Isabel		-	-	243,287	243,287	
Acquisition of Hospital Aeroporto		-	-	171,511	171,511	
Acquisition of Paraná Clínicas		-	-	284,701	284,701	
Acquisition of Sompo Saúde		-	-	199,384	199,384	
Acquisition of Prodent		-	-	106,681	106,681	
Acquisition of SASA		1,820,625	1,820,625	1,820,625	1,820,625	
Other goodwill		48,650	48,650	560,005	601,825	
Trademark – SASA		2,068,575	2,068,575	2,068,575	2,068,575	
Trademarks and patents (a)		190,810	190,810	193,162	192,239	
	=	7,400,446	7,508,728	16,135,850	16,449,568	

Software development costs and licenses

These refer mainly to expenditures incurred with the development of technological infrastructure, applications, improvements in the companies' website and in operations of Sul América S.A., development of own systems, and acquisition of software licenses used in operations.

<u>Impairment</u>

Goodwill is allocated to the Cash-Generating Units (CGU) identified by management, i.e. each hospital, as shown in the table above.

The recoverable amount of a CGU is determined based on the calculation of value in use. Value in use calculations use cash flow projections based on financial budgets approved by management covering a five-year period.

 ⁽a) This mainly refers to the Hospital São Luiz trademark registered upon its acquisition in 2010.
 (b) The disposal refers to the intangible assets of D'Or Consultoria. For more details, see note 1.

Notes to interim financial information (Continued) September 30, 2024 (In thousands of reais, unless otherwise stated)

10. Intangible assets (Continued)

Impairment (Continued)

Discount rates represent the current market assessment of the risks specific to each CGU, taking into consideration the time value of money and individual risks of the underlying assets that have not been incorporated in the cash flow estimates. The discount rate calculation is based on the specific circumstances of the Company and is derived from its weighted average cost of capital (WACC). The WACC takes into consideration both debt and equity. The cost of equity is derived from the expected return on investment by the investors. The cost of debt is based on the interest-bearing financing the Company is obliged to service. Segment-specific risk is incorporated by applying individual beta factors. The beta factors are evaluated annually based on publicly available market data.

There is no indication of impairment of intangible assets to date.

11. Right of use

Balance breakdown

			Indiv	idual			
		09/30/2024		12/31/2023			
Description	Cost	Amortization	Net	Cost	Amortization	Net	
Properties	3,469,688	(1.144.040)	2,325,648	3.108.775	(950,269)	2.158.506	
-1	3,469,688	(1,144,040)	2,325,648	3,108,775	(950,269)	2,158,506	
			Conso	lidated			
		09/30/2024			12/31/2023		
Description	Cost	Amortization	Net	Cost	Amortization	Net	
Hospital machinery and							
equipment	885	(616)	269	2,531	(1,646)	885	
Properties	4,505,824	(1,588,571)	2,917,253	4,024,562	(1,344,985)	2,679,577	
Vehicles	1,471	(545)	926	3,684	(3,684)	· · · -	
	4,508,180	(1,589,732)	2,918,448	4,030,777	(1,350,315)	2,680,462	

المنالة أبياله مرا

Notes to interim financial information (Continued) September 30, 2024 (In thousands of reais, unless otherwise stated)

11. Right of use (Continued)

Changes - Individual

	12/31/2023	Additions (a)	Write-offs	Amortization	09/30/2024
Cost					
Properties	3,108,775	360,913	-	-	3,469,688
·	3,108,775	360,913	-	-	3,469,688
Amortization					
Properties	(950,269)	-	-	(193,771)	(1,144,040)
·	(950,269)	-	-	(193,771)	(1,144,040)
Right of use, net	2,158,506	360,913	-	(193,771)	2,325,648
	12/31/2022	Additions (a)	Write-offs (b)	Amortization	09/30/2023
Cost			` '		
Hospital machinery and equipment	32,473	-	(32,473)	-	-
Properties	2,949,485	112,993	-	-	3,062,478
•	2,981,958	112,993	(32,473)	-	3,062,478
Amortization				-	
Hospital machinery and equipment	(23,701)	187	24,832	(1,318)	-
Properties	(694,803)	-	· -	(183,520)	(878,323)
·	(718,504)	187	24,832	(184,838)	(878,323)
Right of use, net	2,263,454	113,180	(7,641)	(184,838)	2,184,155

Changes - Consolidated

				Amortizatio	
	12/31/2023	Additions (a)	Write-offs (b)	n	09/30/2024
Cost					
Hospital machinery and equipment	2,531	-	(1,646)	-	885
Properties	4,024,562	481,262	-	-	4,505,824
Vehicles	3,684	1,471	(3,684)	-	1,471
	4,030,777	482,733	(5,330)	-	4,508,180
Amortization			-		
Hospital machinery and equipment	(1,646)	-	1,646	(616)	(616)
Properties	(1,344,985)	-	· -	(243,586)	(1,588,571)
Vehicles	(3,684)	-	3,684	(545)	(545)
	(1,350,315)	-	5,330	(244,747)	(1,589,732)
Right of use, net	2,680,462	482,733	-	(244,747)	2,918,448

Notes to interim financial information (Continued) September 30, 2024 (In thousands of reais, unless otherwise stated)

11. Right of use (Continued)

Changes - Consolidated (Continued)

	12/31/2022	Additions (a)	Write-offs (b)	Amortization	09/30/2023
Cost					
Hospital machinery and equipment	64,520	-	(61,989)	-	2,531
Properties	3,808,087	158,025	-	-	3,966,112
Vehicles	3,764	-	(39)	-	3,725
	3,876,371	158,025	(62,028)	-	3,972,368
Amortization					
Hospital machinery and equipment	(44,620)	-	46,960	(3,773)	(1,433)
Properties	(994,642)	-	· -	(272,773)	(1,267,415)
Vehicles	(2,509)	-	-	(930)	(3,439)
	(1,041,771)	-	46,960	(277,476)	(1,272,287)
Right of use, net	2,834,600	158,025	(15,068)	(277,476)	2,700,081

⁽a) Additions referring to new agreements and renewals due to maturities.

The rights of use are amortized during the lease contract term and take into consideration the expected renewal, when management intends to exercise this right, and in accordance with the terms of the contracts.

12. Insurance contract assets and liabilities

	09/3	0/2024	12/31/2023		
Insurance contracts	Assets	Liabilities	Assets	Liabilities	
Long-term contracts (BBA/VFA)	19,471	17,192,488	5,667	15,783,019	
Short-term contracts (PAA)	21,137	2,601,985	76,347	1,359,504	
Total	40,608	19,794,473	82,014	17,142,523	
Current	13,202	6,703,043	41,419	4,683,939	
Noncurrent	27,406	13,091,430	40,595	12,458,584	

⁽b) Write-offs referring to contract termination.

Notes to interim financial information (Continued) September 30, 2024 (In thousands of reais, unless otherwise stated)

12. Insurance contract assets and liabilities (Continued)

12.1. Changes in assets or liabilities for remaining coverage and claims incurred relating to insurance contracts

Short-term contracts (PAA)

	_	Consolidated					
	·-	Asset/liability for remaining	Liability				
	_	coverage	claims inc	urred	Assets for		
			Estimated future		insurance		
		Less loss	cash flows at	Risk	acquisition		
	-	component	present value	adjustment	costs	Total	
Insurance contract liabilities at 12/31/2023		(742,794)	3,752,308	144,542	(1,794,552)	1,359,504	
Insurance contract assets at 12/31/2023		(61,658)	28,477	79	(43,245)	(76,347)	
Total insurance contracts at 12/31/2023	-	(804,452)	3,780,785	144,621	(1,837,797)	1,283,157	
Insurance revenue	Note 18.2	(19,606,818)	-	-	-	(19,606,818)	
Insurance costs	(Note 19.2/ (f)	2,277,119	11,046,521	25,703	-	13,349,343	
Income from (loss on) insurance services		(17,329,699)	11,046,521	25,703	-	(6,257,475)	
Finance income (costs) from insurance operations	Note 22	-	539,984	13,783	-	553,767	
Changes in other comprehensive income		-	(25,374)	(772)	-	(26,146)	
Total changes that impact P&L or other comprehensive income	_	(17,329,699)	11,561,131	38,714	-	(5,729,854)	
Premiums and other cash flows received from policyholders	(a)	19,687,788	-	-	-	19,687,788	
Claims and other benefits paid to policyholders or their beneficiaries	(a) (f)		(10,408,134)	-	-	(10,408,134)	
Acquisition cash flows paid	(b)	(1,052,581)	-	-	(473,561)	(1,526,142)	
Other expenses allocated to the insurance service	(c)	(732,051)	-	-	=	(732,051)	
Total cash flows	_	17,903,156	(10,408,134)	-	(473,561)	7,021,461	
Allocation of acquisition costs prepaid to insurance cash flows	(d)	(86,521)	-	-	86,521	-	
Other	(e)	(12,632)	18,716	-	-	6,084	
Total insurance contracts at 09/30/2024	_	(330,148)	4,952,498	183,335	(2,224,837)	2,580,848	
Insurance contract liabilities at 09/30/2024	_	(298,269)	4,912,364	183,243	(2,195,353)	2,601,985	
Insurance contract assets at 09/30/2024		(31,879)	40,134	92	(29,484)	(21,137)	

⁽a) Any premium reimbursements were included in this line.

⁽b) Insurance acquisition cash flows paid before initial recognition of the respective group are adjusted to the liability/asset for remaining coverage only when these groups are recognized. Insurance acquisition cash flows paid before the related group is recognized are included in cash flows from assets for acquisition until the group is recognized.

⁽c) Other changes within insurance assets or liabilities that affect other statement of financial position lines, as well as expenses allocated to insurance contracts not directly related to claims (such as costs with issue and maintenance of contracts, costs to comply with regulatory requirements, among others) and acquisition cash flows, which are not recorded in assets/liabilities from insurance and reinsurance contracts and were included in Insurance Costs line.

⁽d) Other changes from acquisition cash flows include the reclassification of liabilities for insurance acquisition cash flows that have been recognized before the group recognition by the determination of another CPC/IFRS.

⁽e) Refers to the elimination of transactions between group companies.

⁽f) Includes the eliminations of claims incurred and other expenses to be allocated to insurance contracts between the Group's companies.

Notes to interim financial information (Continued) September 30, 2024 (In thousands of reais, unless otherwise stated)

12. Insurance contract assets and liabilities (Continued)

12.1. Changes in assets or liabilities for remaining coverage and claims incurred relating to insurance contracts (Continued)

Short-term contracts (PAA) - Continued

			Consc	olidated		
		Asset/liability for remaining coverage	Liability for claims incurr		Assets for insurance	
			Estimated future cash	Risk	acquisition	
		Less loss component	flows at present value	adjustment	costs	Total
Insurance contract liabilities at 01/01/2023		(683,679)	2,849,478	95,789	(1,962,972)	298,616
Insurance contract assets at 01/01/2023		(83,224)	28,003	298	(94,585)	(149,508)
Total insurance contracts at 01/01/2023		(766,903)	2,877,481	96,087	(2,057,557)	149,108
Insurance revenue		(23,707,681)	-	-	-	(23,707,681)
Insurance costs	(f)	3,026,033	14,662,351	33,943	-	17,722,327
Income from (loss on) insurance services	* * * * * * * * * * * * * * * * * * * *	(20,681,648)	14,662,351	33,943	-	(5,985,354)
Finance income (costs) from insurance operations		-	611,984	14,553	-	626,537
Changes in other comprehensive income		-	(690)	38	-	(652)
Total changes that impact P&L or other comprehensive income		(20,681,648)	15,273,645	48,534	-	(5,359,469)
Premiums and other cash flows received from policyholders	(a)	23,540,195	-	-	-	23,540,195
Claims and other benefits paid to policyholders or their beneficiaries	(f)	· · · · · -	(14,392,693)	-	-	(14,392,693)
Acquisition cash flows paid	(b)	(1,344,475)	· · · · · · · · · · · · · · · · · · ·	-	(424,090)	(1,768,565)
Other expenses allocated to the insurance service	(c)	(894,885)	-	-		(894,885)
Total cash flows		21,300,835	(14,392,693)	-	(424,090)	6,484,052
Allocation of acquisition costs prepaid to insurance cash flows	(d)	(643,850)	=	-	643,850	-
Other	(e)	(12,886)	22,352	-	-	9,466
Total insurance contracts at 12/31/2023		(804,452)	3,780,785	144,621	(1,837,797)	1,283,157
Insurance contract liabilities at 12/31/2023		(742,794)	3,752,308	144,542	(1,794,552)	1,359,504
Insurance contract assets at 12/31/2023		(61,658)	28,477	79	(43,245)	(76,347)

⁽a) Any premium reimbursements were included in this line.

b) Insurance acquisition cash flows paid before initial recognition of the respective group are adjusted to the liability/asset for remaining coverage only when these groups are recognized. Insurance acquisition cash flows paid before the related group is recognized are included in cash flows from assets for acquisition until the group is recognized.

⁽c) Other changes within insurance assets or liabilities that affect other statement of financial position lines, as well as expenses allocated to insurance contracts not directly related to claims (such as costs with issue and maintenance of contracts, costs to comply with regulatory requirements, among others) and acquisition cash flows, which are not recorded in assets/liabilities from insurance and reinsurance contracts and were included in Insurance Costs line.

⁽d) Other changes from acquisition cash flows include the reclassification of liabilities for insurance acquisition cash flows that have been recognized before the group recognition by the determination of another CPC/IFRS.

⁽e) Refers to the elimination of transactions between group companies.

⁽f) Includes the eliminations of claims incurred and other expenses to be allocated to insurance contracts between the Group's companies.

Notes to interim financial information (Continued) September 30, 2024 (In thousands of reais, unless otherwise stated)

12. Insurance contract assets and liabilities (Continued)

12.1. Changes in assets or liabilities for remaining coverage and claims incurred relating to insurance contracts (Continued)

Long-term contracts (BBA/VFA)

		Consolidated					
		Asset/liab	•	Liability			
		remaining	coverage	claims incu	ırred		
		Less loss component	Loss component	Estimated future cash flows at present value	Risk adjustment	Total	
Insurance contract liabilities at 12/31/2023		14,304,162	936,095	522,426	20,336	15,783,019	
Insurance contract assets at 12/31/2023		(8,519)	-	2,849	3	(5,667)	
Total insurance contracts at 12/31/2023	_	14,295,643	936,095	525,275	20,339	15,777,352	
Insurance revenue	Note 18.2	(2,131,593)	-	-	-	(2,131,593)	
Insurance costs	(Note 19.2 (d)	118,433	58,602	1,662,927	1,000	1,840,962	
Contribution for investments	(e)	(2,043,669)	-	2,043,669		-	
Income from (loss on) insurance services	_	(4,056,829)	58,602	3,706,596	1,000	(290,631)	
Finance income (costs) from insurance operations	Note 22	942,859	66,945	73,763	1,825	1,085,392	
Changes in other comprehensive income		(388,388)	(56,233)	(3,196)	(88)	(447,905)	
Total changes that impact P&L or other comprehensive income	_	(3,502,358)	69,314	3,777,163	2,737	346,856	
Premiums and other cash flows received from policyholders	(a)	4,810,588	-	=	-	4,810,588	
Claims and other benefits paid to policyholders or their beneficiaries	(d)	-	-	(3,661,086)	-	(3,661,086)	
Acquisition cash flows paid	(b)	(56,232)	-	-	-	(56,232)	
Provision for social security amounts to be regularized		(15,224)	-	-	-	(15,224)	
Other expenses allocated to the insurance service	(c)	(29,237)				(29,237)	
Total cash flows		4,709,895	-	(3,661,086)	-	1,048,809	
Total insurance contracts at 09/30/2024	<u> </u>	15,503,180	1,005,409	641,352	23,076	17,173,017	
Insurance contract liabilities at 09/30/2024		15,526,226	1,005,409	637,781	23,072	17,192,488	
Insurance contract assets at 09/30/2024		(23,046)	-	3,571	4	(19,471)	

⁽a) Any premium reimbursements were included in this line.

⁽b) Insurance acquisition cash flows paid before initial recognition of the respective group are adjusted to the liability/asset for remaining coverage only when these groups are recognized. Insurance acquisition cash flows paid before the related group is recognized are included in cash flows from assets for acquisition until the group is recognized.

⁽c) Other changes within insurance assets or liabilities that affect other statement of financial position lines, as well as expenses allocated to insurance contracts not directly related to claims (such as costs with issue and maintenance of contracts, costs to comply with regulatory requirements, among others) and acquisition cash flows, which are not recorded in assets/liabilities from insurance and reinsurance contracts and were included in Insurance Costs line.

Cash flows related to investment and redemptions of non-separable pension investment components (VGBL/PGBL) were also included in this line.

⁽d) Includes the eliminations of claims incurred and other expenses to be allocated to insurance contracts between the Group's companies.

⁽e) In the long-term products, there is a transfer of the investment component from the Asset/Liability for remaining coverage to the Liability for claims incurred in the amount of R\$2,043,669 as of September 30, 2024 (R\$2,264,95 as of September 30, 2023) related to the payment of benefits (annual fees), redemptions and portability of pension plan exit.

Notes to interim financial information (Continued) September 30, 2024 (In thousands of reais, unless otherwise stated)

12. Insurance contract assets and liabilities (Continued)

12.1. Changes in assets or liabilities for remaining coverage and claims incurred relating to insurance contracts (Continued)

Long-term contracts (BBA/VFA) - Continued

		Consolidated					
		Asset/lia	bility for	Liabilit	y for		
		remaining	coverage	claims in			
				Estimated			
				future cash			
		Less loss	Loss	flows at present	Risk		
		component	component	value	adjustment	Total	
Insurance contract liabilities at 01/01/2023		13,308,357	1,067,575	452,983	14,809	14,843,724	
Total insurance contracts at 01/01/2023		13,308,357	1,067,575	452,983	14,809	14,843,724	
Insurance revenue		(3,012,071)	-	-	-	(3,012,071)	
Insurance costs	(d)	(2,727,718)	(227,582)	5,074,978	3,559	2,123,237	
Income from (loss on) insurance services		(5,739,789)	(227,582)	5,074,978	3,559	(888,834)	
Finance income (costs) from insurance operations		1,439,238	89,442	83,123	1,945	1,613,748	
Changes in other comprehensive income		20,116	6,660	763	26	27,565	
Total changes that impact P&L or other comprehensive income		(4,280,435)	(131,480)	5,158,864	5,530	752,479	
Premiums and other cash flows received from policyholders	(a)	5,395,438	-	=	-	5,395,438	
Claims and other benefits paid to policyholders or their beneficiaries	(d)	=	-	(5,086,572)	-	(5,086,572)	
Acquisition cash flows paid	(b)	(74,023)	-	=	-	(74,023)	
Provision for social security amounts to be regularized		12,003	-	-	-	12,003	
Other expenses allocated to the insurance service	(c)	(65,697)	-	-	-	(65,697)	
Total cash flows		5,267,721	-	(5,086,572)	-	181,149	
Total insurance contracts at 12/31/2023		14,295,643	936,095	525,275	20,339	15,777,352	
Insurance contract liabilities at 12/31/2023		14,304,162	936,095	522,426	20,336	15,783,019	
Insurance contract assets at 12/31/2023		(8,519)	=	2,849	3	(5,667)	

⁽a) Any premium reimbursements were included in this line.

⁽b) Insurance acquisition cash flows paid before initial recognition of the respective group are adjusted to the liability/asset for remaining coverage only when these groups are recognized. Insurance acquisition cash flows paid before the related group is recognized are included in cash flows from assets for acquisition until the group is recognized.

⁽c) Other changes within insurance assets or liabilities that affect other statement of financial position lines, as well as expenses allocated to insurance contracts not directly related to claims (such as costs with issue and maintenance of contracts, costs to comply with regulatory requirements, among others) and acquisition cash flows, which are not recorded in assets/liabilities from insurance and reinsurance contracts and were included in Insurance Costs line.

Cash flows related to investment and redemptions of non-separable pension investment components (VGBL/PGBL) were also included in this line.

⁽d) Includes the eliminations of claims incurred and other expenses to be allocated to insurance contracts between the Group's companies.

Notes to interim financial information (Continued) September 30, 2024 (In thousands of reais, unless otherwise stated)

12. Insurance contract assets and liabilities (Continued)

12.2. Contracts held showing cash flow estimate at present value, risk adjustment, and contractual service margin

	Consolidated					
	Estimated present value of future cash flows	Risk adjustment	Contractual service margin	Total		
Insurance contract assets at 12/31/2023	(2,619)	50	(3,098)	(5,667)		
Insurance contract liabilities at 12/31/2023	14,587,203	739,783	456,033	15,783,019		
Total insurance contracts at 12/31/2023	14,584,584	739,833	452,935	15,777,352		
Changes related to contractual services	(164,145)	(51,297)	(31,120)	(246,562)		
Contractual service margin recognized for services rendered	-	-	(31,120)	(31,120)		
Recognized risk adjustment for the expired risk	-	(51,297)	· -	(51,297)		
Experience adjustments	(164,145)	· -	-	(164,145)		
Changes related to future services	119,214	(48,104)	70,302	141,412		
Contracts initially recognized in the period (a)	(43,985)	526	43,459	-		
Changes to estimates that adjust the contractual service margin	(23,236)	(3,607)	26,843	-		
Changes to estimates that do not adjust the contractual service margin	186,435	(45,023)	-	141,412		
Changes related to prior services	(236,511)	51,030	-	(185,481)		
Adjustments of liabilities for claims incurred	(236,511)	51,030	-	(185,481)		
Income from (loss on) insurance services	(281,442)	(48,371)	39,182	(290,631)		
Finance costs from insurance	1,020,676	60,353	4,363	1,085,392		
Effects of changes in interest rates	(398,691)	(49,214)	-	(447,905)		
Total	340,543	(37,232)	43,545	346,856		
Earned premiums	4,810,588	-	-	4,810,588		
Other expenses payable	(3,705,547)	-	-	(3,705,547)		
Insurance acquisition cash flows	(56,232)	-	-	(56,232)		
Net insurance contract (assets)/liabilities at 09/30/2024	15,973,936	702,601	496,480	17,173,017		
Insurance contract liabilities at 09/30/2024	15,982,367	702,548	507,573	17,192,488		
Insurance contract assets at 09/30/2024	(8,431)	53	(11,093)	(19,471)		

⁽a) The estimated present value of future cash flows for the contracts initially recognized in the period includes an estimate of R\$2,105,918 in net written premiums, R\$2,045,521 in claims and other insurance service expenses, and R\$16,412 in acquisition cash flows.

Notes to interim financial information (Continued) September 30, 2024 (In thousands of reais, unless otherwise stated)

12. Insurance contract assets and liabilities (Continued)

12.2. Contracts held showing cash flow estimate at present value, risk adjustment, and contractual service margin (Continued)

	Consolidated					
	Estimated present value of future cash flows	Risk adjustment	Contractual service margin	Total		
Insurance contract liabilities at 01/01/2023	13,628,788	652,408	562,528	14,843,724		
Total insurance contracts at 01/01/2023 (a)	13,628,788	652,408	562,528	14,843,724		
Changes related to contractual services	(509,093)	(60,564)	(38,593)	(608,250)		
Contractual service margin recognized for services rendered	-		(38,593)	(38,593)		
Recognized risk adjustment for the expired risk	·	(60,564)	-	(60,564)		
Experience adjustments	(509,093)	-	-	(509,093)		
Changes related to future services	(145,307)	2,479	(84,754)	(227,582)		
Contracts initially recognized in the period (b)	(78,548)	611	77,937	-		
Changes to estimates that adjust the contractual service margin	168,927	(6,236)	(162,691)	-		
Changes to estimates that do not adjust the contractual service margin	(235,686)	8,104	-	(227,582)		
Changes related to prior services	(115,424)	62,422	-	(53,002)		
Adjustments of liabilities for claims incurred	(115,424)	62,422	-	(53,002)		
Income from (loss on) insurance services	(769,824)	4,337	(123,347)	(888,834)		
Finance income (costs) from insurance operations	1,520,981	79,013	13,754	1,613,748		
Changes in other comprehensive income	23,490	4,075	-	27,565		
Total	774,647	87,425	(109,593)	752,479		
Premiums and other cash flows received from policyholders	5,395,438	-	-	5,395,438		
Claims and other benefits paid to policyholders or their beneficiaries	(5,140,266)	-	-	(5,140,266)		
Insurance acquisition cash flows	(74,023)	-	-	(74,023)		
Total insurance contracts at 12/31/2023	14,584,584	739,833	452,935	15,777,352		
Insurance contract liabilities at 12/31/2023	14,587,203	739,783	456,033	15,783,019		
Insurance contract assets at 12/31/2023	(2,619)	50	(3,098)	(5,667)		

⁽a) All contracts in force on 01/01/2023 were acquired through a business combination.

b) The estimated present value of future cash flows for the contracts initially recognized in the period includes an estimate of R\$1,738,549 in net written premiums, R\$1,630,166 in claims and other insurance service expenses, and R\$29,835 in acquisition cash flows.

Notes to interim financial information (Continued) September 30, 2024 (In thousands of reais, unless otherwise stated)

12. Insurance contract assets and liabilities (Continued)

12.3. Expected recognition of contractual service margin (CSM) in coming years

	Consolidated Long-term contracts (BBA/VFA)							
	2024	2025 to 2029	From 2029 onwards	09/30/2024				
Release of CSM	12,017	148,268	336,195	496,480				
		Conso	lidated					
	2024	2025 to 2029	From 2029 onwards	12/31/2023				
Release of CSM	39,344	156,855	256,736	452,935				

12.4. Expected recognition of acquisition cash flows in coming years

	Consolidated Short-term contracts (PAA)					
	1 year	5 years	Above 5 years	09/30/2024		
Release of acquisition cash flow assets	722,817	1,366,499	135,521	2,224,837		
		Conso	olidated			
	Shor	t-term contracts	(PAA)			
	·		Above 5			
	1 year	5 years	years	12/31/2023		
Release of acquisition cash flow assets	604,228	1,105,393	128,176	1,837,797		

Notes to interim financial information (Continued) September 30, 2024 (In thousands of reais, unless otherwise stated)

12. Insurance contract assets and liabilities (Continued)

12.5. Guarantee for technical reserves

The subsidiaries regulated by Brazil's Private Insurance Supervisory Office ("SUSEP") and the Brazilian Regulatory Agency for Private Health Insurance and Plans ("ANS"), based on the regulatory guidance established by these agencies, have to keep assets offered as guarantee for their technical reserves (liabilities representing the obligations of these companies to the policyholders/beneficiaries), measured based on accounting standards defined by such regulators, which differ materially from CPC 50/IFRS 17.

The assets offered as guarantee for such technical reserves are recorded in clearinghouses in the technical reserve account. SUSEP and ANS may authorize the free movement of assets offered as guarantee by the regulated companies, provided that all financial requirements regarding the coverage of technical reserves and sufficiency of capital, as well as all accounting obligations, are met.

As at September 30, 2024, the subsidiaries regulated by SUSEP and ANS were compliant with the requirements for coverage of technical reserves.

Notes to interim financial information (Continued) September 30, 2024 (In thousands of reais, unless otherwise stated)

13. Loans, financing and debentures

									Indivi	dual	Conso	lidated
Transaction/Instrument	Index	Spread	Currency	Principal (R\$)	Beginning	Maturity	Amortization	Guarantees	09/30/2024	12/31/2023	09/30/2024	12/31/2023
•												
FINEP	TJLP/Fixed rate	0.5%/4.0%	R\$	170,252	Feb/15	Sept/24	Monthly	Surety bond	-	17,925	-	17,925
Citibank III (a)	SOFR	0.99%	US\$	304,158	Apr/23	Apr/27	Annual	n/a	336,285	299,144	336,285	299,144
BofA II (a)	Fixed rate	0.88%	EUR€	400,520	Jun/21	Jun/25	Bullet	n/a	395,824	341,912	395,824	341,912
JP Morgan II (a)	Fixed rate	1.58%	US\$	520,000	Jul/20	Jul/25	Bullet	n/a	526,882	455,269	526,882	455,269
CCB Bank of China	100% of DI	1.20%	R\$	85,000	May/20	May/26	Bullet	n/a	88,554	86,492	88,554	86,492
Other	CDI/Fixed		R\$	n/a	n/a	Mar/28	Monthly	Credit rights/Surety			31,439	3.577
	rate/IPCA	-	Кφ	II/a	II/a	IVIAI/20	WOTHIN	Credit rights/Surety	•	-	31,439	3,377
Debentures – 3 rd issue - Esperança	110.85% of DI	-	R\$	1,000,000	Aug/17	Aug/24	Semiannual	n/a	-	-	-	260,593
Debentures - 4th issue - Esperança	100% of DI	1.27%/1.50%	R\$	1,000,000	Feb/18	Dec/27	Annual	n/a	-	-	1,024,792	992,073
Debentures – 10th issue (a)	Fixed rate	11.82%	R\$	1,628,100	Jan/18	Jan/28	Bullet	n/a	1,556,819	1,723,193	32,460	33,407
Debentures – 13 th issue	100% of DI	1.02%	R\$	1,400,000	Sept/18	Sept/24	Annual	n/a	-	725,575	-	725,575
Debentures – 14th issue (b)	106% of DI	-	R\$	500,000	Oct/2018	Oct/26	Annual	Property	390,438	380,509	390,438	380,509
Debentures – 17th issue 3rd series (b)	100% of DI	0.79%	R\$	1,000,000	Jun/19	Jun/29	Annual	n/a	1,024,870	995,788	1,024,870	995,788
Debentures – 17 th issue 2nd series	100% of DI	1.25%	R\$	2,500,000	Dec/19	Dec/26	Annual	n/a	2,565,511	2,489,661	2,565,511	2,489,661
Debentures – 17th issue 1st series (a)	Fixed rate	8.75%	R\$	3,198,350	Apr/20	Jan/30	Bullet	n/a	2,460,215	2,773,950	-	-
Debentures - 19th issue 2nd series	100% of DI	1.90%	R\$	2,500,000	Aug/21	Aug/31	Annual	n/a	2,519,074	2,605,127	2,519,074	2,605,127
Debentures - 19th issue 3 rd series	100% of DI	1.90%	R\$	1,500,000	Sept/21	Aug/31	Annual	n/a	1,511,445	1,563,076	1,511,445	1,563,076
Debentures – 23th issue 1st series	100% of DI	1.40%	R\$	900,000	May/22	May/28	Bullet	n/a	934,376	907,338	934,376	907,338
Debentures - 23th issue 2nd series	100% of DI	1.90%	R\$	850,000	May/22	May/32	Annual	n/a	884,139	857,449	884,139	857,449
Debentures - 23rd issue 3rd series	100% of DI	1.90%	R\$	625,000	May/22	May/32	Annual	n/a	650,102	630,477	650,102	630,477
Debentures - 25th issue 1st series	100% of DI	2.00%	R\$	450,000	Oct/22	Oct/32	Bullet	n/a	472,979	459,220	472,979	459,220
Debentures - 25th issue 2nd series	100% of DI	1.95%	R\$	150,000	Oct/22	Oct/32	Annual	n/a	157,623	153,058	157,623	153,058
Debentures - 27th issue	100% of DI	1.70%	R\$	1,100,000	Feb/23	Feb/30	Annual	n/a	1,108,142	1,145,537	1,108,142	1,145,537
Debentures - 28th issue	100% of DI	1.90%	R\$	490,000	Jun/23	May/28	Bullet	n/a	507,778	526,848	507,778	526,848
Debentures - 29th issue	100% of DI	2.25%	R\$	1,000,000	ago/23	Jul/31	Annual	n/a	1,016,791	1,050,067	1,016,791	1,050,067
Debentures - 31st issue	100% of DI	2.00%	R\$	500,000	Oct/23	Oct/31	Annual	n/a	527,049	510,525	527,049	510,525
Debentures - 33 rd issue (d)	100% of DI	1.70%	R\$	2,000,000	May/24	May/34	Bullet	n/a	2,078,755	-	2,078,755	-
Debentures (SULA) - 8th issue 1st series (c)	100% of DI	1.50%	R\$	233,000	Feb/21	Feb/24	Bullet	n/a	-	245,925	-	245,925
Debentures (SULA) - 8th issue 2nd series (c)	100% of DI	1.80%	R\$	467,000	Feb/21	Feb/26	Annual	n/a	-	497,845	-	497,845
Debentures (SULA) - 9th issue 1st series	100% of DI	1.50%	R\$	750,000	Nov/21	Nov/26	Annual	n/a	794,359	769,731	794,359	769,731
Debentures (SULA) - 9th issue 2nd series	100% of DI	1.70%	R\$	750,000	Nov/21	Nov/28	Annual	n/a	794,992	769,948	794,992	769,948
Debentures GGSH	100% of DI	2.80%	R\$	360,000	Apr/21	Apr/26	Semiannual	n/a		-	-	363,127
Debentures GGSH	100% of DI	2.20%	R\$	100,000	Dec/23	Dec/28	Semiannual	n/a	-	-	103,565	100,869
Debentures GGSH	100% of DI	1.70%	R\$	500,000	Apr/24	Apr/29	Annual	n/a	-	-	517,826	-
CCB GGSH	100% of DI	2.42%	R\$	125,000	ago/23	ago/28	Semiannual	Surety	-	-	125,165	129,295
Senior Notes I (a)	Fixed rate	4.95%	US\$	1,596,400	Jan/18	Jan/28	Bullet	n/a	-	-	2,619,088	2,361,259

Notes to interim financial information (Continued) September 30, 2024 (In thousands of reais, unless otherwise stated)

13. Loans, financing and debentures (Continued)

									Indiv	ridual	Conso	lidated
Transaction/Instrument	Index	Spread	Currency	Principal (R\$)	Beginning	Maturity	Amortization	Guarantees	09/30/2024	12/31/2023	09/30/2024	12/31/2023
Senior Notes II (a)	Fixed rate	4.50%	US\$	5,062,504	Jan/20	Jan/30	Bullet	n/a	-	-	3,495,407	3,188,554
Mortgage-backed Securities (CRIs) – 2nd issue	IPCA	6.06%	R\$	300,000	Jul/18	Jul/25	Bullet	n/a	417,591	404,243	417,591	404,243
Mortgage-backed Securities (CRIs) – 3rd issue 2nd series	IPCA	4.66%	R\$	372,949	Dec/18	Dec/25	Bullet	n/a	519,543	485,165	519,543	485,165
Mortgage-backed Securities (CRIs) – 4th issue 2nd series	IPCA	3.93%	R\$	30,100	Feb/19	Feb/26	Bullet	n/a	40,408	39,406	40,408	39,406
Mortgage-backed Securities (CRIs) – 5th issue	IPCA	3.45%	R\$	538,328	Sept/19	Aug/29	Annual	n/a	708,042	689,664	708,042	689,664
Mortgage-backed Securities (CRIs) – 6th issue (a)	IPCA	4.93%	R\$	1,500,000	May/21	May/36	Annual	n/a	1,408,881	1,498,027	1,408,881	1,498,027
Mortgage-backed Securities (CRIs) – 7th issue 1st series (a)	IPCA	5.58%	R\$	400,000	Dec/21	Dec/31	Annual	n/a	420,688	432,387	420,688	432,387
Mortgage-backed Securities (CRIs) – 7th issue 2nd series (a)	IPCA	6.10%	R\$	600,000	Dec/21	Dec/36	Annual	n/a	605,348	643,616	605,348	643,616
Mortgage-backed Securities (CRIs) – 8th issue 2nd series (a)	IPCA	5.83%	R\$	798,634	Jun/22	Jun/29	Bullet	n/a	821,386	834,344	821,386	834,344
Mortgage-backed Securities (CRIs) – 8th issue 3rd series (a)	IPCA	6.01%	R\$	341,867	Jun/22	Jun/32	Annual	n/a	347,943	358,827	347,943	358,827
Mortgage-backed Securities (CRIs) – 9th issue 1st series (a)	IPCA	6.38%	R\$	30,000	Aug/22	Jul/29	Bullet	n/a	31,361	32,878	31,361	32,878
Mortgage-backed Securities (CRIs) – 9th issue 2nd series (a)	IPCA	6.54%	R\$	70,000	Aug/22	Jul/32	Bullet	n/a	72,751	77,891	72,751	77,891
Mortgage-backed Securities (CRIs) – 9th issue 3rd series (a)	IPCA	6.77%	R\$	400,000	Aug/22	Jul/37	Bullet	n/a	414,234	455,707	414,234	455,707
Mortgage-backed Securities (CRIs) – 10th issue 1st series	100% of DI	0.75%	R\$	86,186	Dec/22	Dec/27	Bullet	n/a	86,936	84,389	86,936	84,389
Mortgage-backed Securities (CRIs) – 10th issue 2nd series	100% of DI	1.00%	R\$	176,323	Dec/22	Dec/29	Bullet	n/a	215,839	197,673	215,839	197,673
Mortgage-backed Securities (CRIs) - 10h issue 3rd series (a)	IPCA	6.79%	R\$	82,487	Dec/22	Dec/29	Bullet	n/a	85,984	88,031	85,984	88,031
Mortgage-backed Securities (CRIs) - 10h issue 4th series (a)	IPCA	6.94%	R\$	55,004	Dec/22	Dec/32	Annual	n/a	56,929	59,112	56,929	59,112
Mortgage-backed Securities (CRIs) – 11th issue 1st series	100% of DI	1.00%	R\$	429,340	Aug/23	Aug/28	Bullet	n/a	425,417	437,256	425,417	437,256
Mortgage-backed Securities (CRIs) - 11h issue 2nd series (a)	IPCA	6.20%	R\$	557,457	Aug/23	Aug/30	Bullet	n/a	543,511	573,663	543,511	573,663
Mortgage-backed Securities (CRIs) - 11h issue 3rd series (a)	IPCA	6.55%	R\$	524,038	Aug/23	Aug/33	Annual	n/a	505,686	543,196	505,686	543,196
Mortgage-backed Securities (CRIs) - 12h issue 1st series (a)	IPCA	6.69%	R\$	250,000	Dec/23	Dec/33	Annual	n/a	248,852	244,414	248,852	244,414
Mortgage-backed Securities (CRIs) - 12h issue 2nd series (a)	IPCA	6.95%	R\$	500,000	Dec/23	Dec/38	Annual	n/a	494,135	488,860	494,135	488,860
									31,774,467	31,650,338	35,707,175	34,585,949
								Current	2,960,243	2,587,944	3,006,658	2,918,435
										•	. ,	31,667,514
								Noncurrent	28,814,224	29,062,394	32,700,517	

⁽a) As mentioned in Note 24, the Group enters into derivative financial instruments to hedge foreign exchange differences and interest rate (Fixed rate, SOFR and IPCA) and has adopted the fair value hedge accounting as accounting practice; therefore, these debts are recorded at fair value through profit or loss.

⁽b) As mentioned in Note 24, the Group enters into derivative financial instruments to hedge interest rate (CDI) and has adopted the cash flow hedge accounting as accounting practice; therefore, these debts are recorded at amortized cost and derivatives at fair value; the effective portion of the debt is recorded at fair value through other comprehensive income and any ineffective portion and interest at fair value through profit or loss.

⁽c) On February 1, 2024, Rede D'Or exercised the Optional Early Redemption in Full of the Eighth Issue of Debentures of Sul América S.A., which was succeeded by Rede D'Or due to merger. As of that date, there are no covenants related to the Eighth Issue of Debentures of Sul América S.A. (see Note 13.1.).

⁽d) On May 15, 2024, Rede D'Or paid in the 33rd issue of Debentures in a single series, in the total amount of R\$2,000,0000, maturing on May 5, 2034. This debenture issue is indexed to the CDI + 1.70% p.a., payable semiannually. There are no guarantees.

Notes to interim financial information (Continued) September 30, 2024 (In thousands of reais, unless otherwise stated)

13. Loans, financing and debentures (Continued)

Significant loans, financing and debentures were taken out for general corporate purposes, in order to acquire companies, expand hospitals and build new units.

Total costs related to the issues of loans, financing and debentures, in the amount of R\$298,301 at September 30, 2024 (R\$347,517 at December 31, 2023), were recorded as a reduction of the balances and have been amortized over the term of the agreements, as established by CPC 08 - Transactions Costs and Premiums on Issue of Marketable Securities.

Before the SASA business combination, the Company did not have covenants relating to debt ratios, nor corresponding ratios based on net debt, EBITDA and finance costs rather than the guarantees listed above. Since, as a result of the merger, the Company is the successor, there are covenants whose application is suspended, as shown in Note 13.1. below.

At September 30, 2024, the maturity of noncurrent balances is as follows:

	09/	30/2024	
Ind	ividual	Cons	solidated
Year	Amount	Year	Net
2025	1,995,481	2025	1,994,015
2026	1,508,234	2026	2,082,373
2027	1,169,146	2027	1,913,626
2028	4,258,876	2028	5,585,414
2029	4,236,702	2029	4,405,585
2030 to 2038	15,645,785	2030 to 2038	16,719,504
	28,814,224		32,700,517

13.1. Covenants

The Company is exempt from the obligation to meet any financial ratios (financial *covenants*) until the quarters stated below, per transaction, as approved at the general meeting of debenture holders held on August 18, 2022.

Issue	Exempt until
Ninth issue of debentures of Sul América S.A.	3rd quarter of 2025

The Company may settle in advance the respective issues before the *covenants* mentioned above become applicable.

Notes to interim financial information (Continued) September 30, 2024 (In thousands of reais, unless otherwise stated)

13. Loans, financing and debentures (Continued)

13.1. Covenants (Continued)

From the quarters above, and in accordance with the early maturity clauses contained in the debenture indentures of the Ninth Issue of Debentures of Sul América S.A., the Company will have to maintain certain financial ratios within the previously established thresholds (financial covenants). The table below presents the financial *covenants* to which the Company will be subject.

	С	Covenant	Ratio
--	---	----------	-------

Financial ratio I - net financial debt/cash generation

Financial ratio II - cash generation/net finance income (cost) Financial ratio III - cash generation

Equal to or lower than 2 times the cash generation
Equal to or higher than 4 times the net finance
income (cost)
Equal to or higher than zero

<u>Net financial debt:</u> financial obligations less cash, cash equivalents and short-term investments, net of technical reserves to be covered.

Cash generation: profit or loss before income taxes, less depreciation and amortization.

Notes to interim financial information (Continued) September 30, 2024 (In thousands of reais, unless otherwise stated)

14. Provision for contingencies and judicial deposits

The Company and its subsidiaries are parties to various tax, civil and labor claims. The judicial deposits will only be released in the event of a decision favorable to the Company. Based on the opinion of its internal and external legal advisors, management recognized a provision for losses that is deemed sufficient to cover probable losses, as follows:

		Indi	vidual	
	09/30/2	2024	12/31/2	2023
	Provision for contingencies	Judicial deposits	Provision for contingencies	Judicial deposits
Tax and social security	463,014	(343,681)	526,597	(321,576)
Labor	131,092	(36,933)	136,284	(37,163)
Civil	157,616	(3,627)	157,304	(3,627)
	751,722	(384,241)	820,185	(362,366)

		Cons	olidated	
	09/30/	2024	12/31/	2023
	Provision for contingencies	Judicial deposits	Provision for contingencies	Judicial deposits
Tax and social security	1,697,662	(2,086,637)	1,714,567	(2,107,976)
Labor	283,489	(119,528)	293,306	(126,887)
Civil	1,391,519	(543,434)	1,260,481	(447,693)
	3,372,670	(2,749,599)	3,268,354	(2,682,556)

Notes to interim financial information (Continued) September 30, 2024 (In thousands of reais, unless otherwise stated)

14. Provision for contingencies and judicial deposits (Continued)

14.1. Proceedings assessed as probable loss

Changes in provisions for contingencies for the periods ended September 30, 2024 and 2023 were as follows:

Individual

		Indi	vidual			
	Tax and social security	Labor	Civil	Total		
			-			
Balances at December 31, 2022	931,974	106,200	170,768	1,208,942		
Additions, net of reversals	(431,762)	17,102	(17,062)	(431,722)		
Monetary restatement	6	4,700	3,840	8,546		
Payments	(236)	(188)	(849)	(1,273)		
Balances at September 30, 2023	499,982	127,814	156,697	784,493		
Balances at December 31, 2023	526,597	136,284	157,304	820,185		
Additions, net of reversals	(64,869)	-	-	(64,869)		
Monetary restatement	1,289	4,763	2,086	8,138		
Payments	(3)	(9,955)	(1,774)	(11,732)		
Balances at September 30, 2024	463,014	131,092	157,616	751,722		
	Consolidated					
	Tax and social	COIISO	iluateu			
	security	Labor	Civil	Total		
Balances at December 31, 2022	2,379,022	267,772	1,145,378	3,792,172		
Additions, net of reversals	(433,213)	12,661	221,987	(198,565)		
Monetary restatement	52,725	16,788	82,158	151,671		
Changes in equity	-	8,719	-	8,719		
Payments	(296,044)	(14,614)	(217,417)	(528,075)		
Balances at September 30, 2023	1,702,490	291,326	1,232,106	3,225,922		
Balances at December 31, 2023	1,714,567	293,306	1,260,481	3,268,354		
Additions, net of reversals	(64,438)	2,585	326,639	264,786		
Monetary restatement	44,882	14,061	90,334	149,277		
Payments	(319)	(26,463)	(285,935)	(312,717)		
Additions from business combinations	2,970	-	-	2,970		
Balances at September 30, 2024	1,697,662	283,489	1,391,519	3,372,670		

Notes to interim financial information (Continued) September 30, 2024 (In thousands of reais, unless otherwise stated)

14. Provision for contingencies and judicial deposits (Continued)

14.2. Proceedings assessed as possible loss

The proceedings assessed as possible loss by the Company and its legal advisors, for which no provisions have been recorded, are summarized below:

	Individual		Conso	lidated
	09/30/2024	12/31/2023	09/30/2024	12/31/2023
Tax and social security (a) (b)	917,829	2,125,838	2,606,336	3,649,564
Labor (c)	345,645	343,495	649,307	597,694
Civil (d)	359,130	333,865	751,304	684,233
	1,622,604	2,803,198	4,006,947	4,931,491

- (a) Administrative Proceedings No. 10166-720689/2017-18 and 10166-730.893/2017-39, which addressed tax assessments that required Social Security Contributions on outsourced medical activities - workers hired as legal entities rather than under an employment agreement ('pejotização') and Stock Option Grant Plans - had their voluntary appeals deemed founded for substantial cancellation of the assessment notices, keeping only approximately R\$2,000 in the sessions of 02/06/2024 and 02/07/2024 of CARF, respectively. Considering that the Company was notified of the final decisions, the amounts related to these proceedings were written off.
- (b) At 09/30/2024, of the total amount of R\$1,329,938 (R\$1,273,029 at 12/31/2023), the amount of R\$41,586 (R\$40,225 at 12/31/2023) is provisioned, since it basically refers to legal obligations. The non-provisioned portion, in the amount of R\$1,265,148 (R\$1,232,804 at 12/31/2023) is mainly composed of: (i) assessment notices issued against subsidiaries CIA. SAÚDE and TRADITIO, in which the deductibility of amortization of goodwill arising from the merger of parent companies SLT Participações S.A. and STA Participações S.A., respectively, in calendar years 2005, 2006 and 2007, was challenged; (ii) non-approval of tax offsetting at the administrative level; (iii) disallowance of income tax loss and social contribution loss carryforwards; and (iv) claim aimed at charging ISS debits arising from the alleged failure to pay tax on the services provided in the City of São Paulo, at the appellate phase, given the favorable decision in the Stay of Execution filed by SulAmérica.
- (c) Proceedings largely derived from overtime payment, 13th monthly salary, 30-day resignation notice, vacation pay and Unemployment Compensation Fund (FGTS). There are no individually significant proceedings.
- (d) Proceedings related to compensation for alleged property and pain and suffering damages. There are no individually significant proceedings.

Considering the complexities of the lawsuits, as well as of the Brazilian legal system, the Company cannot estimate with reasonable accuracy a timeframe for the judgment to take place and whether any amounts will be disbursed in connection with these legal proceedings.

Notes to interim financial information (Continued) September 30, 2024 (In thousands of reais, unless otherwise stated)

15. Leases

	Individual			
	09/30/2024	12/31/2023		
Nominal value of future payments	6,461,799	6,351,952		
Present value adjustment	(3,676,863)	(3,779,618)		
	2,784,936	2,572,334		
Current	621,323	534,822		
Noncurrent	2,163,613	2,037,512		
	Conso	lidated		
	09/30/2024	12/31/2023		
Nominal value of future payments	8,851,234	8,397,767		
Present value adjustment	(5,397,548)	(5,225,142)		
	3,453,686	3,172,625		
Current	777,973	872,949		
Noncurrent	2,675,713	2,299,676		

The liabilities were measured at the present value of the remaining lease payments discounted at the average rate of 14.70% at September 30, 2024.

At September 30, 2024, the maturity of noncurrent balances is as follows:

Individu	ıal	Consolid	lated
Year	Amount	Year	Amount
2025	146,179	2025	177,680
2026	535,271	2026	634,481
2027	514,159	2027	584,964
2028	467,756	2028	529,649
2029	384,440	2029	465,161
2030 to 2059	3,792,787	2030 to 2082	5,664,235
Undiscounted amounts	5,840,592	Undiscounted amounts	8,056,170
Embedded interest	(3,676,979)	Embedded interest	(5,380,457)
Balance at 09/30/2024	2,163,613	Balance at 09/30/2024	2,675,713

Notes to interim financial information (Continued) September 30, 2024 (In thousands of reais, unless otherwise stated)

16. Equity

a) Capital

The Company's capital is broken down as follows:

	09/30	0/2024	12/31/2023			
Shareholders	Number of shares	Equity interest	Number of shares	Equity interest		
Controlling interests Outstanding shares	1,082,078,826 1,160,005,301	47.27% 50.67%	1,068,474,126 1,186,132,584	46.67% 51.81%		
Treasury shares	47,208,463	2.06%	34,685,880	1.52%		
Total common shares	2,289,292,590	100%	2,289,292,590	100.00%		

Subscribed and paid-in capital at September 30, 2024 amounts to R\$15,711,360 represented by 2,289,292,590 common registered no-par-value shares (R\$15,711,360 at December 31, 2023 represented by 2,289,292,590 common registered no-par-value shares). As approved in the Company's Articles of Incorporation, the limit of authorized capital is up to 8 billion shares (units).

Under the Company's Articles of Incorporation, each common share is entitled to a vote at the Company's general meetings.

On December 8, 2020, in connection with the IPO, the Company increased capital by R\$4,218,850 and increased capital reserve by R\$4,218,820. On May 26, 2021, in connection with the follow-on, the Company increased capital by R\$888,920 and increased capital reserve by R\$888,920. Other events took place in 2021 and 2022 that reduced the capital reserve.

At the Special General Meeting (SGM) held on September 24, 2020, shareholders approved the Company's capital increase in the amount of R\$1,600,000, without issue of new shares, through capitalization of part of the legal reserve.

The premium reserve on issue of shares derived substantially from capital contributions made (i) on March 31, 2015, by the former shareholder BTG Pactual Saúde Fundo de Investimento em Participações, in the amount of R\$600,000, of which R\$147,664 were recorded as capital increase and R\$452,336 as premium reserve on the subscription of shares; and (ii) on April 27, 2015, by HPT Participações S.A. (Carlyle Group investee), in the amount of R\$1,819,435, of which R\$181,943 for capital increase and R\$1,637,491 as premium reserve on the subscription of shares.

Notes to interim financial information (Continued) September 30, 2024 (In thousands of reais, unless otherwise stated)

16. Equity (Continued)

b) Allocations of income

Changes in the balances of dividends and interest on equity payable in the periods ended September 30, 2024 and 2023 were as follows:

	2024	2023
Balance payable at December 31	99,769	145,085
Allocation of dividends and IOE	1,000,000	416,288
Reinvested dividends	(25,066)	-
Additions from business combination	`17,60 4	-
Allocation of dividends and IOE - noncontrolling interests	65,263	52,963
Payment of dividends and IOE	(712,412)	(161,690)
Withholding income tax	(114,005)	(48,936)
Balance payable at September 30	331,153	403,710

The distribution and payments of dividends and interest on equity were approved at the Board of Directors' Meeting held on March 21, 2024, June 25, 2024 and September 23, 2024, ad referendum of the Company's Annual General Meeting (AGM).

c) <u>Treasury shares</u>

Changes in treasury shares are as follows:

		09/30/2024			09/30/2023	
	Number of shares	Share value (in reais)	Total	Number of shares	Share value (in reais)	Total
Balance at December 31	34,685,880	14.97	519,418	36,334,156	14.99	544,610
Share buyback (a)	12,912,900	26.46	341,739	-	-	-
Returns	121,909	-	-	32,473	-	-
Disposals	(512,226)	14.97	(7,671)	(1,680,749)	14.99	(25,193)
Balance at September 30	47,208,463	18.08	853,486	34,685,880	14.97	519,417

⁽a) On June 11, 2024, the buyback program of shares issued by the Company was approved for maintenance in treasury and subsequent cancellation or disposal.

Notes to interim financial information (Continued) September 30, 2024 (In thousands of reais, unless otherwise stated)

16. Equity (Continued)

d) Share-based payment (Restricted shares)

Restricted Stock Option Plan

The plan establishes the terms and conditions for the granting of common shares issued by the Company, subject to certain restrictions, to managing officers, employees and service providers of the Company, or of other companies under its control.

1st Restricted Stock Option Program

In 2020, the Company's Board of Directors approved the 1st Restricted Stock Option Program and established the conditions for the granting of the Company's common registered no-par-value shares to managing officers and employees.

The rights of beneficiaries in relation to restricted shares will only be fully vested if their contract with the Company or with any entity under its control, as the case may be, is not terminated for a certain period, subject to the conditions for the release of trading restrictions, as defined by the Board of Directors, with specific conditions in case of termination.

The total restricted shares delivered through the Restricted Stock Option Plan cannot exceed the maximum limit of 5% (five percent) of shares issued by the Company, which at September 30, 2024 was equivalent to a total of 114,464,630 shares.

In the nine-month period ended September 30, 2024, a total of 706,519 Restricted Shares was granted to the elected beneficiaries, referring exclusively to the 1st Restricted Stock Option Program, at the weighted average price of R\$18.85. All restricted shares granted in the nine-month period ended September 2024, 2024 were *vested* immediately on January 02, 2024, and there are no restricted shares already granted that have not been vested.

Of the total shares mentioned above, for purposes of measuring shareholder dilution, the total amount of shares effectively vested for the beneficiaries under the 1st Restricted Stock Option Program was 512,226 shares, referring exclusively to the Restricted Stock Option Plan, in accordance with item 33-E of Accounting Pronouncement CPC 10 - Share-Based Payment.

For calculating the expenses to be allocated, a projected cancellation rate of 7.14% was used for 2024, based on the average historical cancellations of the Company's plans.

Notes to interim financial information (Continued) September 30, 2024 (In thousands of reais, unless otherwise stated)

16. Equity (Continued)

d) Share-based payment (restricted shares) - Continued

Restricted Stock Option Plan (Continued)

2nd Restricted Stock Option Program

Within the scope of the Restricted Stock Option Plan, the Company's Board of Directors approved the 2nd Restricted Stock Option Program, beginning January 2022, which established the specific conditions for receiving a certain amount of units of reference that will entitle to the settlement of awards provided for in the individual grant agreements, which can be settled with common registered no-par-value shares of the Company to its managing officers, employees and service providers, or in cash, at the Company's discretion, depending, in that case, on the appreciation of the RDOR3 share price in a certain period of time, or on the variation of multiples of the Company's EBITDA, under the terms of the individual agreements.

During the nine-month period ended in September 2022, 3,245,809 Units of Reference in total were granted to the elected beneficiaries, exclusively related to the 2nd Restricted Stock Option Program, which is not yet fully vested.

The 2nd Restricted Stock Option Program is measured and recognized at fair value, using the Company's valuation identification model (Market cap) and deducting the reference value agreed with each executive officer, duly restated by reference to the IPCA or by the variation of multiples of the Company's EBITDA, according to Accounting Pronouncement CPC 10 - Share-Based Payment.

The rights of the beneficiaries in relation to the restricted shares will only be fully vested if their contract with the Company or any entity under its control, as the case may be, is not terminated for a certain period and if the result of the award arising from the exercise of their units of reference is positive in the specific settlement windows provided for in the individual agreements, which implies that the RDOR3 share price at the time of the settlement window, or there has been progress in the result of the formula that observes the variation of EBITDA, for the Beneficiary to be entitled to receive it, with specific conditions in case of termination. The Company pays all taxes and charges levied on the award at the time of its settlement in shares, or in cash, at its sole discretion.

Notes to interim financial information (Continued) September 30, 2024 (In thousands of reais, unless otherwise stated)

16. Equity (Continued)

d) Share-based payment (restricted shares) - Continued

Restricted Stock Option Plan (Continued)

2nd Restricted Stock Option Program (Continued)

For calculating the expenses to be allocated, a cancellation rate of 7.14% was used in 2024, based on the average historical cancellations of the Company's plans.

Like previous plans, the 1st Restricted Stock Option Program was measured and recognized at fair value using the Black, Scholes & Merton (1973) model, according to Accounting Pronouncement CPC 10 - Share-Based Payment, whose main assumptions are described below.

The 2nd Restricted Stock Option Program is measured and recognized at fair value, using the Company's valuation identification model (Market cap) and deducting the reference value agreed with each executive officer, duly restated by reference to the IPCA, according to Accounting Pronouncement CPC 10 - Share-Based Payment.

			Number of	Annual	Risk-free	Weighted average of fair value of shares		Options
Program	Year	Grace period	shares	volatility	rate	(in reais)	Vesting status	canceled
1st program	2020	05/29/2020 to 05/29/2027	46,591,300	26.36%	4.66%	7.45	Partially vested	-
1st program	2021	04/01/2021 to 04/01/2028	5,361,026	28.81%	5.98%	25.50	Partially vested	-
1 st program	2022	01/01/2022 to 01/01/2028	3,577,793	32.75%	11.55%	15.03	Partially vested	-
2nd program	2022	01/01/2022 to 12/31/2028	2,392,730	-	-	29.16	Partially vested	75,002
1 st program	2023	01/01/2023 to 12/31/2028	2,371,279	44.56%	11.64%	12.95	Partially vested	-
2nd program	2023	01/01/2023 to 12/31/2029	2,731,014	-	-	19.15	Partially vested	3,572
1 st program	2024	01/01/2024 to 12/31/2028	706,519	43.61%	9.77%	11.07	Partially vested	-
2nd program	2024	01/01/2024 to 12/31/2030	3,245,809	-	-	22.70	Partially vested	2,857

Notes to interim financial information (Continued) September 30, 2024 (In thousands of reais, unless otherwise stated)

16. Equity (Continued)

d) Share-based payment (restricted shares) - Continued

Restricted Stock Option Plan (Continued)

The effects of the share-based payment plans, covering all granted and outstanding options, on equity and profit or loss for the year, are as follows:

	Fair value of	Effect on P&L for		Cumulative effect on liabilities and
	options per year	the year	Changes - RSU	equity
2011	1,457	1,457	_	1,457
2012	16,234	16,234	_	17,691
2013	20,656	20,656	_	38,347
2014	27,363	27,363	_	65,710
2015	51,949	51,949	_	117,659
2016	30,864	30,864	_	148,523
2017	32,599	32,599	_	181,122
2018	40,662	40,662	_	221,784
2019	40,656	40,656	_	262,440
2020	80,071	80,071	(80,071)	
2021	120,427	120,427	(120,427)	-
2022	124,276	124,276	(70,623)	53,653
2023	78,400	78,400	(42,769)	37,179
2024	58,430	58,430	(14,198)	44,232
2025	11,670	•	, ,	,
2026	11,670			
2027	11,670			
	759,054	_		

e) Other comprehensive income

In the nine-month period ended September 30, 2024, the effects of the cash flow *hedge* taken out for debt hedging purposes were recognized as other comprehensive income, decreasing equity for the period by R\$855.

Notes to interim financial information (Continued) September 30, 2024 (In thousands of reais, unless otherwise stated)

17. Current and deferred taxes

Income and social contribution tax expenses for the nine-month periods ended September 30, 2024 and 2023 are as follows:

	Indiv	idual	Consolidated		
	09/30/2024	09/30/2023	09/30/2024	09/30/2023	
Deferred					
Corporate Income Tax (IRPJ)	110,298	12,814	198,882	170,103	
Social Contribution Tax on Net Profit (CSLL)	40,449	4,614	69,369	88,758	
·	150,747	17,428	268,251	258,861	
Current					
Corporate Income Tax (IRPJ) Social Contribution Tax on Net Profit	1,060	-	(697,867)	(385,990)	
(CSLL)	421	-	(328,143)	(153,986)	
·	1,481	-	(1,026,010)	(539,976)	
Income and social contribution tax	·		•	• •	
expenses	152,228	17,428	(757,759)	(281,115)	

Notes to interim financial information (Continued) September 30, 2024 (In thousands of reais, unless otherwise stated)

17. Current and deferred taxes (Continued)

Changes in deferred income and social contribution tax assets and liabilities for the nine-month periods ended September 30, 2024 and 2023 were as follows:

	Individual				Consolidated						
	12/31/2023	Additional benefits (expenses) recorded	Other comprehensive income	Other (1)	09/30/2024	12/31/2023	Additional benefits (expenses)	Other comprehensiv e income	Other (1)	Additions from business combination	09/30/2024
Assets											
Income tax losses	625,977	15,152	-	(138,524)	502,605	1,213,641	(59,066)	-	(140,992)	33	1,013,616
Social contribution tax losses	225,352	6,196	-	(15,330)	216,218	427,944	(46,095)	-	(15,913)	20	365,956
Allowance for expected credit losses and											
provision for disallowances	329,421	195,683	-	-	525,104	675,202	271,237	-	-	-	946,439
Provision for contingencies	76,002	(1,222)	-	-	74,780	847,002	81,013	-	-	1,060	929,075
Provision for bonuses	30,416	42,228	-	-	72,644	31,873	60,739	-	-	-	92,612
Deferred gain on property sales	21,909	(1,000)	-	-	20,909	16,538	(1,000)	-	-	•	15,538
Amortization of right of use (IFRS 16)	344,484	65,882	-	-	410,366	576,645	97,274	-	-	•	673,919
PVA allocation (IFRS 16)	571,059	100,849	•	-	671,908	803,240	152,289	-	-	-	955,529
D'Or Finance	59,062	6,637	•	-	65,699	59,062	6,637	-	-	-	65,699
Actuarial gain/loss on defined benefit						44.040					44.040
pension plans	-	-	•	-	•	11,910	(04.000)	•	-	•	11,910
Impairment of tax credits Insurance contracts - IFRS 17	-	-	•	-	•	76,559	(31,282)	(400 E20)	-	•	45,277 1,494,110
Other provisions	37,355	185	•	-	37,540	1,524,585	159,055	(189,530)	•	•	1,494,110
Total deferred tax assets	2,321,037	430,590		(153,854)	2,597,773	6,264,201	690,801	(189,530)	(156,905)	1,113	6,609,680
Total deletred tax assets	2,321,037	430,390		(153,654)	2,591,773	0,204,201	090,801	(169,530)	(136,903)	1,113	0,009,000
Liabilities											
Differences between accounting and tax											
bases of goodwill	(735,080)	(45,314)		_	(780,394)	(1,119,531)	(157,215)	_	-		(1,276,746)
Gain on acquisition in stages	(99,040)	(10,01.1)		_	(99,040)	(124,003)	(.0.,=.0,	_			(124,003)
Swap difference	(82,804)	(121,569)		_	(204,373)	(49,721)	(121,569)	_			(171,290)
Foreign exchange differences	(34,791)	50.066		-	15.275	(34,791)	50,287	-	-	-	15,496
Leases (IFRS 16)	(755,084)	(150,113)		-	(905,197)	(1,151,821)	(220,415)	-	-	-	(1,372,236)
Cash flow hedge	(61,744)	-	(4,358)	-	(66,102)	(82,637)	-, -,	(441)	-		(83,078)
Deferred revenue	(2,666)	-	•	-	(2,666)	(7,601)	-	· · ·	-		(7,601)
Variable income investment	-	-	-	-	•	(6,812)	-	-	-	-	(6,812)
Revaluation surplus - business			-	-	(550,027)			-	-	-	
combinations	(537,114)	(12,913)				(537,114)	(12,913)				(550,027)
Gain/loss on market value adjustment	-	-	-	-	_	(26,358)	2,506	7,473	-	-	(16,379)
Other provisions	(22,106)	-	-	-	(22,106)	(69,199)	36,769		-	2,685	(29,745)
Total deferred tax liabilities	(2,330,429)	(279,843)	(4,358)	-	(2,614,630)	(3,209,588)	(422,550)	7,032	-	2,685	(3,622,421)
Net effect - asset (liability)	14,506	150.747	-	(153,854)	11,399	3,154,935	268,251	_	(156,905)	3,798	3,270,079
Net effect - deferred PIS/COFINS	21,614	-		(.00,00.)	41,919	376,838			(.00,000,	-	498,904
Effect on equity	(23,898)	-	(4,358)	-	(28,256)	(100,322)	-	(182,498)	-	-	(282,820)
Assets as per statement of financial position	12,222				25,062	3,600,118					3,720,803
Liabilities as per statement of financial position	-				-	(168,667)					(234,640)

⁽¹⁾ The reduction in the balance of tax credits recognized on income and social contribution tax loss derived notably from the use of this total within the scope of the tax self-regularization program set forth by the Brazilian IRS.

Notes to interim financial information (Continued) September 30, 2024 (In thousands of reais, unless otherwise stated)

17. Current and deferred taxes (Continued)

Assets Income tax losses Social contribution tax losses Allowance for expected credit losses and provision for disallowances Provision for contingencies Provision for bonuses Deferred gain on property sales Amortization of right of use (IFRS 16) PVA allocation (IFRS 16) D'Or Finance Actuarial gain/loss on defined benefit pension plans Impairment of tax credits Insurance contracts - IFRS 17	12/31/2022	Additional benefits (expenses)	Other comprehensive				Other	
Income tax losses Social contribution tax losses Allowance for expected credit losses and provision for disallowances Provision for contingencies Provision for bonuses Deferred gain on property sales Amortization of right of use (IFRS 16) PVA allocation (IFRS 16) D'Or Finance Actuarial gain/loss on defined benefit pension plans Impairment of tax credits	12/31/2022		comprehensive					
Income tax losses Social contribution tax losses Allowance for expected credit losses and provision for disallowances Provision for contingencies Provision for bonuses Deferred gain on property sales Amortization of right of use (IFRS 16) PVA allocation (IFRS 16) D'Or Finance Actuarial gain/loss on defined benefit pension plans Impairment of tax credits	12/31/2022					Additional benefits	comprehensive	
Income tax losses Social contribution tax losses Allowance for expected credit losses and provision for disallowances Provision for contingencies Provision for bonuses Deferred gain on property sales Amortization of right of use (IFRS 16) PVA allocation (IFRS 16) D'Or Finance Actuarial gain/loss on defined benefit pension plans Impairment of tax credits		recorded	income	09/30/2023	12/31/2022	(expenses)	income	09/30/2023
Social contribution tax losses Allowance for expected credit losses and provision for disallowances Provision for contingencies Provision for bonuses Deferred gain on property sales Amortization of right of use (IFRS 16) PVA allocation (IFRS 16) D'Or Finance Actuarial gain/loss on defined benefit pension plans Impairment of tax credits								
Allowance for expected credit losses and provision for disallowances Provision for contingencies Provision for bonuses Deferred gain on property sales Amortization of right of use (IFRS 16) PVA allocation (IFRS 16) D'Or Finance Actuarial gain/loss on defined benefit pension plans Impairment of tax credits	392.468	133,990	-	526,458	967,814	197.494	-	1,165,308
disallowances Provision for contingencies Provision for bonuses Deferred gain on property sales Amortization of right of use (IFRS 16) PVA allocation (IFRS 16) D'Or Finance Actuarial gain/loss on defined benefit pension plans Impairment of tax credits	141,288	48,236	-	189,524	349,821	70,589	-	420,410
disallowances Provision for contingencies Provision for bonuses Deferred gain on property sales Amortization of right of use (IFRS 16) PVA allocation (IFRS 16) D'Or Finance Actuarial gain/loss on defined benefit pension plans Impairment of tax credits	,	-,		/-	,-	-,		-,
Provision for bonuses Deferred gain on property sales Amortization of right of use (IFRS 16) PVA allocation (IFRS 16) D'Or Finance Actuarial gain/loss on defined benefit pension plans Impairment of tax credits	285,442	39,691	-	325,133	589,369	80,987	-	670,356
Provision for bonuses Deferred gain on property sales Amortization of right of use (IFRS 16) PVA allocation (IFRS 16) D'Or Finance Actuarial gain/loss on defined benefit pension plans Impairment of tax credits	50,848	8,144	-	58,992	786,169	31,463	_	817,632
Deferred gain on property sales Amortization of right of use (IFRS 16) PVA allocation (IFRS 16) D'Or Finance Actuarial gain/loss on defined benefit pension plans Impairment of tax credits	24,038	(1,974)	-	22.064	25.517	16.613	_	42,130
Amortization of right of use (IFRS 16) PVA allocation (IFRS 16) D'Or Finance Actuarial gain/loss on defined benefit pension plans Impairment of tax credits	23,242	(1,000)	-	22,242	17,871	1,453	_	19,324
PVA allocation (IFRS 16) D'Or Finance Actuarial gain/loss on defined benefit pension plans Impairment of tax credits	255,703	62,845	_	318,548	401,700	139,738	_	541,438
D'Or Finance Actuarial gain/loss on defined benefit pension plans Impairment of tax credits	428,916	95,402		524,318	591,927	156,378		748,305
Actuarial gain/loss on defined benefit pension plans Impairment of tax credits	53,103	5,984	_	59,087	53,103	5,984	_	59,087
Impairment of tax credits	-	0,004	_	-	11.910	0,004	_	11,910
	_	_		_	73,704	5,501		79,205
	_	_	_	_	1,378,144	119,080	65,661	1,562,885
Other provisions	24.421	7,958	-	32,379	1,570,144	113,000	00,001	1,302,003
Total deferred tax assets	1,679,469	399,276		2,078,745	5,247,049	825,280	65,661	6,137,990
Liabilities								
Differences between accounting and tax bases of	(744.044)	(44.004)		(700.040)	(000, 400)	(404 000)		(4.004.754)
goodwill	(711,911)	(11,001)	-	(722,912)	(930,432)	(134,322)	-	(1,064,754)
Gain on acquisition in stages	(99,040)	(40.070)	-	(99,040)	(124,003)	-	-	(124,003)
Swap difference	(65,308)	(18,273)	-	(83,581)	(62,459)	11,961	-	(50,498)
Foreign exchange differences	30,105	(53,770)	-	(23,665)	30,105	(53,770)	-	(23,665)
Lease (IFRS 16)	(563,923)	(136,178)		(700,101)	(818,725)	(260,086)		(1,078,811)
Cash flow hedge	(133,621)	-	48,539	(85,082)	(159,738)	-	52,456	(107,282)
Deferred revenue	(2,666)	-	-	(2,666)	(7,601)	-	-	(7,601)
Variable income investment	-	. .	(6,812)	. .	-	(6,812)
Revaluation surplus - business combinations	(402,540)	(137,643)	-	(540,183)	(402,540)	(137,643)		(540,183)
Gain/loss on market value adjustment	-	-	-	-	13,158	(18,262)	(13,457)	(18,561)
Other provisions	-	(24,983)	-	(24,983)	(55,315)	25,725		(29,590)
Total deferred tax liabilities	(1,948,904)	(381,848)	48,539	(2,282,213)	(2,524,362)	(566,397)	38,999	(3,051,760)
Net effect - asset (liability)	(135,814)	17,428	-	(118,386)	2,882,425	258,883	-	3,141,308
Net effect - deferred PIS/COFINS	-	, -	-	. ,,	238,461	-	-	308,112
Effect on equity	(133,621)	-	48,539	(85,082)	(159,738)	-	104,660	(55,078)
Assets as per statement of financial position	_	_	_		3.366.280			3.716.487
Liabilities as per statement of financial position								J. / ID.40/

Notes to interim financial information (Continued) September 30, 2024 (In thousands of reais, unless otherwise stated)

17. Current and deferred taxes (Continued)

The reconciliation of income and social contribution taxes to the amount determined at the statutory rate as at September 30, 2024 and 2023 is as follows:

	Indiv	ridual	Consolidated	
	09/30/2024	09/30/2023	09/30/2024	09/30/2023
Income before income and social contribution				
taxes	2,769,692	1,255,138	3,757,095	1,603,343
Income and social contribution tax expenses at statutory rates Social contribution tax rate difference (a)	941,695	426,747 -	1,277,412 69,588	545,137 26,956
Adjustments to determine the effective rate: Equity pickup, net of any gains earned abroad Interest on equity	(699,309) (340,000)	(301,841) (141,538)	(11,609) (340,000)	(19,400) (141,538)
Accrual (reversal) of tax credit on temporary differences Restatement of judicial deposits	-	-	2,168 (13,808)	(72,979) (7,865)
Unduly paid taxes computed Deduction from programs under tax incentive First-time adoption - SUSEP Circular No.	(51,741)	-	(14,745) (53,225)	(22,759) -
678/2022 Impact on companies taxed due to rate	-	-	(49,323)	-
difference Deferred and recorded (Workers' Meal	-	-	(38,153)	(36,077)
Program - PAT) Other	(2,873)	(796)	(36,042) (34,504)	9,640
Expenses (credit) recorded in the statement of profit or loss	(152,228)	(17,428)	757,759	281,115

⁽a) Refers to the difference in the social contribution rate between financial and similar companies (15%) and non-financial subsidiaries (9%).

Accumulated income and social contribution tax losses may be carried indefinitely; however, offsetting is limited to 30% of taxable profit generated in each fiscal year.

The Company expects that deferred tax credits over its tax loss carryforwards will be realized within 1 or 5 years, except for the deferred gain related to the sale of real estate, whose realization will occur over the contractual rent period.

Notes to interim financial information (Continued) September 30, 2024 (In thousands of reais, unless otherwise stated)

18. Net revenue

		Individual		Consolidated	
Description	Note	09/30/2024	09/30/2023	09/30/2024	09/30/2023
Hospital services	18,1	10,855,502	9,932,677	16,106,060	15,025,030
Insurance revenue	18,2	-	-	21,548,407	19,671,320
Revenue from asset management		-	-	67,830	=
•		10,855,502	9,932,677	37,722,297	34,696,350

18.1. Hospital services

	Indiv	vidual 💮	Consolidated	
	09/30/2024	09/30/2023	09/30/2024	09/30/2023
Gross revenue (a)	12,109,767	11,068,543	18,482,512	17,166,858
Deductions from revenue				
Cancellations and rebates (a)	(577,306)	(519,376)	(1,004,909)	(927,111)
Taxes on revenues	(676,959)	(616,490)	(1,371,543)	(1,214,717)
Net revenue from hospital services	10,855,502	9,932,677	16,106,060	15,025,030

⁽a) Includes eliminations of Gross Revenue and Cancellations and rebates between the Group companies in the net amount of R\$4,654,118 at September 30, 2024 (R\$4,002,050 at September 30, 2023).

18.2. Insurance revenue

Breakdown of total insurance revenue recognized in the period per measurement model is as follows:

		Consolidated	Consolidated
		09/30/2024	09/30/2023
Amounts relating to changes in liability/asset for remaining			
coverage			
Expected insurance expenses	(a)	2,063,583	2,175,829
Changes in non-financial risk adjustment	(b)	1,267	1,263
Recognition of CSM in P&L for the period	(c)	31,120	29,785
Allocation of portion of premiums relating to recovery of insurance			
acquisition cash flows	(d)	35,623	51,121
Insurance revenue - Long-term products (BBA/VFA)		2,131,593	2,257,998
Premium release due to provision of insurance services	(e)	19,606,818	17,546,287
Insurance revenue - Short-term products (PAA)		19,606,818	17,546,287
Gross insurance revenues		21,738,411	19,804,285
Taxes on revenues		(190,004)	(132,965)
Net insurance revenues		21,548,407	19,671,320

⁽a) Expected expenses for the period due to the provision of insurance services that comprise claims and other expenses that the Company expects to incur to cover insured events that occurred during the period.

⁽b) The change in risk adjustment shows the amount of risk that expired during the period.
(c) CSM is recognized in P&L during the coverage period of the corresponding group of contracts based on coverage units.
(d) Premiums relating to acquisition cash flows are systematically allocated, on a straight-line basis, based on the passage of time over the coverage remind of the group of contracts or according to the portfolio's permanence curve.
 Amount recognized as insurance revenue for services rendered in the period.

Notes to interim financial information (Continued) September 30, 2024 (In thousands of reais, unless otherwise stated)

19. Cost of services

		Individual		Conso	lidated
Description	Note	09/30/2024	09/30/2023	09/30/2024	09/30/2023
Hospital services	19,1	(7,483,323)	(6,804,763)	(15,464,426)	(14,359,652)
Insurance costs	19,2		-	(15,190,305)	(14,949,281)
Cost with asset management		-	-	(3,323)	=
		(7,483,323)	(6,804,763)	(30,658,054)	(29,308,933)

19.1. Hospital services

	Indiv	idual	Consolidated		
	09/30/2024	09/30/2023	09/30/2024	09/30/2023	
Personnel	(2,810,764)	(2,459,279)	(5,497,691)	(5,046,386)	
Materials and medicines	(2,020,586)	(2,002,133)	(4,505,342)	(4,358,068)	
Third-party services	(1,940,587)	(1,661,924)	(4,092,926)	(3,582,203)	
Utilities and services	(162,206)	(145,343)	(325,220)	(305,935)	
Rents	(7,661)	(5,703)	(76,156)	(67,951)	
Depreciation and amortization	(541,519)	(530,381)	(967,091)	(999,109)	
	(7,483,323)	(6,804,763)	(15,464,426)	(14,359,652)	

19.2. Insurance costs

				Consolidated		
		Long-term բ (BBA/V		Short-term pro	ducts (PAA)	
		Liability for remaining coverage	Liability for claims incurred	Liability for remaining coverage	Liability for claims incurred	09/30/2024
Claims incurred and other expenses allocated to insurance						
contracts Amortization of acquisition cash	(a)	(82,811)	(1,663,927)	(732,051)	(11,072,224)	(13,551,013)
flows Amortization of allocation of consideration paid in business combinations to the insurance	(b)	(35,622)	-	(1,074,790)	-	(1,110,412)
portfolios Losses or reversal of losses on	(c)	-	-	(470,278)	-	(470,278)
onerous contracts Reclassification of the investment	(d)	(58,602)	-	-	-	(58,602)
component	(e)	2,043,669	(2,043,669)	-	-	-
-		1,866,634	(3,707,596)	(2,277,119)	(11,072,224)	(15,190,305)

Notes to interim financial information (Continued) September 30, 2024 (In thousands of reais, unless otherwise stated)

19. Cost of services (Continued)

19.2. Insurance costs (Continued)

	_			Consolidated		
		•	n products /VFA)	Short-term products (PAA)		09/30/2023
	_	Liability for remaining coverage	Liability for claims incurred	Liability for remaining coverage	Liability for claims incurred	_
Claims incurred and other expenses allocated to insurance	-	_				
contracts Amortization of acquisition cash	(a)	(101,290)	(1,579,920)	(676,889)	(10,972,526)	(13,330,625)
flows Amortization of allocation of consideration paid in business combinations to the insurance	(b)	(51,112)	-	(952,804)	-	(1,003,916)
portfolios Losses or reversal of losses on	(c)	-	-	(642,013)	-	(642,013)
onerous contracts Reclassification of the investment	(d)	27,273	-	-	-	27,273
component	(e)	2,264,935	(2,264,935)			-
	_	2,139,806	(3,844,855)	(2,271,706)	(10,972,526)	(14,949,281)

- (a) The most significant expenses are linked to claims incurred. This balance also includes expenses related to loss adjustments, issue, maintenance and collection of premiums, compliance with regulatory requirements, among other requirements necessary for the fulfillment of the Company's obligations linked to insurance contracts. Includes the elimination of claims incurred and other expenses to be allocated to insurance contracts between the Group's companies in the amount of R\$4,654,1118 as of September 30, 2024 (R\$4,030,496 as of September 30, 2023).
- (b) Acquisition cash flows are systematically allocated, on a straight-line basis, based on the passage of time over the coverage period of the group of contracts or according to the portfolio's permanence curve.
- (c) Amortization of the asset fair value computed by means of acquisition Purchase Price Allocation (PPA) allocated to the insurance contract portfolios, which was systematically and rationally allocated to the liability for remaining coverage, a portion of the contracts in force in 2023, and to the acquisition cash flow asset, portion of futures contracts (renewals).
- (d) Amortization of part of the liability fair value determined in the acquisition PPA allocated to the insurance contract portfolios as a loss component, experience adjustments, changes in estimated cash flows, and onerous contract group risk adjustment.
- (e) In the long-term products, there is a transfer of the investment component from the Asset/Liability for remaining coverage to the Liability for claims incurred in the amount of R\$2,043,669 as of September 30, 2024 (R\$2,264,95 as of September 30, 2023) related to the payment of benefits (annual fees), redemptions and portability of pension plan exit.

20. General and administrative expenses

	Indiv	ridual	Consolidated	
	09/30/2024 09/30/2023		09/30/2024	09/30/2023
Personnel	(593,345)	(517,968)	(709,313)	(621,742)
Third-party services	(122,517)	(105.464)	(210,897)	(186,015)
Travel and lodging	(33,376)	(26,627)	(56,692)	(52,378)
Depreciation and amortization	(153,829)	(134,546)	(231,748)	(225,264)
Reversal of/provision for contingencies	64,869	431,722	(264,786)	198,565
	(838,198)	(352,883)	(1,473,436)	(886,834)

Notes to interim financial information (Continued) September 30, 2024 (In thousands of reais, unless otherwise stated)

21. Other operating income (expenses), net

	Indi	vidual	Consolidated	
	09/30/2024	09/30/2023	09/30/2024	09/30/2023
Taxes, charges and penalties	(65,561)	(49,124)	(126,206)	(85,770)
Gain on property sales	2,940	2,940	2,940	2,940
Lease of machinery and equipment	(14,445)	(8,101)	(36,306)	(26,712)
Freight expenses	(10,371)	(7,448)	(44,197)	(29,353)
Legal fees	(539)	(21,937)	(3,310)	(29,894)
Gain on sale of corporate interest (a)	35 4 ,103	· · · · · · · · · · · · · · · · · · ·	354,103	· · · · · ·
Other income and expenses	(46,314)	(17,761)	(62,669)	(151,158)
·	219,813	(101,431)	84,355	(319,947)

⁽a) Gain from sale of the stake held in the share capital of D'Or Consultoria, as described in note 1.

22. Finance income (costs), net

Finance income (costs) for the nine-month periods ended September 30, 2024 and 2023 are broken down as follows:

	Indiv	idual	Consolidated		
	09/30/2024	09/30/2023	09/30/2024	09/30/2023	
Short-term investment yield	647,424	955,974	2,675,169	2,759,886	
Net foreign exchange differences on financing	(146,245)	54,489	(912,955)	324,336	
Fair value of debt	903,529	(504,258)	674,119	(167,996)	
Fair value of derivatives (swaps)	(878,818)	181,572	5,170	(592,586)	
Interest and monetary difference on financing and	• • •				
debentures	(2,526,058)	(2,639,847)	(2,607,238)	(2,760,003)	
Interest on lease liabilities	(296,616)	(280,594)	(346,107)	(356,677)	
Taxes on finance income (costs)	(48,747)	(53,165)	(67,644)	(67,461)	
Finance income (costs) from insurance contracts	-	=	(1,639,159)	(1,618,426)	
Other income and expenses	320,205	17,375	296,314	74,863	
	(2,025,326)	(2,268,454)	(1,922,331)	(2,404,064)	
Total finance income	1,804,135	2,749,055	5,537,007	6,828,022	
Total finance costs	(3,829,461)	(5,017,509)	(7,459,338)	(9,232,086)	
- -	(2,025,326)	(2,268,454)	(1,922,331)	(2,404,064)	

Notes to interim financial information (Continued) September 30, 2024 (In thousands of reais, unless otherwise stated)

23. Earnings per share

a) Basic

Basic earnings per share are calculated by dividing the profit attributable to the shareholders of the Company by the weighted average number of common shares issued over the year, excluding common shares purchased by the Company and held as treasury shares.

	09/30/2024	09/30/2023
Income attributable to the Company's controlling shareholders	2,921,920	1,272,566
Weighted average number of common shares issued (in thousands)	2,242,084	2,254,607
Basic earnings per share - in reais (R\$)	1.3032	0.5644

b) <u>Diluted</u>

Diluted earnings per share are calculated by adjusting the weighted average number of common shares outstanding to assume conversion of all potentially dilutive common shares.

	09/30/2024	09/30/2023
Income attributable to the Company's controlling shareholders	2,921,920	1,272,566
Weighted average number of common shares issued, including dilution factors (in thousands)	2,242,084	2,254,607
Diluted earnings per share - in reais (R\$)	1.3032	0.5644

Notes to interim financial information (Continued) September 30, 2024 (In thousands of reais, unless otherwise stated)

24. Financial instruments and financial risk management

24.1. Financial instruments by category (Continued)

Fair value hierarchy

The financial instruments recognized at fair value are measured at levels from 1 to 3, based on the fair value measurement, as follows:

Level 1: fair value measurement derives from quoted (unadjusted) prices in active markets for identical assets or liabilities;

Level 2: fair value measurement derives from other inputs included in Level 1, which are quoted through an asset or liability directly (i.e. as prices) or indirectly (i.e. derived from prices);

Level 3: fair value measurement derives from valuation techniques that include an asset or liability that is not included in an active market.

The following tables present breakdown of financial assets and liabilities at September 30, 2024 and December 31, 2023:

	Individual			
		Fair value	Book b	palance
Financial assets	Classification by category	hierarchy	09/30/2024	12/31/2023
Cash and cash equivalents Fair value through profit or loss		Level 2	495.446	257,423
Marketable securities (corporate bonds and	Fair value through profit or		100,110	20:,:20
investment fund shares)	loss	Level 2	7,839,684	9,239,876
Accounts receivable	Amortized cost		5,227,784	4,840,796
Dividends receivable	Amortized cost		45,782	70,593
Judicial deposits	Amortized cost		384,241	362,366
Derivatives	Fair value through profit or loss and other			
	comprehensive income	Level 2	434,042	620,063
			14,426,979	15,391,117

Notes to interim financial information (Continued) September 30, 2024 (In thousands of reais, unless otherwise stated)

24. Financial instruments and financial risk management

24.1. Financial instruments by category (Continued)

Fair value hierarchy (Continued)

		Fair value	Book b	palance
Financial liabilities	Classification by category	hierarchy	09/30/2024	12/31/2023
Trade accounts payable	Amortized cost		635,946	636,124
Loans, financing and debentures Salaries, accruals and social charges	Amortized cost (a) Amortized cost Fair value through profit or loss	Level 2	31,774,467 615,738	31,650,338 539,971
Derivatives	and other comprehensive income	Level 2	1,344,746	1,037,392
			34,370,897	33,863,825

⁽a) The debt portion recorded as hedge accounting (fair value hedge) is measured at fair value through profit or loss and at September 30, 2024 totaled R\$11,444,092 (R\$11,290,310 at December 31, 2023).

Consolidated				
		Fair value	Book b	palance
Financial assets	Classification by category	hierarchy	09/30/2024	12/31/2023
Cash and cash equivalents Marketable securities (shares and	Fair value through profit or loss	Level 2	5,499,255	3,267,408
government securities)	Fair value through profit or loss	Level 1	7,129,026	6,684,499
Marketable securities (corporate bonds				
and investment fund shares)	Fair value through profit or loss Fair value through profit or loss	Level 2	19,576,309	19,120,058
Marketable securities (government securities)	and other comprehensive income	Level 1	1,379,050	1,351,377
, , , , , , , , , , , , , , , , , , , ,	Fair value through profit or loss			, ,
Marketable securities (government securities)	and other comprehensive income	Level 2	1,567,815	1,254,429
Marketable securities	Amortized cost		1,813,695	1,755,979
Accounts receivable	Amortized cost		11,683,216	10,763,986
Judicial deposits	Amortized cost		2,749,599	2,682,556
	Fair value through profit or loss			
	and other comprehensive		2,784,095	
Derivatives	income	Level 2	2,704,093	1,967,424
			54,182,060	48,847,716

Notes to interim financial information (Continued) September 30, 2024 (In thousands of reais, unless otherwise stated)

24. Financial instruments and financial risk management

24.1. Financial instruments by category (Continued)

Fair value hierarchy (Continued)

		Fair value	Book b	palance
Financial liabilities	Classification by category	hierarchy	09/30/2024	12/31/2023
Trade accounts payable	Amortized cost		1,469,934	1,355,666
Loans, financing and debentures Salaries, accruals and social charges	Amortized cost (a) Amortized cost Fair value through profit or loss	Level 2	35,707,175 1,270,907	34,585,949 1,101,223
Derivatives	and other comprehensive income	Level 2	1,472,647	1,210,922
			39,920,663	38,253,760

⁽a) The debt portion recorded as hedge accounting (fair value hedge) is measured at fair value through profit or loss and at September 30, 2024 totaled R\$13,589,470 (R\$12,395,118 at December 31, 2023). As mentioned in Note 13, the debenture HSPE 14 - 4th issue of Debentures of Hospital Esperança had its maturity extended and its cost reduced, and these changes had no impact on the respective hedging instrument. Therefore, the cash flow hedge no longer offsets changes in cash flows of the risk associated with the recognized liabilities of this debt and was then written down to profit or loss, deferred over the debt maturity.

The financial assets and liabilities recorded at amortized cost are close to their respective fair values, as they are adjusted for provisions, present values and/or restated by post-fixed market rates.

24.2. Risk management

The Company's financial transactions are conducted by the financial function in accordance with the strategy previously approved by the executive board and shareholders. The Company's risk management strategies and the corresponding effects on the individual and consolidated financial statements can be summarized as follows:

a) Capital management

The main purpose of capital management is to ensure the Company's ability to continue as a going concern and maximize return to shareholders.

Notes to interim financial information (Continued) September 30, 2024 (In thousands of reais, unless otherwise stated)

24. Financial instruments and financial risk management (Continued)

24.2. Risk management (Continued)

a) Capital management (Continued)

The Company uses own and third-party capital to finance its activities, and the use of third-party capital seeks to optimize its capital structure. The Company monitors its capital structure and makes adjustments in light of changes in economic conditions. At September 30, 2024 and December 31, 2023, the Company has the following capital structure:

	Individual		09/30/2024	
	09/30/2024	12/31/2023	09/30/2024	12/31/2023
Cash and cash equivalents Marketable securities Technical reserves	495,446 7,839,684	257,423 9,239,876	5,499,255 31,465,895	3,267,408 30,166,342
Insurance (b) Private pension (b)	- -	-	(6,816,084) (12,641,428)	(5,334,887) (10,881,042)
(1)	8,335,130	9,497,299	17,507,638	17,217,821
Loans, financing and debentures	(31,774,467)	(31,650,338)	(35,707,175)	(34,585,949)
Derivatives	(910,704)	(417,329)	1,311,448	756,502
Cash flow hedge	(194,418)	(181,599)	(244,351)	(243,056)
Net debt (a)	(24,544,459)	(22,751,967)	(17,132,440)	(16,854,682)
Total equity	24,469,270	22,539,706	26,456,503	23,835,646
Total net debt and equity	(75,189)	(212,261)	9,324,063	6,980,964
Leverage ratio	1.00	1.01	0.65	0.71

⁽a) The net debt corresponds to the sum of the balances of loans, financing and debentures, derivative financial instruments, net (current and noncurrent) plus the cash flow hedge effect of other comprehensive income (the Company has swaps accounted for in accordance with the fair value and cash flow hedge accounting, for purposes of hedging the Company against fluctuations in foreign currency and interest rates, respectively) deducted of the balance of cash and cash equivalents and marketable securities.

b) Interest rate risk

The Company has loans, financing and debentures in local currency subject particularly to the fluctuation of the CDI and IPCA rates. The risk inherent to these liabilities arises from the possibility of fluctuations in these rates that impact the Company's cash flows.

⁽b) Technical reserve balances recorded in the subsidiaries regulated by SUSEP and ANS, based on regulatory guidance established by these agencies, which includes eliminations upon consolidation.

Notes to interim financial information (Continued) September 30, 2024 (In thousands of reais, unless otherwise stated)

24. Financial instruments and financial risk management (Continued)

24.2. Risk management (Continued)

b) Interest rate risk (Continued)

The sensitivity analysis of interest on loans, financing and debentures, net of short-term yields, considered as probable scenario (Scenario I) the reference rates obtained with BM&FBOVESPA at September 30, 2024, and Scenarios II and III take into consideration a rate increase by 25% and 50%, respectively. The results, in nominal values, are as follows:

Scenarios	Scenario I current	Scenario II + 25%	Scenario III + 50%
CDI rate (p.a.)	10.65%	13.31%	15.98%
IPCA rate (p.a.)	4.42%	5.53%	6.63%
Projected interest expenses (in millions)	13,663	16,829	19,995

c) Credit risk

Credit risk is the risk that a counterparty to a business arrangement will not meet its obligations under a financial instrument or customer contract, leading to a financial loss. The Company is exposed to credit risk from its operating activities (primarily trade accounts receivable) and from its financing activities, including deposits with banks and financial institutions, foreign exchange transactions and other financial instruments. In the case of identification of imminent risk of non-realization of these assets, the Company records provisions to bring them to their probable realizable value.

d) Liquidity risk

Liquidity risks arise from the possibility of lack of readily available resources to honor commitments made on a timely basis due to the mismatch between payment and receipt flows.

SulAmérica's Investment Policy provides for and describes minimum amounts that must be invested in highly liquid assets to mitigate the risk of non-payment of claims and benefits.

Daily cash projections and stress tests are carried out to anticipate any abnormal situation, having a daily control over liquidity risk.

Notes to interim financial information (Continued) September 30, 2024 (In thousands of reais, unless otherwise stated)

24. Financial instruments and financial risk management (Continued)

24.2. Risk management (Continued)

d) Liquidity risk (Continued)

Daily cash projections and stress tests are carried out to anticipate any abnormal situation, having a daily control over liquidity risk.

The following table presents the expected maturities and payments of the main financial insurance assets and liabilities, except for those related to the benefit accumulation phase of the PGBL and VGBL plans, whereby the exposure falls on the participant.

The amounts disclosed below are projected considering inflation and interest through to maturity.

Trade accounts payable Loans, financing and debentures Salaries, accruals and social charges Derivatives

Within	From	From	Over	Total financial
1 year	1 to 2 years	2 to 5 years	5 years	liabilities
635,946	-	-	-	635,946
3,073,324	2,392,614	11,741,677	19,605,644	36,813,259
615,738		-	-	615,738
(385,153)	(443,616)	(837,995)	2,431,468	764,704
3,939,855	1,948,998	10,903,682	22,037,112	38,829,647

Trade accounts payable Loans, financing and debentures Insurance liabilities Salaries, accruals and social charges Derivatives

Consolidated - 09/30/2024					
	From	From	Over	Total financial	
Within 1 year	1 to 2 years	2 to 5 years	5 years	liabilities	
1,469,934	-	-	-	1,469,934	
3,121,512	2,441,702	14,894,908	20,901,543	41,359,665	
10,038,611	2,130,803	4,235,932	8,379,239	24,784,585	
1,270,907	-	-	-	1,270,907	
(524,387)	(557,567)	829,393	5,169,761	4,917,200	
15,376,577	4,014,938	19,960,233	34,450,543	73,802,291	

Notes to interim financial information (Continued) September 30, 2024 (In thousands of reais, unless otherwise stated)

24. Financial instruments and financial risk management (Continued)

24.2. Risk management (Continued)

d) <u>Liquidity risk</u> (Continued)

Trade accounts payable Loans, financing and debentures Salaries, accruals and social charges Derivatives

Within	Within From From Over Total financia						
1 vear	1 to 2 years	2 to 5 years	5 years	liabilities			
. year	i to 2 years	2 to 0 years	o years	nasinties			
636,124	-	-	-	636,124			
2,647,407	3,578,583	8,266,903	22,292,653	36,785,546			
539,971	-	-	-	539,971			
(494,513)	(333,305)	(1,001,828)	3,196,802	1,367,156			
3,328,989	3,245,278	7,265,075	25,489,455	39,328,797			

Trade accounts payable
Loans, financing and debentures
Insurance liabilities
Salaries, accruals and social charges
Derivatives

Consolidated - 12/31/2023						
Within	From	From	Over	Total financial		
1 year	1 to 2 years	2 to 5 years	5 years	liabilities		
1,355,666	-	-	-	1,355,666		
2,985,336	3,742,177	10,525,715	22,863,866	40,117,094		
8,086,747	1,646,259	3,687,124	8,351,999	21,772,129		
1,101,223	-	-	-	1,101,223		
(661,476)	(488,790)	181,620	5,255,870	4,287,224		
12,867,496	4,899,646	14,394,459	36,471,735	68,633,336		

e) Foreign currency

The Company has loans and financing and trade accounts payable in foreign currency (mainly the US dollar). The risk related to these assets and liabilities arises from the possibility of incurring losses due to fluctuations in exchange rates. Liabilities in foreign currency represent 17.6% of total gross debt at September 30, 2024 (18.5% at December 31, 2023). The Company has derivative financial instruments to hedge loans and financing against foreign exchange rate fluctuation (see topic below). Management understands that the risk of exposure to foreign currency is not significant in relation to its financial position.

f) Derivatives

At September 30, 2024, the Company has swaps recorded based on fair value and cash flow hedge accounting, in order to hedge the Company against fluctuations in foreign currency and interest rate, respectively. The swaps exchange (i) the flow of interest and principal in foreign currency for Brazilian reais plus a percentage of CDI or CDI + spread; (ii) floating interest rate for fixed interest rate; and (iii) inflation rate IPCA + spread for a percentage of CDI or CDI + spread.

Notes to interim financial information (Continued) September 30, 2024 (In thousands of reais, unless otherwise stated)

24. Financial instruments and financial risk management (Continued)

24.2. Risk management (Continued)

f) <u>Derivatives</u> (Continued)

The fair value of those instruments at the reporting date is as follows:

				Indiv	/idual
				09/30/2024	12/31/2023
	Maturity ranges		erence value		_
Description	month/year		(notional)	Fair v	alue
Swap (currency)	06/30/2025	ELID	07.400		
Long position Short position	EUR/BRL + 1.0366% CDI+1.35%	R\$	67,428 409.414	(4,463)	(58,425)
Short position	CDI+1.33%	ĽΦ	409,414	(4,463)	(30,423)
Swap (currency)	04/27/2027				
Long position	USD SOFR + 0.99%	US\$	61,634		
Short position	CDI + 1.63%	R\$	335,788	16,992	(11,363)
Swap (currency)	07/01/2025				
Long position	USD/BRL + 1.8588%	+	100,399	(0.000)	(00 = (0)
Short position	CDI + 1.323%	R\$	546,986	(8,093)	(99,512)
Swap (index)	01/18/2028				
Gwap (macx)	BRL Fixed rate				
Long position	(11.82%)	R\$	1,634,663		
Short position	CDI + 2.01%	R\$	1,634,663	(112,546)	(11,625)
·				, , ,	, , ,
Swap (index)	01/22/2030				
	BRL Fixed rate		2,135,109		
Long position	(8.80%)	R\$		(F00 CC2)	(404.202)
Short position	CDI + 2.125%	R\$	2,135,109	(529,663)	(404,392)
Swap (index)	01/22/2030				
ewap (maex)	BRL Fixed rate		4 440 004		
Long position	(8.65%)	R\$	1,116,094		
Short position	CDI + 2.40%	R\$	1,116,094	(309,807)	(246,894)
Swap (index)	06/20/2029	D.A.	4 004 050		
Long position	CDI + 0.79% BRL Fixed rate	R\$	1,031,052		
Short position	(7.71%)	R\$	1,031,052	182,774	121,728
Short position	(1.11/0)	ΙζΨ		102,774	121,720
Swap (index)	10/26/2026				
Long position	106.0% CDI	R\$	392,793		
	BRL Fixed rate		392,793		
Short position	(6.765%)	R\$	332,133	28,072	24,937

Notes to interim financial information (Continued) September 30, 2024 (In thousands of reais, unless otherwise stated)

24. Financial instruments and financial risk management (Continued)

24.2. Risk management (Continued)

				Individ	ual
			Reference value	09/30/2024	12/31/2023
Description	Maturity ranges month/year	Maturity ranges month/year		Fair value	
Swap (index)	05/15/2036				
Long position	IPCA + 4.9347%	R\$	1,534,371		
Short position	CDI + 1.35%	R\$	1,534,371	(122,518)	12,649
Swap (index)	12/15/2031				
Long position	IPCA + 5.5758%	R\$	407,493		
Short position	CDI + 0.56%	R\$	407,493	17,316	40,651
Swap (index)	12/15/2036				
Long position	IPCA + 6.1017%	R\$	612,278		
Short position	CDI + 1.403%	R\$	612,278	(1,226)	55,823
Swap (index)	06/15/2029				
Long position	IPCA + 5.83%	R\$	813,379		
Short position	102.7% CDI	R\$	813,379	16,728	52,287
Swap (index)	06/15/2032				
Long position	IPCA + 6.01%	R\$	348,370		
Short position	104.1% CDI	R\$	348,370	3,355	24,035
Swap (index)	07/16/2029				
Long position	IPCA + 6.3828%	R\$	30,442		
Short position	103.65% CDI	R\$	30,442	1,374	1,912
Swap (index)	07/15/2032				
Long position	IPCA + 6.5445%	R\$	71,056		
Short position	104.8% CDI	R\$	71,056	2,764	5,592
Swap (index)	07/15/2037				
Long position	IPCA + 6.7692%	R\$	406,238		
Short position	107.9% CDI	R\$	406,238	14,041	41,866
Swap (index)	12/17/2029				
Long position	IPCA + 6.7947%	R\$	84,249		
Short position	108.1% CDI	R\$	84,249	2,744	7,236
Swap (index)	12/15/2032				
Long position	IPCA + 6.9354%	R\$	56,203		
Short position	110.1% CDI	R\$	56,203	1,391	5,232
Swap (index)	08/15/2030				
Long position	IPCA + 6.20%	R\$	561.919		
Short position	106.6% CDI	R\$	561,919	(36,234)	9,067
Swap (index)	08/15/2033				
Long position	IPCA + 6.55%	R\$	528,463		
Short position	109.3% CDI	R\$	528,463	(39,283)	11,867
Swap (index)	12/15/2033				
Long position	IPCA + 6.6941%	R\$	255,030		
Short position	CDI + 0.73%	R\$	255,030	(10,123)	-
Swap (index)	12/15/2038				
Long position	IPCA + 6.9527%	R\$	510,439		
Short position	CDI + 1.02%	R\$	510,439	(24,299)	-
Current assets position				72,434	49,550
Noncurrent assets position				361,608	570,513
Current liabilities position				(421,464)	(466,050)
Noncurrent liabilities position Effect on profit or loss for the year (fair value of	derivatives			(923,282)	(571,342)
- swaps)				(878,818)	532,789
Effect on equity for the year (fair value of deriva	atives -			12,819	(211 402)
swaps)				12,019	(211,403)

Notes to interim financial information (Continued) September 30, 2024 (In thousands of reais, unless otherwise stated)

24. Financial instruments and financial risk management (Continued)

24.2. Risk management (Continued)

				Consoli	dated	
				09/30/2024	12/31/2023	
Description	Maturity ranges month/year		Reference value (notional)	Fair value		
Swap (currency)	06/30/2025					
Long position	EUR/BRL + 1.0366%	EUR	67,428			
Short position	CDI+1.35%	R\$	409,414	(4,463)	(58,425)	
		•	,	() ,	(, -,	
Swap (currency)	04/27/2027					
Long position	USD SOFR + 0.99%	US\$	61,634			
Short position	CDI + 1.63%	R\$	335,788	16,992	(11,363)	
Swap (currency)	07/01/2025					
Long position	USD/BRL + 1.8588%	US\$	100,399			
Short position	CDI + 1.323%	R\$	546,986	(8,093)	(99,512)	
Short position	CDI + 1.323%	ĽΦ	540,900	(0,093)	(99,512)	
Swap (currency)	01/18/2028					
Long position	USD Fixed rate (4.95%)	US\$	505,019			
Short position	BRL Fixed rate (11.82%)	R\$	2,751,393	1,103,034	681,463	
Swap (index)	01/18/2028					
Long position	BRL Fixed rate (11.82%)	R\$	1,634,663			
Short position	CDI + 2.01%	R\$	1,634,663	(112,546)	(11,625)	
		•	, ,	,,	(,,	
Swap (index)	01/22/2030					
Long position	USD Fixed rate (4.525%)	US\$	504,250			
Short position	BRL Fixed rate (8.80%)	R\$	2,747,204	774,785	354,729	
Swap (index)	01/22/2030					
Long position	BRL Fixed rate (8.80%)	R\$	2,135,109			
Short position	CDI + 2.125%	R\$	2,135,109	(529,663)	(404,392)	
Course (in day)	04/00/0000					
Swap (index) Long position	01/22/2030 USD Fixed rate (4.51%)	US\$	252,125			
Short position	BRL Fixed rate (8.65%)	R\$	1,373,602	344,334	137,638	
Short position	BRL Fixed fale (6.65%)	ĽΦ	1,373,002	344,334	137,030	
Swap (index)	01/22/2030					
Long position	BRL Fixed rate (8.65%)	R\$	1,116,094			
Short position	CDI + 2.40%	R\$	1,116,094	(309,807)	(246,894)	
Swap (index)	06/20/2029					
Long position	CDI + 0.79%	R\$	1,031,052			
Short position	BRL Fixed rate (7.71%)	R\$	1,031,052	182,774	121,728	
Onort pooliion	Bite i Mod falle (1.1 170)	ιψ	1,001,002	102,774	121,720	
Swap (index)	10/26/2026					
Long position	106.0% CDI	R\$	392,793			
Short position	BRL Fixed rate (6.765%)	R\$	392,793	28,072	24,937	

Notes to interim financial information (Continued) September 30, 2024 (In thousands of reais, unless otherwise stated)

24. Financial instruments and financial risk management (Continued)

24.2. Risk management (Continued)

				Consoli	dated
				09/30/2024	12/31/2023
Description	Maturity ranges month/year		nce value otional)	Fair value	
		•			
Swap (index)	05/15/2036 IPCA + 4.9347%	R\$	1.534.371		
Long position Short position	CDI + 1.35%	R\$	1,534,371	(122,518)	12,649
Ghort position	ODI 1 1.5570	Ιζψ	1,554,571	(122,310)	12,043
Swap (index)	12/15/2031				
Long position	IPCA + 5.5758%	R\$	407,493		
Short position	CDI + 0.56%	R\$	407,493	17,316	40,651
Swap (index)	12/15/2036				
Long position	IPCA + 6.1017%	R\$	612,278		
Short position	CDI + 1.403%	R\$	612,278	(1,226)	55,823
		*	, -	() - ,	,-
Swap (index)	06/15/2029				
Long position	IPCA + 5.83%	R\$	813,379	40	== ===
Short position	102.7% CDI	R\$	813,379	16,728	52,287
Swap (index)	06/15/2032				
Long position	IPCA + 6.01%	R\$	348,370		
Short position	104.1% CDI	R\$	348,370	3,355	24,035
Swap (index)	07/16/2029				
Long position	IPCA + 6.3828%	R\$	30,442		4.040
Short position	103.65% CDI	R\$	30,442	1,374	1,912
Swap (index)	07/15/2032				
Long position	IPCA + 6.5445%	R\$	71,056		
Short position	104.8% CDI	R\$	71,056	2,764	5,592
Swap (index)	07/15/2037				
Long position	IPCA + 6.7692%	R\$	406,238		
Short position	107.9% CDI	R\$	406,238	14,041	41,866
•		•	,	,-	,
Swap (index)	12/17/2029				
Long position	IPCA + 6.7947%	R\$	84,249		= 000
Short position	108.1% CDI	R\$	84,249	2,744	7,236
Swap (index)	15/12/2032				
Long position	IPCA + 6.9354%	R\$	56,203		
Short position	110.1% CDI	R\$	56,203	1,391	5,232
Course (index)	00/45/0020				
Swap (index)	08/15/2030	R\$	EG1 010		
Long position Short position	IPCA + 6.20% 106.6% CDI	R\$	561,919 561,919	(26.224)	9.067
Short position	100.0 % CDI	KΦ	301,919	(36,234)	9,007
Swap (index)	08/15/2033				
Long position	IPCA + 6.55%	R\$	528,463		
Short position	109.3% CDI	R\$	528,463	(39,283)	11,867
Swap (index)	12/15/2033				
Long position	IPCA + 6.6941%	R\$	255,030		
Short position	CDI + 0.73%	R\$	255,030	(10,122)	_
F			0,000	(,)	
Swap (index)	12/15/2038				
Long position	IPCA + 6.9527%	R\$	510,439		
Short position	CDI + 1.02%	R\$	510,439	(24,299)	-

Notes to interim financial information (Continued) September 30, 2024 (In thousands of reais, unless otherwise stated)

24. Financial instruments and financial risk management (Continued)

24.2. Risk management (Continued)

f) <u>Derivatives</u> (Continued)

			Conso	lidated
			09/30/2024	12/31/2023
Description	Maturity ranges month/year	Reference value (notional)	Fair v	alue
Current assets position			72,434	49,550
Noncurrent assets position			2,711,661	1,917,874
Current liabilities position			(549,364)	(639,580)
Noncurrent liabilities position			(923,283)	(571,342)
Effect on profit or loss for the year (fair				
value of derivatives - swaps)			5,170	(459,885)
Effect on equity for the year (fair value				
of derivatives - swaps)			1,296	(226,767)

Given the changes in market rates, these amounts may suffer changes as well as early settlement or maturity of the transactions.

For derivative financial instruments, the Company considers as probable scenario +5% (Scenario I) future exchange rates of the Brazilian real in relation to the US -Dollar, euro, IPCA inflation rates and future ID interest rate, obtained from BM&FBOVESPA at their maturities, calculated based on the nominal amount of the agreement.

The Company adopted the scenarios corresponding to -25% (Scenario II), -50% (Scenario III), +25% (Scenario IV) and +50% (Scenario V) in relation to the exchange rates and DI rates used to determine the probable scenario.

Notes to interim financial information (Continued) September 30, 2024 (In thousands of reais, unless otherwise stated)

24. Financial instruments and financial risk management (Continued)

24.2. Risk management (Continued)

Debt - Citibank and JP Morgan	Scenario I	Scenario II	Scenario III	Scenario IV	Scenario V
Exchange rate fluctuation Depreciation of US\$ (rate in R\$) Appreciation of US\$ (rate in R\$)	5% - 5.7205	(25%) 4.2904 -	(50%) 2.8603 -	25% - 7.1506	50% - 8.5808
Effect on liabilities Loan 4131 - Citibank and JP Morgan	44,178	(220,889)	(441,779)	220,889	441,779
Effect on derivatives Swap Net effect	(44,178) -	220,889	441,779 -	(220,889)	(441,779) -
Debt - Senior Notes I	Scenario I	Scenario II	Scenario III	Scenario IV	Scenario V
Exchange rate fluctuation Depreciation of US\$ (rate in R\$) Appreciation of US\$ (rate in R\$)	5% - 5.7205	(25%) 4.2904 -	(50%) 2.8603 -	25% - 7.1506	50% - 8.5808
Effect on liabilities Senior Notes	131,392	(656,958)	(1,313,917)	656,958	1,313,917
Effect on derivatives Swap Net effect	(131,392) -	656,958 -	1,313,917 -	(656,958) -	(1,313,917) -
Debt - Senior Notes II	Scenario I	Scenario II	Scenario III	Scenario IV	Scenario V
Exchange rate fluctuation Depreciation of US\$ (rate in R\$) Appreciation of US\$ (rate in R\$)	5% - 5.7205	(25%) 4.2904 -	(50%) 2.8603 -	25% - 7.1506	50% - 8.5808
Effect on liabilities in US\$ Senior Notes II	175,109	(875,545)	(1,751,089)	875,545	1,751,089
Effect on derivatives Swap Net effect	(175,109) -	875,545 -	1,751,089	(875,545) -	(1,751,089) -

Notes to interim financial information (Continued) September 30, 2024 (In thousands of reais, unless otherwise stated)

24. Financial instruments and financial risk management (Continued)

24.2. Risk management (Continued)

Debt - Debentures	Scenario I	Scenario II	Scenario III	Scenario IV	Scenario V
Fluctuation in DI rate Depreciation of the DI rate Appreciation of the DI rate	5% - 11.1825%	(25%) 8.3869% -	(50%) 5.5913% -	25% - 13.9781%	50% - 16.7738%
Effect on liabilities Debentures	7,582	(32,223)	(72,029)	47,387	87,193
Effect on derivatives Swap Net effect	(7,582) -	32,223 -	72,029 -	(47,387) -	(87,193) -
Debt - Debentures (CRI)	Scenario I	Scenario II	Scenario III	Scenario IV	Scenario V
Fluctuation of the IPCA rate Depreciation of the IPCA rate	5%	(25%) 3.4808%	(50%) 2.3205%	25%	50%
Appreciation of the IPCA rate	4.6410%	-	-	5.8013%	6.9615%
Effect on liabilities Debentures	13,701	(58,229)	(130,159)	85,631	157,561
Effect on derivatives Swap Net effect	(13,701) -	58,229 -	130,159 -	(85,631) -	(157,561) -
Debt - BofA	Scenario I	Scenario II	Scenario III	Scenario IV	Scenario V
Exchange rate fluctuation Depreciation of EUR€(rate in R\$)	5% -	(25%) 4.7816	(50%) 3.1877	25% -	50% -
Appreciation of EUR€(rate in R\$)	6.3755	-	-	7.9694	9.5632
Effect on liabilities Loan 4131 - BofA	20,471	(102,353)	(204,707)	102,353	204,707
Effect on derivatives Swap Net effect	(20,471)	102,353 -	204,707	(102,353) -	(204,707) -

Notes to interim financial information (Continued) September 30, 2024 (In thousands of reais, unless otherwise stated)

24. Financial instruments and financial risk management (Continued)

24.2. Risk management (Continued)

g) Pricing risk

Currently, the Company has specific actuarial pricing models for each of its products, which ensure accuracy in determining the prices in view of the expected contractual commitments and expenses used to sell and manage contracts.

For insurance with higher individual risks and portfolios with less predictability or exposed to catastrophes, the Company uses reinsurance contracts, mitigating the risk of large and unexpected losses on contracts and transferring such risks to the reinsurers, assuming in return the credit risk of these partners. The purchase of reinsurance follows a specific policy established and described by the Company.

One of the ways to measure possible impacts on profit or loss and equity, arising from underwriting risks, is the sensitivity analysis of the variables that may be affected by the product underwriting process, inadequacy of prices or even insufficiency of technical reserves.

The following sensitivity analyses simulate the possible impacts on P&L and equity of changes in operating parameters before and after the purchase of reinsurance.

Sensitivity analysis - Health

The sensitivity analysis considers a scenario where the stressed assumptions suffer a 5% impact (Increase and Decrease) and how this change would impact the Company's consolidated P&L and equity.

This type of analysis is based on the history of the Company's products and judges their results independently. Shocks of 5% mentioned in the table are determined by the total value of the amount calculated from the base for the reference period multiplied by the factor of 1.05 (in cases of increase) or 0.95 (in cases of decrease).

Notes to interim financial information (Continued) September 30, 2024 (In thousands of reais, unless otherwise stated)

24. Financial instruments and financial risk management (Continued)

24.2. Risk management (Continued)

g) Pricing risk (Continued)

Sensitivity analysis - Health (Continued)

Impacts are evaluated in the amount of P&L realized, which as at September 30, 2024 are as follows:

Consolidated - 09/30/2024					
Assumptions	Income before income taxes	Income after taxes			
5% increase in claims	(869,416)	(521,649)			
5% increase in cancelations	(980,341)	(588,205)			
5% increase in interest rate	289,916	173,950			
5% decrease in claims	869,416	521,649			
5% decrease in cancelations	980,341	588,205			
5% increase in interest rate	(309,347)	(185,608)			

Notes to interim financial information (Continued) September 30, 2024 (In thousands of reais, unless otherwise stated)

24. Financial instruments and financial risk management (Continued)

24.3. Changes in liabilities from financing activities

					Indivi	dual				
Individual	12/31/2023	Loans, financing and debentures raise	Interest, monetary variations and FX differences, net	Payment of acquisitions and principal	Payment of interest	Fair value of debt	Allocation of dividends and IOE	Payment of dividends and IOE	Other	09/30/2024
Loans, financing, debentures and leases Derivatives Dividends and IOE payable	34,222,672 1,037,392 88,499	2,000,000 - -	3,089,876 679,978 -	(1,863,819) (372,624)	(2,374,535)	(903,529) - -	- - 1,000,000	- - (641,063)	388,738 - (139,071)	34,559,403 1,344,746 308,365
	35,348,563	2,000,000	3,769,854	(2,236,443)	(2,374,535)	(903,529)	1,000,000	(641,063)	249,667	36,212,514
Current Noncurrent	3,307,598 32,040,965									4,311,395 31,901,119
					Indiv	idual				
Consolidated	12/31/2022	Loans, financing and debentures raised and leases	Interest, monetary variations and FX differences, net	Payment of acquisitions and principal	Indiv Payment of interest	ridual Fair value of debt	Allocation of dividends and IOE	Payment of dividends and IOE	Other	09/30/2023
Consolidated Loans, financing, debentures and leases Derivatives Dividends and IOE payable	12/31/2022 36,215,627 1,959,016 145,085	financing and debentures raised and	monetary variations and FX differences,	acquisitions	Payment of	Fair value of	dividends and	dividends and	Other 129,112 39,777 (48,936)	09/30/2023 36,965,733 1,460,157 403,710

Notes to interim financial information (Continued) September 30, 2024 (In thousands of reais, unless otherwise stated)

24. Financial instruments and financial risk management (Continued)

24.3. Changes in liabilities from financing activities (Continued)

					Consc	olidated				
Consolidated	12/31/2023	Loans, financing and debentures raised and leases	Interest, monetary variations and FX differences, net	Payment of acquisitions and principal	Payment of interest	Fair value of debt	Allocation of dividends and IOE	Payment of dividends and IOE	Other	09/30/2024
Loans, financing, debentures and leases Derivatives Dividends and IOE payable	37,758,574 1,210,922 99,769	2,518,901	3,987,242 798,682 -	(2,570,631) (536,957) -	(2,341,957)	(674,119) - - -	1,065,263	- (712,412)	482,851 - (121,467)	39,160,861 1,472,647 331,153
Current Noncurrent	39,069,265 4,390,701 34,678,564	2,518,901	4,785,924	(3,107,588)	(2,341,957)	(674,119)	1,065,263	(712,412)	361,384	40,964,661 4,665,148 36,299,513
					Conso	lidated				
Consolidated	12/31/2022	Loans, financing and debentures raised and leases	Interest, monetary variations and FX differences, net	Payment of acquisitions and principal	Conso	lidated Fair value of debt	Allocation of dividends and IOE	Payment of dividends and IOE	Other	09/30/2023
Consolidated Loans, financing, debentures and leases Derivatives Dividends and IOE payable	12/31/2022 36,215,627 1,959,016 145,085 38,319,728	financing and debentures raised and	monetary variations and FX differences,	acquisitions	Payment of	Fair value of	dividends and	dividends and	Other 129,112 39,777 (48,936) 119,953	09/30/2023 36,965,733 1,460,157 403,710 38,829,600

Notes to interim financial information (Continued) September 30, 2024 (In thousands of reais, unless otherwise stated)

25. Assets, liabilities, revenues and expenses per segment

				Consolidated			
				09/30/2024			
	Hospital	Health	Life	Corporate	Total segments	Eliminations	Consolidated
Net revenues							
Foreign customers	20,760,178	20,942,292	623,909	85,743	42,412,122	(4,689,825)	37,722,297
Intersegment	-	167	12,396	-	12,563	(12,563)	-
Other revenues and expenses							
Operating expenses	(15,464,426)	(19,255,615)	(614,364)	(3,323)	(35,337,728)	4,679,674	(30,658,054)
Administrative expenses	(856,683)	(484,110)	(14,849)	(90,676)	(1,446,318)	(27,118)	(1,473,436)
Finance income (costs)	(2,279,109)	9	242,751	90,991	(1,945,358)	23,027	(1,922,331)
Other amounts that have an impact on	761,960	(416,624)	(69,623)	20,046	295,759	(1,042,315)	(746,556)
income (a)							
Net income	2,921,920	786,119	180,220	102,781	3,991,040	(1,069,120)	2,921,920
Assets	71,509,106	26,189,913	13,958,795	10,468,205	122,126,019	(24,265,203)	97,860,816
Liabilities	45,052,603	15,792,608	12,914,135	777,170	74,536,516	`(3,132,203)	71,404,313

⁽a) Mainly composed of the intragroup equity pickup eliminated in the "Eliminations" column in the total of R\$1,077,948.

				Consolidated			
				09/30/2023			
	Hospital	Health	Life	Corporate	Total segments	Eliminations	Consolidated
Net revenues							
Foreign customers	19,047,079	19,053,084	621,126	32,208	38,753,497	(4,057,147)	34,696,350
Intersegment	-	175	10,172	-	10,347	(10,347)	-
Other revenues and expenses					-		-
Operating expenses	(14,359,651)	(18,346,501)	(655,988)	-	(33,362,140)	4,053,207	(29,308,933)
Administrative expenses	(374,505)	(452,710)	(5,813)	(56,845)	(889,873)	3,039	(886,834)
Finance income (costs)	(2,541,290)	(51,641)	36,957	151,910	(2,404,064)	-	(2,404,064)
Other amounts that have an impact on income (a)	(449,405)	(256,515)	14,100	(462,043)	(1,153,863)	379,572	(774,291)
Net income	1,322,228	(54,108)	20,554	(334,770)	953,904	368,324	1,322,228
Assets Liabilities	48,361,019 40,824,163	21,495,905 13,315,085	11,923,157 11,080,361	17,554,863 3,503,697	99,334,944 68,723,306	(7,253,048) (50,311)	92,081,896 68,672,995

⁽a) Mainly composed of the intragroup equity pickup eliminated in the "Eliminations" column in the total of R\$272,030.

Notes to interim financial information (Continued) September 30, 2024 (In thousands of reais, unless otherwise stated)

26. Insurance coverage

At September 30, 2024, the Company maintains insurance coverage at amounts deemed sufficient by management to cover risks, if any, on its assets and/or liabilities.

Type of coverage	Amount insured
Property risk	5,517,975
Civil liability (D&O)	749,405
General civil liability	13,000
Engineering risks	4,446,324

27. Events after the reporting period

On October 11, 2024, Rede D'Or paid in the 34th issue of debentures in three series, in the total amount of R\$5,9 billion, maturing on September 15, 2027, September 15, 2031 and September 15, 2034. The first series is indexed to the CDI + 0.65% p.a., the second series to the CDI + 1.10% p.a., and the third series to the CDI + 1.30% p.a., payable semiannually. There are no guarantees.

On October 18, 2024, Hospital Esperança carried out the optional early redemption in full of its 4th Issue of Debentures, in the principal amount of R\$1 billion, and Rede D'Or carried out the optional early redemption in full of its 1st Series of the 23rd Issue of Debentures of Rede D'Or São Luiz S.A, in the principal amount of R\$900 million as well as of its 28th Issue of Debentures of Rede D'Or São Luiz S.A, in the principal amount of R\$490 million.

On November 01, 2024, the Company entered into a Purchase and Investment Agreement and Other Covenants with Atlântica Hospitais e Participações S.A. - company focused on investing in hospitals, being an indirect subsidiary of Bradseg Participações S.A., which is the controlling shareholder of Grupo Bradesco Seguros - for contribution of Hospital São Luiz Campinas to the network of "Atlântica D'Or" hospitals, a corporate partnership held 50.01% by the Company, its hospital operator, and 49.99% by Atlântica Hospitais. The consummation of the Partnership is subject to compliance with certain suspensive conditions usual in operations of this nature, including the necessary regulatory approvals.

On November 8, 2024, Sul América S.A., succeeded by Rede D'Or São Luiz S.A. due to Merger, carried out the optional early redemption in full of the 1st Series of its 9th Issue of Debentures, in the principal amount of R\$750 million.